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1. Introduction 
 
In a healthy situation, the body is provided with homeostatic mechanisms and buffers to 
maintain physiological concentrations of free metal ions, thus preventing their abnormal 
decompartmentalization, release and trafficking. The main reasons for the anomalous 
accumulation of non-essential metal ions in the body are environmental exposure and 
administration of metallodrugs for therapy or diagnosis, which may cause competition 
for biometals, generation of oxidative stress and disregulation of several metal-enzyme 
systems. Inorganic medicinal chemistry has to deal with the introduction of metal ions 
in the body, but also with their removal or passivation through the use of chelators. In 
these terms, thermodynamics and kinetics of complex formation are very important for 
a correct understanding of the role of metal ions in human diseases.  
During my PhD work, some new ligands were synthesized and their complex formation 
equilibria with toxic, essential and other metal ions of biomedical interest were studied.  
In particular, some derivatives of kojic acid have been synthesized and their protonation 
and chelating properties toward the target metal ions Fe3+ and Al3+, and the two 
essential Cu2+ and Zn2+ have been characterized. Furthermore, the complex formation 
equilibria of some drugs actually in clinical use with the essential metal ions Cu2+ and 
Zn2+ were studied to give evidence of their possible implications in copper chelation. 
Moreover, the tyrosinase inhibitory properties of the kojic derivative[1] (5-hydroxy-4-
oxo-4H-pyran-2-yl)methyl3-({[(5-hydroxy-4-oxo-4H-pyran-2yl)methoxy]carbonyl} 
amino)propanoate and its complex formation equilibria with copper have been studied, 
since the inhibitory effect may result from the interaction with copper ions in the active 
center of the enzyme. 
This thesis is divided in an Introduction, dedicated to a description of metals, to their 
chemistry and their overload or deficiency, to chelation therapy, to the characteristics of 
chelators for metal overload treatment and to the improvements induced on some 
pathological conditions in diabetic patients. Further attention is devoted to tyrosinase 
inhibition and radiopharmaceutical labelling. An Experimental part describes the 
synthesis of new chelators and the methods used for a complete characterization. In the 
section Results and Discussion the determination of protonation constants for all 
ligands, together with that of their complex formation constants with metals of interest 
like Fe3+, Al3+, Ga3+, Cu2+ and Zn2+, is presented, in order to evaluate their therapeutic 
application in metal overload diseases. Complex stability studies of two new ligands 
with lanthanum to be used in the treatment of bone disorders are also presented as a part 
of a collaboration during my three month period at the University of British Columbia, 
Vancouver-Canada. A brief section Conclusions summarizes the presented results. 
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1.1. Metal homeostasis and chelation therapy. 
 
A number of metal ions play a crucial role in living organisms. Metals can easily lose 
electrons from the elemental or metallic state to give cations, which are soluble in 
biological fluids, and can interact with biological molecules. Metal ions, which are 
electron deficient, can bind and interact with electron rich biological molecules such as 
proteins and DNA. 
Natural evolution has incorporated many metal ions into essential biological functions. 
Haemoglobin, an iron-containing protein, binds to oxygen through its iron atom and 
carries it throughout the body. Calcium-containing minerals are the basis of bones, the 
structural framework of the human body. Zinc is a natural component of insulin, a 
substance crucial to the regulation of sugar metabolism. Metals such as copper, zinc, 
iron and manganese are incorporated into catalytic proteins (metalloenzymes) which 
facilitate a multitude of chemical reactions needed for life[2].  
Nowadays in the industrial society, exposure to metal ions is ever increasing. Metal 
compounds are used in medicine for either therapeutic or diagnostic purposes, in 
alimentary industries, in water purification plants, in cosmetics, in painting and so on. 
According to the role that metal ions exert in the human physiology, at least three 
categories can be roughly distinguished: essential, inert and toxic[3].  
Any metal ion or complex, or indeed any chemical compound, is subject to the potential 
limitations in the Bertrand diagram (Figure 1.1).  
 
  
Figure 1.1. Bertrand diagram indicating the relationship between positive/negative effects from an element 
and its concentration[3]. 
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Toxic compounds can be tolerated in low doses, at which may even exert therapeutic 
effects, and essential metals can become toxic at high concentrations[4]. For a true 
knowledge of the behavior of an element in the human body, it is important not only its 
range concentration, but also its speciation and oxidation state. One of the principal 
ways to counteract metal toxicity in humans consists in the treatment with metal 
chelators, which transform the toxic metal ion in a less dangerous species and favour its 
excretion from the organism. 
 
1.2. Chelation therapy and metal chelators 
 
The word “chelation” derives from the Greek χηλη - that means claw. Chelators have 
at least two binding atoms that form either two covalent, or one covalent and one 
coordinate, or two coordinate linkages. Atoms like S, N and O are the main binding 
atoms, in chemical groups like -SH, -S-S, -NH2, =NH, -OH, -OPO3H or –C=O. 
Bidentate or multidentate chelators form ring structures that include the metal ion with 
at least two-ligand atoms attached to the metal (Figure 1.2). In the chelation therapy, 
metal binding molecules are most often organic compounds with suitable chelating 
properties. Metal chelators interact with metal ions and they can be used either to 
remove toxic metals from the body in metal overload conditions or for diagnostic and 
radionuclear therapeutic applications. 
 
 
 
                                                        Monodentate Ligand 
                                        
 
 
 
                                                         Bidentate Ligand 
 
 
 
                                                        
                                                         Polydentate Ligand 
 
 
 
Figure 1.2. Metal-Ligand complex formation using mono, bi and polydentate ligands. 
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Many ligands act as bidentate ligands and five-membered chelate rings are especially 
stable. There are also examples of inorganic chelates which form five membered rings 
with metal ions. The complexation of metal ions with i molecules of a monodentate 
ligand, L, or with one molecule of an i dentate ligand λ can be expressed as: 
M + iL ⇋ MLi 
M + λ  ⇋ Mλ 
The overall stability constants can be expressed by the equations: 
βL = [MLi] / [M][L]i 
βλ = [Mλ] / [M][λ] 
The stability of the complex depends on the thermodynamic equation: 
∆G0 = ∆H0 - T∆S0 = -RT lnβ 
The formation of the MLi complex depends in a larger extent on the concentration of the 
ligand (L is at the i’th power in βML) than does the formation of the Mλ complex (λ is at 
the first power in βMλ). Especially at low ligand concentration, chelates are far more 
stable than the corresponding complexes with monodentate ligands. The change in log β 
for complexes with multidentate ligands with increasing numbers of identical donor 
groups gives evidence of the size of the chelate effect [5]. A favourable entropy change 
occurs upon the exchange of many monodentate ligands for fewer multidentate ligands 
to bind a given metal ion. The denticity of the ligands determines the number and 
stoichiometry of the formed complexes. As a general rule, hexadentate ligands are 
preferred because they form only one kind of complex. Ligands with low denticity form 
multiple complexes, whose speciation pattern depends on both ligand concentration and 
ligand/metal molar ratio. The stability of the complex respects the trend monodentate < 
bidentate < tridentate < tetradentate < …< hexadentate ligands.  
 
1.2.1. Characteristics of chelating agents 
 
In designing a therapeutic metal chelator, one must consider the hard-soft acid-base 
(HASAB) theory for the appropriate interaction of donor atoms with the target metal 
ion. Their interaction will determine the stability of the final complex and the selectivity 
of the ligand for the target metal ion, in an environment where many metal ions are free 
in solution, such as Ca2+, Mg2+ and K+. 
The HASAB theory describes the propensity of electron acceptors (metal ions) to bind 
electron donors (coordinating molecules) preferentially of similar “hardness” or 
“softness”. For a metal ion, the term “hardness” or “softness” means how easily its 
empty orbitals accept electron density. For donor atoms this definition means how 
deformable are the outer electron orbitals[6]. “Hard” metal ions such as Fe3+ or Al3+ bind 
preferentially with “hard” donors such as oxygen in carboxylate groups. On the other 
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hand, “soft” metals ions such Hg2+ are well coordinated by ligands with “soft” donors 
atoms such as sulphur (Table 1.1). 
 
Table 1.1. Acid and base classification according to the HASAB theory of Pearson. 
Acids 
Hard                                                                         
 
H+, Li+, Na+, K+, Be2+, Mg2+, Ca2+, Sr2+, 
Ba2+, Al3+, Sc3+, Ga3+, In3+, La3+,Gd3+, 
Lu3+, Cr3+, Co3+, Fe3+, As3+, Si4+, Ti4+, 
Zr4+, Hf4+, Th4+, U4+, Pu4+, Ce4+, WO4+, 
Sn4+, UO2+, VO2+, MoO3+ 
Soft 
                                                                   
Cu+, Ag+, Au+, Ti+, Hg+, Pd2+, Cd2+, 
Pt2+, Hg2+, CH3Hg+, Co(CN)52-, Pt4+, 
Te4+, Br+, I+ 
Borderline                                                                                                                                           
Fe2+, Co2+, Ni2+, Cu2+, Zn2+, Pb2+, Sn2+, Sb3+, Bi3+, Rh3+, Ir3+, B(CH3)3 
Bases 
Hard            
                                                                    
H2O, OH-, F-, CH3CO2-, PO43-, SO42-, Cl, 
CO32-, ClO4-, NO3-, ROH, RO-, R2O, 
NH3,RNH2, NH2NH2                                                                    
Soft                      
                                                                    
R2S, RSH, RS-, I-, SCN-, S2O32-, R3P, 
R3As, CO, (RO)3P, CN-, RNC, C2H4, H-, 
R- 
Borderline                                                                                                                                 
C5H5NH2, C5H5N, N3-, Br-, NO2-, N2, SO32- 
                                                                                                                                         
 
The introduction of chelating agents in biological systems requires the comparison 
between the affinity of the chelator for the target metal ion and that of endogenous 
ligands. This is because metal ions, especially those which are redox-active under 
physiological conditions, such as Cu+/2+ or Fe2+/3+, are generally bound to biomolecules 
such as proteins, nucleic acids or others, and the introduced chelating agent must 
participate in a series of ligand exchange competition reactions to form the stable 
desired complex that can be later dislocated or excreted. Complexation can further 
protect the metal ion from deleterious reactions, such as the reduction of Fe3+ to Fe2+, 
which via Fenton reaction produces reactive oxygen species (ROS). 
The stability constant of a complex MepLqHr is related to its formation equilibrium, 
pMe + qL + rH ⇋ MepLqHr, starting from the completely deprotonated ligand. 
However, the complex formation in vivo occurs with the ligand in its prevailing form at 
physiological pH according to its speciation pattern determined by the protonation 
constants. Taking into consideration that complex formation is a competitive reaction 
between proton and metal for the same basic binding sites on the ligand, and that 
complexes of  different stoichiometries can be formed depending on the denticity and 
kind of the ligand, stability constants cannot be used to compare the effectiveness of 
different ligands. A more useful standard comparison is the pMn+ value[7], defined as the 
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negative logarithm of the concentration of free metal (M+n) in solution. Typically pMn+ 
values are calculated for total [ligand] = 10-5 M, total [metal] = 10-6 M at pH 7.4. The so 
calculated pM+n values allow a direct comparison of ligands  because they take into 
account the effects of ligand protonation, denticity and the differences in complex 
stoichiometries[8]. Iron chelators with high pFe+3 values are predicted not only to 
scavenge iron effectively at low ligand concentrations, but also to dissociate less 
readily, forming low concentrations of the partially coordinated complexes[7]. 
The requirements of chelating agents have been better and better defined on the bases of 
many chemical and biomedical considerations, and they are the starting point for the 
design of a successful metal chelator. These can be summarized: 
 
• Low toxicity of the chelator itself and of the resulting complex. The side effects 
that often occur after a period of use require the suspension and/or substitution 
with a different chelator; 
• High stability of the formed complex in comparison with the stability of those 
formed with endogenous ligands; 
• High ligand selectivity, mainly determined by the hardness-softness character 
and by the chelate effect; 
• Biochemical metabolism of the chelating agent once entered into the body; 
• Kinetics of exchange with endogenous ligands; 
• Factors affecting absorption and bioavailability; 
• Absence of effects on the activity of metal ion-dependent enzymes;  
• Kinetic stability of the complex to ensure efficient transport and excretion; 
 
Selectivity toward the target metal ion is one of the main requisites of chelation therapy. 
For example, to counteract iron overload, iron binding should be not perturbed by the 
presence of other essential metal ions such as copper and zinc, and at the same time the 
ligand should not affect their homeostatic equilibrium. The design of the chelator should 
localize its activity in the target tissue or even in the cell compartment where the metal 
ion overload is located. Many research groups have tried different strategies to achieve 
this localization through the synthesis of specific pro-ligands that can be transformed 
inside the organism and can become active where it is needed, or by appending 
targeting molecules to the ligand, as is the case of the bifunctional chelators for 
radiopharmaceutical applications. 
The ideal chelator should possess cell membrane permeability in order to be effectively 
absorbed, but the metal ion complex should not cross the blood-brain barrier (BBB) to 
prevent unexpected neurological damages. Chelators should be efficiently absorbed by 
the gastrointestinal tract, and this depends on membrane permeability through 
parameters like molecular size, lipophilicity and net charge[9]: 
• Molecular weight < 500 g/mol; 
• The octanol/ water partition coefficient (log P) > 5; 
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• Less than 10 hydrogen bond donors in the molecule (OH and NH) groups; 
• Less than 10 hydrogen bond acceptors present in the molecule (N and O atoms); 
• Ionisation state. 
 
Uncharged molecules penetrates cell membranes more rapidly than charged 
molecules[10]. To achieve absorption greater than 70% subsequent to oral application, 
the chelator molecular weight needs to be less than 300, while non facilitated diffusion 
is generally considered to be dominant for drugs with molecular weights < 200. 
It is important to remember that the ability of a compound to penetrate BBB critically 
depends on the partition coefficient as well as on the molecular weight[11]. The BBB 
permeability is predicted to be low for the most hexadentate compounds, by virtue of 
their molecular weight[8]. Compounds with molecular weight > 300, and log Pwater/octanol 
values less than -1.3 tend to penetrate inefficiently[12]. 
 
1.3. Iron 
 
Iron is the second most abundant metal, after aluminium, and the fourth most abundant 
element in the earth’s crust. Iron is a very important metal for a wide variety of cellular 
events, indeed no life form is possible without the presence of this element. This 
important role of iron resides on its facile redox chemistry and on its affinity for 
oxygen. Iron possesses incomplete filled d-orbitals and can exist in various valence 
states, the most common in aqueous media being Fe2+ and Fe3+. Fe3+ is quite insoluble 
in neutral water (Ksp=10-39M and at pH 7.0 [Fe3+]= 10-18 M), and significant 
concentrations of water-soluble Fe3+ species can be attained only when it is in a strong 
complexed form. In contrast, Fe2+ is extremely water soluble. High spin Fe3+ is a 
spherically symmetrical tripositive cation with an ionic radius of 0.067 nm and it is 
classified as a “hard” Lewis acid by virtue of its high charge density. It forms more 
stable bonds with “hard” oxygen ligands such as phenolate and carboxylate rather than 
with imidazole or thiolate. In contrast, the Fe2+ cation with an ionic radius of 0.083 nm 
has lower charge density and it is on the borderline between “hard” and “soft”, 
favouring nitrogen (imidazole and pyrrole) and sulphur ligands (thiolate and 
methionine) over oxygen ligands. 
The most frequent geometry associated with coordination number 6 is the octahedral, 
for both Fe2+ and Fe3+, but also four coordinated complexes (tetrahedral) and five 
coordinated complexes (trigonal bipyramidal or square pyramidal) can be found. While 
low-spin complexes are obtained with strong-field ligands, such as F- and OH-, high-
spin complexes are formed in the presence of weak-field binding groups, such as CO 
and CN-. Changes of spin state affect ion size of both Fe2+ and Fe3+, the high-spin ion 
being significantly larger that the low-spin ion. Both oxidation states are Lewis acids, 
particularly the ferric state[13]. 
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The solution chemistry of iron is essentially characterized by the hydrolysis and 
polymerisation of aqueous Fe3+ to insoluble and potentially biologically inaccessible 
ferric hydroxides and oxyhydroxides. Living organisms have overcome this 
accessibility problem by excreting low molecular weight ligands (mainly derived from 
catechols, or from hydroxamic acids) designed as siderophores. These molecules can 
specifically sequester iron in a soluble form[14], allowing microorganisms to take up 
these complexes via specific transport systems. Once inside the cell the iron is released 
either by reduction to Fe2+ (for which the siderophore have little affinity) or by 
hydrolysis of the ferri-siderophore accompanied by release of its iron. In general 
multicellular organisms do not possess a system of siderophores with their appropriate 
receptors so they must find the required iron from alimentation. The role of the transport 
of iron to the different cell within the organism and its resorption from the dietary 
sources is assured by the serum globulin transferrin, which complexes iron, transports it 
in the circulation, and via specific receptors it is taken up by the cells of the organism. 
The release of iron is pH-dependent and the availability of proton pumps within specific 
intracellular compartments assures the intracellular release of iron; the iron-free protein 
is recycled from the cell and released into the circulation for reutilisation. Once the iron 
is released within the cell, either the iron which liberated from its soluble siderophore 
complex will be complexed by an intracellular chelator, or it will follow its inexorable 
hydrolysis and polymerisation towards biological inaccessibility. As an evolution of the 
capacity of living organisms to assimilate and utilize iron, there are intracellular iron 
storage compounds, which allow the cell in physiological conditions to dispose of a 
pool of bioavailable, soluble and non-toxic iron. The archetype of these compounds is 
the iron storage protein, ferritin. 
The importance that such iron storage compounds should be non-toxic is because the 
potential toxicity of iron related to its redox chemistry. Iron ions, as other transition 
metal ions, are intimately associated with many of oxidative stress events, especially in 
the process of lipid peroxidations, which lead to the cells and tissues damage. 
In the Fenton reaction a Fe2+ in presence of H2O2 produces the •OH radical: 
Fe2+ + H2O2 → Fe3+ + •OH + OH- 
In the presence of trace amount of iron, superoxide can than reduce Fe3+ to molecular 
oxygen and Fe2+.     
Fe3+ + O2- → Fe2+ +O2 
O2- + H2O2 → O2 + •OH + OH- 
Since the oxidation of ferrous iron by molecular oxygen can be represented by the 
sequence of reactions below, it is immediately apparent that if 'free' iron exists within a 
cell, it could provoke the production of hydroxyl radicals, with disastrous consequences 
for the cell. The system is in fact used by macrophages in the killing of bacteria: 
Fe2+ + O2→ Fe3+ +O2•- 
2O2- + 2H+ → H2O2 + O2• 
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Therefore the complexation of iron within a cell necessitates that the iron storage 
protein must guard its iron in a soluble, bio-available and non-toxic form as ferritin 
does. In fact iron metabolism in man is highly conservative, and since man lacks a 
physiological mechanism to eliminate iron, iron homeostasis in the normal individual is 
achieved by a tight regulation of iron absorption from the gastrointestinal tract. 
However there are situations when the iron status can change, either locally as in 
ischaemic tissue, or systematically due to the genetic haemochromatosis or transfusion-
induced iron overload. The most common iron overload is a genetically determined 
disorder, the homozygous state for hereditary hemochromatosis, occurring in as much 
as 0.5% of the population or as many as 1 million individuals[15]. There are other forms 
of iron overload, less frequent but affecting several thousand patients with iron-loading 
or transfusion-dependent anaemias such as thalassemia major and acquired refractory 
anaemias. Dietary iron-overload resulting from intake of iron in brewed beverages is a 
common problem affecting many populations in Sub-Saharan Africa[16]. In such 
circumstances, the elevated levels of iron ultimately accumulates in the heart, liver and 
joints, among other tissues, and can lead to free radical-mediated damage and eventual 
death[17].  
 
1.3.1. Iron chelators 
 
To prevent patients from iron toxicity, iron chelating agents have been introduced in 
clinical practices. Unfortunately an ideal chelator to overcome iron overload in humans 
has not been identified yet. Fe3+ forms stable bonds with hard ligands which contain 
oxoanions as a functional groups, such as catechols, hydroxamates, aminocarboxylates, 
hydroxycarboxilates, hydroxypyridinones (HPOs) and hydroxypyrones. 
 
1.3.1.1. Catechols 
 
Catechol, as a functional group is found in Enterobactin (Figure 1.3), which is a 
siderophore that binds iron for microbial systems. It is found mainly in Gram-negative 
bacteria, such as Escherichia coli and Salmonella typhimurium[18]. Molecules such as 
MECAM (1,3,5-N,N’,N”-tris-(2,3-dihydrobenzoyl)triaminomethylbenzene, Figure 1.3)  
have been synthesized in order to mimic the natural siderophore molecule. This 
extremely strong interaction with tripositive metal cations is a result of the high electron 
density of both oxygen atoms. This high charge density is also associated with the high 
affinity for protons (pKa values 12.1 and 8.4)[19]. The complexes forming at pH 7.0 bear 
a net charge and consequently are unlikely to permeate membranes by simple 
diffusion[20]. Such iron complexes tend to be trapped in intracellular compartments. 
Moreover, bidentate catechols form with Fe3+ the 2:1complexes (dominant form in the 
pH range 5.5-7.5), where iron atom being not completely protected from the solvent is 
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able to interact with hydrogen peroxide and oxygen to produce free radicals[8]. The main 
problem with the catechol-based ligands is their susceptibility towards oxidation. 
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Figure 1.3. Hexadentate catechols. 
 
1.3.1.2. Hydroxamates 
 
An important natural hexadentate ligand is deferrioxamine (DFO, Figure 1.4), a fungal 
siderophore. DFO is a hydroxamate-based hexadentate chelator isolated from 
Streptomyces pilosus, and it is the current clinical chelator of choice for the treatment of 
iron overload diseases such as β-thalassemia. Siderophores are natural product iron 
chelators, secreted by microbes as a response to the insoluble nature of iron in the 
environment[21]. These hydroxamates have a lower affinity for iron than catechols, but 
they have the advantage to form neutral tris-complexes with Fe3+ which are able to 
permeate membranes by non-facilitated diffusion[20]. The protonation constant (pKa ~ 9) 
makes lower the proton competition for the binding sites on the ligand at physiological 
pH that in the case of catechol ligands, consequently 3:1 complex predominates at pH 
7.4 and sufficient ligand concentration. Unfortunately, the affinity for a simple bidentate 
hydroxamate ligand (Figure 1.3) is insufficient to solubilize Fe3+ at pH 7.4 at clinical 
concentrations. For this reason, only tetradentate and hexadentate ligands are considered 
as possible Fe3+ scavengers under such conditions. The hexadentate DFO, displays very 
poor oral bioavailability and must be administered via long subcutaneous infusions, 
leading to high cost of treatment and low patient compliance. Many others 
hydroxamates are metabolically labile and poorly absorbed via the oral route[22]. 
However, more lipophilic DFO analogues have been synthesized by reacting the 
terminal primary amino group with fatty and aromatic acid chlorides or anhydrides, but 
none of them has been reported more efficient than DFO administered via subcutaneous 
route[23]. 
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Figure 1.4. Hexadentate deferrioxamine (DFO) and bidentate (L-lysinehydroxamic acid) hydroxamates. 
 
1.3.1.3. Aminocarboxylates 
 
Aminocarboxylates ligands are produced by cereals, for instance wheat, barley, rye and 
oat (i.e. mugineic acid in Figure 1.5). This category includes chelators such as EDTA 
and DTPA (Figure 1.5). They are able to chelate strongly iron. However they are not 
selective for iron and for this reason their use in medical treatment is limited because 
their lack of selectivity leads to zinc depletion in patients[10]. Moreover, the complexes 
formed with iron can catalyse redox reactions. Thus, EDTA is not able to shield the 
surface of the Fe3+ ion, but it forms an open complex. The exposition of the complex to 
the biological environment facilitates the interaction with the metal and consequently 
originates Fenton reactions with reactive oxygen species (ROS)[24]. 
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Figure 1.5. Aminocarboxylates ligands. 
 
1.3.1.4. Hydroxycarboxylates 
 
The hydroxycarboxylate ligands such as citrate (Figure 1.6) are strong chelating agents. 
They only have oxygen coordinating atoms so they are more selective towards Fe3+ than 
aminocarboxylates. The interaction between Fe3+ and citrate has been well established, 
but by virtue of its tridentate nature, a large number of complexes have been identified 
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including iron/citrate polymers. In contrast, the hexadentate hydroxycarboxylate 
ligands, staphloferrin[25] and rhizoferrin (Figure 1.6) form simple 1:1 complexes, 
similarly to DFO[26]. 
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Figure 1.6. Hydrocarboxylates. 
 
1.3.1.5. Hydroxypyridinones 
 
Hydroxypyridinones (HPOs) are acids, which form 5-membered chelate rings in which 
metal is coordinated by two vicinal oxygen atoms. This family of chelators combine the 
characteristics of the functional groups hydroxamates and catechols to chelate 
selectively tribasic metal cations over dibasic species. There are three classes of metal 
chelating HPOs, namely, 1-hydroxypyridin-2-one (1,2-HP), 3-hydroxypyridin-2-one 
(3,2-HP) and 3-hydroxypyridin-4-one (3,4-HP), shown in Figure 1.7. This family of 
ligands can be easily functionalized to improve their properties, above all the 
bioavailability and the chelating ability[27]. Deferiprone (1,2-dimethyl-3-
hydroxypyridin-4-one, DFP) is a member of the bidentate hydroxypyridinone family of 
iron chelators, which is the first orally active treatment of β-thalassemia characterized 
by a value of pFe 20.67. The high pKa value of hydroxyl function of 3-hydroxypyridin-
4-one results from extensive delocalisation of the lone pair associated with the ring 
nitrogen atom. DFP forms neutral 3:1 complexes with Fe3+ that dominate the speciation 
profile in the millimolar concentration range at physiological pH. However, at 
micromolar concentrations at pH 7.4, the 2:1 complex is no more negligible (~10%) and 
the incomplete coordination of iron by deferiprone would enable the access of 
reductants to the iron core and may potentially lead to ROS production[28].  
In order to reduce the presence of redox active complexes and increase complex 
stability[29], various derivatives have been synthesized containing two or three units of 
HPOs[30],[31],[32] (Figure 1.7). These enable the modulation of bioavailability and the 
possibility of interaction with several biological targets.   
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Figure 1.7. Bidentate and hexadentate hydroxypyridinones. 
 
1.3.1.6. Hydroxypyrones 
 
Hydroxypyrones differ from HPOs for the oxygen in the ring, which decreases the 
basicity of the –OH group. For instance, while DFP has a pKa 9.8[24], kojic acid is 
characterized by a pKa 7.7[33]. Hydroxypyrones chelate iron forming five-membered 
rings as their analogues HPOs do. 
Kojic acid (KA) (Figure 1.8) is one of the most studied hydroxypyrones and it is a 
promising molecule for the development of more effective derivatives. An interesting 
iron chelator, 6-[5-hydroxy-2-hydroxymethyl-pyran-4-one]-5-hydroxy-2-
hydroxymethyl-pyran-4-one (L1), demonstrated high efficacy for the in vivo 
mobilization of ferritin-bound iron[34]. Several similar ligands have been studied in these 
last years in our research group[33],[35],[36],[37] (See Figure 1.8). These ligands, constituted 
by two KA units joined by different linkers, form stable iron dinuclear complexes 
characterized by pFe values several orders of magnitude higher than that of the 
precursor. The main advantages and good perspectives are their easy and inexpensive 
synthesis, their relatively low molecular weight (340-450 Da), which makes them 
possible oral chelators; the chances of modulating their binding ability working on 
proper substituents in the KA units and in the linker[27].  
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Figure 1.8. Hydroxypyrones kojic acid derivatives ligands synthesized in our research group. 
 
1.4. Aluminium 
 
Aluminium is the most abundant metallic element, and the third constituent of the 
earth’s crust, after oxygen and silicon. Aluminium, due to its extremely low redox 
potential, occurs ubiquitously in the environment combined in salts and oxide forms. 
Because of its physical and chemical properties, aluminium metal and its compounds 
have a wide variety of uses: building, transportation, food packaging, beverage cans, 
cooking utensils, food additives, pharmaceutical preparations, surgery materials, 
cosmetics, water purification. 
The chemistry of Al3+ is simpler than that of Fe3+[38]. Aluminium is much more soluble 
than Fe3+, and exhibits only one oxidation state in biological systems. Metallic Al is too 
reactive to be found free in nature, and the metal is won from its ores only with 
difficulty[39]. The effective ionic radius of hexa-coordinated Al3+ is 0.054 nm. By way of 
comparison other values are Ga3+ 0.062, Fe3+ 0.065, Mg2+ 0.072, Zn2+ 0.074, Fe2+ 
0.078, and Ca2+ 0.100 nm. On the basis of the radii, though quite small, Al3+ is closest to 
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Fe3+ and Mg2+. Ca2+ is much larger, and in its favoured eight-fold coordination exhibits a 
radius of 0.112 nm, yielding a volume nine times greater than Al3+.  
The fact that no physiological function in the course of evolution has been attributed to 
aluminium implies that its metabolism cannot benefit of any homeostatic regulatory 
process. In particular, its gastrointestinal absorption is not expected to be based on a 
specific active transport system, and it should therefore simply depend on the solution 
chemistry of the Al3+ ion in the gastrointestinal tract, i.e. the solubility of the ingested 
salts within the gastrointestinal pH interval and its complex formation with the anionic 
forms of these salts, which do not only induce Al3+ solubilisation but may also facilitate 
the absorption process[40]. 
Since 1970, aluminium has been recognized to cause serious diseases. Aluminium 
enters into the body from the environment and from diet and medications. Human 
exposure is mainly dietary, less than 5 per cent of oral intake is due to drinking water. 
Antiperspirants can also be a non-negligible source of aluminium absorption. Most 
exposed populations remain patients on dialysis, long-term antacid consumers and 
workers in the aluminium industry. 
In biological systems Al3+ is chelated by the methylmalonate. The metal ion is chelated 
with two oxygen donors of two carboxylate amino acids aspartate and glutamate[41]. 
Despite of greater basicity of methylmalonate[42], it forms a weaker chelate (six-
membered) with Al3+ than those with oxalate (five-membered)[43]. Lactate forms weak 
AlL2+, AlL2+, and AlL3 complexes in acidic solution where the hydroxyl group retains 
its proton[44]. The ligand that incorporates Al3+ into mammals is citrate. Ligand exists 
predominantly in the form of the tricarboxylate anion at pH > 6, and at the 0.1 mM 
concentration in the blood plasma is the predominant small Al3+ binder[39],[45],[46]. While 
citrate is the low molecular weight carrier of Al3+ in serum, transferrin is the high 
molecular weight carrier. The transferrin receptor is specific for transferrin and not for 
Fe3+, and hence Al3+ may enter the central nervous system as does Fe3+. 
Toxic effects of aluminium chronic exposure are mainly neurological effects 
(encephalopathy, cognitive and motor disorders), bone disease (vitamin D resistant 
osteomalacia), and blood effects (microcytic anaemia). Aluminium also causes immune 
and allergic reactions. Other suspected effects are not confirmed, in particular the 
involvement of aluminium in a variety of neurodegenerative diseases (Alzheimer’s 
disease, amyothrophic lateral sclerosis and Parkinson’s disease)[10, 47].  
 
1.4.1. Aluminium chelators 
 
The awareness of aluminium toxicity has led several research groups to study new 
possibilities for chelating agents, some of them being already used for iron chelation. 
Both iron and aluminium, due to their short ionic radius and their high charge, are hard 
metals. As iron, aluminium prefers hard bases containing oxygen atoms, as 
hydroxamates, catecholates, bisphosphonates, salicylates, HPOs and 
hydroxypyrones[47]. The first aluminium chelator in clinical practice was DFO, for the 
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treatment of osteomalacia (Figure 1.7). Recently, some hydroxypyridinone derivatives 
have been studied as chelators for trivalent metal ions by the group of Santos[32] (Figure 
1.9); the tetradentate iminodiacetic acid bis-(3,4-HP) and derivatives called IDAPr(3,4-
HP)2[48]; a ternary system composed by an arylpiperazine-containing bis-
hydroxypyrydinone[49]; two hexadentate ligands, the tris-hydroxypyrydinone-based 
compounds KEMPPr(3,4-HP)3 and KEMPBu(3,4-HP)3, where the KEMP acid scaffold 
is attached to three 3,4-HP chelating moieties via different size spacers[31]; two new 
tris(3,4-HP) hexadentate chelators, NTA(BuHP)3 ad NTP(PrHP)3, in which the three HP 
units were connected by nitrilotriacetic acid (NTA) and nitrilopropionic acid 
(NTP)[50],[51]. High Fe3+ affinity was found for these last two chelators, being pFe = 27.9 
for NTA(BuHP)3 and pFe = 29.4 for NTP(PrHP)3, and pAl = 22.0 and 22.4 respectively. 
Other ligands have been synthesized for tripositive metal ions with high pAl value, is 
the case of the tripodal O-TRENSOX and the similar triscatechol derivate 
TRENCAMS[52]. Bisphosphonates ligands showed high efficiency as Fe3+ and Al3+ 
chelators[53] (Figure 1.9). Hydroxypyrone ligands, studied in our group, based on two 
kojic acid units joined by different likers (Figure 1.8), and especially those designed by 
L1, L2 and L3, have a high affinity for Al3+ with pAl values of 12.8, 11.9 and 13.9 
respectively[35]. 
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Figure 1.9. Aluminium chelators. 
 
1.5. Copper 
 
Copper is present in different concentrations and chemical forms throughout the earth 
crust, surface, deep water and in the atmosphere (in trace amounts).  
It is a micro-element essential for life. Copper is a redox-active metal that is responsible 
for the function of many cellular enzymes and proteins, so it is involved in important 
biological processes including respiration, angiogenesis and neuromodulation. Most of 
copper in human body is bound to biological macromolecules in both the oxidation 
states: Cu+ mainly present in the intracellular space (reducing environments) and Cu2+ 
in the extracellular space (oxidizing environments). Cu+ and Cu2+ have different 
chemical properties. Cu+ is not stable in aqueous solution where it is easily oxidized to 
Cu2+. The standard reduction potential Cu2+/ Cu+ is 0.153 V, thus reflecting the low 
likelihood that Cu2+ is reduced. Cu+ prefers to bind to soft ligands rather than 
intermediate ones as Cu2+ does. In proteins, while Cu2+ is usually anchored to His 
imidazole or N-terminal amino group, stable Cu+ sites are formed by sulfur thiolate or 
thioether from Cys and Met. 
Copper behaves as catalytic cofactor of many human enzymes, like cytochrome-c 
oxidase (CcO), superoxide dismutase (SOD), ceruloplasmin, tyrosinase, peptidyl-α-
monooxygenase and dopamine beta-monooxigenase[54]. The structural basis of the 
activity of copper enzymes and chaperones are becoming well elucidated[55]. Copper 
proteins are classified as either type 1, 2 or 3. Type 1 (blue copper sites) functions in 
single electron transfers[56]. In type 2 copper sites, copper acts as a catalytic centre and 
binds directly to substrates. Type 3 copper sites are binuclear and involved in the 
activation and transport of oxygen. 
Copper can also play a key role in many diseases[57], including copper metabolism 
disorders, i.e. Menkes and Wilson diseases[58], neurodegenerative disorders like familial 
amyotrophic lateral sclerosis (FALS), Alzheimer’s and prion diseases. Aβ plaques 
P P
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OH
OH
O
HO
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found in Alzheimer’s disease brains contain elevated levels of the metals ions copper, 
zinc and iron. Cu and Zn ions are thought to play an important role in binding to the Aβ 
protein and causing some of the aggregation, redox activity and downstream effects that 
lead to the symptoms of AD[59],[60],[61],[62],[63]. In diabetic animals and patients with 
diabetic cardiomyopathy high levels of systemic copper are found, with elevations in 
urinary copper, normal or elevated plasma copper and ceruloplasmin levels, and 
markedly elevated hepatic and renal copper levels[64],[65],[66],[67]. This impaired copper 
regulation has been implied in increased prooxidant stress, defective antioxidant 
defenses[68], and progressive damages to the blood vessels, heart, kidneys and nerves 
(the ‘diabetic complications’)[69]. 
Cu2+ becomes toxic when an excessive intracellular accumulation occurs. In Wilson’s 
disease, the transport of copper into the secretory pathway for incorporation into 
ceruloplasmin for biliary excretion (the only mechanism for copper excretion from the 
body), is impaired[70]. Cu2+ can directly accelerate the production of ROS via the Fenton 
reaction and create a disturbance in the prooxidant-antioxidant balance, which can 
contribute to the development of cell damage and consecutive apoptosis[71]. Cells have 
therefore developed sophisticated machinery composed by a network of proteins to 
ensure tight control of copper in the cell during its acquisition and distribution within 
the biological system, avoiding circulation of “free” copper[72],[73]. “Free” copper ions 
can participate to the production of ROS, so it is necessary that copper adsorption, 
distribution, utilization and excretion is tightly regulated by those specific proteins. In 
addition to the generation of ROS, Cu2+ may manifest its toxicity by displacing other 
metal cofactors from their natural ligands. 
 
1.5.1. Copper chelators 
 
The treatment for copper overloading or intoxication is chelation therapy. Different 
molecules are already in clinical use and others in clinical trials. The three most 
important chelators used for the treatment of Wilson’s disease are D-penicillamine (D-
pen), triethylenetetramine ((N,N’ –bis(2-aminoethyl)-1,2-ethanediamina, trientine, 
TETA, or Trien) and ammonium tetrathiomolibdate (TTM) (Figure 1.10). The first 
metal chelator used for copper overload in WD was BAL (Figure 1.10). This chelating 
agent contains two thiol groups that compete with body protein for copper binding and, 
once copper is chelated, the complex is excreted in the urine. BAL was originally 
developed as an antidote against lewisite during the World War II, and then used to treat 
metals intoxications[74]. D-penicillamine (D-pen), orally active and less toxic than BAL, 
was successively developed. More lipophilic D-pen derivatives have been synthesized 
to theoretically increase cell uptake of the chelator[75]. TETA was introduced in 1982 to 
be used in patients intolerant to D-pen[76]. Tetrathiomolibdate (TTM) can be 
administered to WD patients for initial therapy followed by zinc acetate for maintenance 
therapy with remarkable efficacy, and is thought to be a better choice than the 
traditional chelation by TETA[77].  
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Figure 1.10. Main copper chelators for the treatment of Wilson’s disease. 
 
Examples of tripodal Cys-rich chelators to act as potential Cu+ chelators in vivo have 
been reported (HnLx in Figure 1.11)[78],[79],[80]. Clioquinol ((5-chloro-7-iodo-8-
hydroxyquinoline, CQ, in Figure 1.11) binds in a bidentate fashion with high affinity to 
a range of metal ions. CQ has been used in the past as an antibiotic[81], and recently, as 
antiproliferative agents against tumor cell lines, in the form of copper complexes[82],[83]. 
CQ was also found to reduce the formation of amyloid plaques[84], being able to 
partially disaggregate Cu-triggered Aβ aggregates by virtue of its high affinity for 
Cu2+[85]. Two CQ analogues have been reported in the literature, consisting of two 8-
hydroxyquinoline moieties linked through a spacer (C1, C2, Figure 1.11)[86],[87],[88]. 
These tetradentate ligands, C1 and C2, showed higher copper binding affinities and 
remarkable capacity to reduce the production of ROS. 
        
N
Cl
I
OH                   
N N
HOOH                
N
N
N
H2NNH2  
                   CQ                                                       C1                                                          C2 
 
 
 
                                                                                                           
                      H3L1 : X = OEt 
                      H3L2 : X = NH2 
                      H3L3 : X = OH 
 
Figure 1.11. Copper chelators. 
 
Recently, several bifunctional chelators (BFCs) have been synthesized. They are simply 
chelators with reactive bifunctional groups that can be covalently coupled (conjugated) 
to targeting vectors (e.g. peptides, nucleotides, antibodies, nanoparticles)[89]. The 
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general idea is that the introduction of a second function allows the chelator to work 
under specific conditions, in specific tissues or in the presence of specific 
biomolecules[90]. BFCs chelators for Alzheimer’s disease (AD) have been synthesized 
taking advantage of the ability of some molecules to interact with Aβ. It is the case of 
K0 ligand in Figure 1.13, designed by merging the structural feature of CQ and the 
scaffold IMPY (Figure 1.12)[85],[91]. Also the ligand XH1 in Figure 1.13, where two 
molecules of Tht (Figure 1.12) are linked to DTPA[92]. Finally, in Cyc-KLVFF (Figure 
1.13) a cyclen moiety is attached to a N-terminus of the KLVFF fragment (Figure 1.12) 
which is a β-sheet breaker that inhibits Aβ aggregation[93],[94],[95],[96],[97].  
 
             
N
N
I
N
                         
N
S
N
 
                                         IMPY                                                                            Tht 
NH2
H2N
O
N
H
O
H
N
O
N
H
O
H
N
O
OH
 
KLVFF 
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Figure 1.13. Examples of copper bifunctional chelators. 
 
Moreover, defective copper regulation is widespread in diabetes, where it has been 
linked to the causation of cardiovascular disease[67] and is now serving as a target for 
experimental therapeutic intervention by treatment with a Cu2+-selective chelator[69],[98]. 
In this thesis the complex formation equilibria of two pharmaceutical agents to treat 
hypertension in diabetic patients with the essential metal ions Cu2+ and Zn2+ have been 
studied. 
 
1.6. Zinc 
 
Zinc (atomic weight 65.41 g/mol) is a soft, bluish-white metal (density 7.14 g/mL). It 
presents the oxidation states 0, +2. After iron is the most abundant trace element in the 
body and its higher concentrations are found in the brain and also in pancreatic cells. 
There are about 2.6 g of zinc in the body, and Zn2+ is involved in nearly all aspects of 
molecular and cell biology[99]. Zinc proteins account for about 10% of the human 
proteome, ca 3000 zinc proteins with physiological functions[100]. Zinc plays a role in 
the structure of proteins as well as in enzymatic catalysis. Its coordination chemistry 
within proteins has been widely studied[101]. The most common amino acids that supply 
ligands for Zn within the catalytic sites are Hys, Glu, Asp and Cys. In catalytic sites Zn 
usually forms complexes with water and any three nitrogen, oxygen and sulfur donors 
with His being the predominant chosen amino acid. Zinc, in its ionic form, can also 
exert important modulatory effects on neurotransmission and synaptic function, as well 
as regulate many signalling pathways[57].  In some cells relatively high concentrations of 
zinc can be reached in vesicles (milimolar, especially in synaptic vesicles in the brain) 
where it is stored and undergoes controlled release[102]. Zinc deficiency is therefore 
accompanied by dramatic consequences as erosion of the gastrointestinal tract, skin 
lesions, cardiac failure, malformations of brain and of male reproductive system[103]. 
However, zinc, and above all its “free” or loosely bound form, is very toxic to 
mammalian cells, and evidence of this is that zinc is a key factor in neuronal death 
associated with ischemia and seizures and in other neurological diseases states, as its 
implication as a trigger for neuronal loss in several neurological conditions. In fact, 
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deregulation of Zn2+ homeostasis is believed to be connected with mitochondrial 
dysfunction and oxidative stress, making the cation a possible contributor to the 
activation of pathophysiological pathways involved in brain aging and/or 
neurodegeneration. Thus, exposure to high Zn2+ concentrations both in vitro and in vivo 
promote neuronal death, and elevated Zn2+ levels are linked to the neuronal loss 
observed in epilepsy, ischemia and traumatic brain injury[104]. Metallothioneins (MTs) 
exert a crucial role in maintaining Zn2+ homeostasis. MTs are small proteins with a 
highly conserved sequence of 20 Cys residues yielding two domains for Zn2+ binding. 
Cellular oxidants may promote Zn2+ release from MTs and reducing agents may 
facilitate Zn2+ binding[105]. Therefore, the ability to release Zn2+ upon changes in the 
cellular redox state, renders MTs a reservoir of readily available Zn2+ under conditions 
of oxidative stress. 
It is not only the right amount of zinc in the diet that maintains health. At least as 
important is the proper functioning of the dozens of proteins that control cellular zinc 
homeostasis, regulate intracellular traffic of zinc between the cytosol and 
vesicles/organelles, and determine the fluctuations of signalling Zn2+ ions. Cellular zinc 
deficiency or overload compromise the redox balance. Zinc supplementation may not 
readily remedy zinc deficiency if other factors limit the capability of a cell to control 
zinc. The role of zinc in human diseases requires a general understanding of the wide 
spectrum of functions of zinc, how zinc is controlled, how it interacts with the 
metabolism of other metal ions, in particular copper and iron, and how perturbation of 
specific zinc-dependent molecular processes causes disease and influences the 
progression of disease. 
 
1.6.1. Zinc chelators 
 
Although metal chelating agents represent a needed therapeutic strategy, they are 
accompanied by several undesirable side-effects. Long term use of not tissue-specific 
chelators, such as DFO, leads to affect the homeostasis of numerous biometals and 
disturbs the normal physiological functions of essential metal-dependent biomolecules 
such as metalloenzymes[106]. The ability to target specific tissues selectively, using 
bifunctional chelators may minimize the toxicity of metal chelators and enhance their 
effectiveness. Using the approach of synthesizing bifunctional chelators, a DTPA 
analog, XH1 (Figure 1.13) ligand, was developed to chelate excess of metals (especially 
Cu, Zn and Fe) and disturb aberrant metal-peptide interactions in AD. 
Others ligands have been designed in order to act as metalloenzymes inhibitors[107]. 
They are a series of pyrone-based inhibitors of Zn2+-dependent matrix 
metalloproteinases which could chelate the catalytic Zn2+ site and also anchor the 
compound via noncovalent interactions within the active site (Figure 1.14). 
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Figure 1.14. A pyrone matrix metalloproteinase inhibitor (left) and pyridinone glycosides (right) conjugate 
metal chelators. 
 
A family of pyridinones glycosides have been synthesized by the group of Orvig[82] in 
order to passivate and/or remove excess of metal ions from the brain of AD patients 
using a multifunctional approach (Figure 1.14). This approach intend to functionalize 
the 3-hydroxy position of the 3,4-HP, to prevent premature systemic metal chelation 
prior to passage across the blood brain barrier (BBB). The use of glucose to protect the 
pyridinone allows glucose conjugates to gain access to the brain. Glycoconjugates have 
been used to deliver many drugs across the BBB[108],[109],[110],[111],[112].  
Acute zinc intoxication, accidental or suicide is uncommon and limited cases are 
reported, and chelators as BAL and/or EDTA were used[113]. 
 
1.7. Gallium and its role in medicinal chemistry 
 
Gallium occurs in nature as Ga3+ compounds, in trace amounts in zinc ores and in 
bauxite. Its stable oxidation state in solution is +3. Ionic radius (0.062 nm) and high 
charge dictate that Ga3+ is a hard acid in the HASAB theory, forming the strongest 
complexes with hard ligands such as hydroxide, fluoride, sulphate and phosphate, and 
weaker complexes with chloride and bisulfide ligands[6]. Ga3+ contains a full 
complement of 10 d-electrons in its valence shell, leading to high degree of covalent 
bonding in complexes compared to Al3+[114]. Although gallium has no natural function 
in biology, gallium ions interact with processes in the body in a similar manner to Fe3+. 
Indeed, in many pathological proliferating cells processes (which involve Fe3+ uptake), 
the presence of Ga3+ can induce an antiproliferative effect, particularly in cancer cells 
and some bacteria[115],[116] ,[117],[118]. Non-redox-active Ga3+ can inhibit (redox-active) 
Fe3+-dependent pathways, including iron pathways in bacteria[119]. Moreover the 
possibility of using various ligands as metal carriers in chemotherapy has increased the 
need of a more exhaustive study of the aqueous coordination chemistry of gallium and 
its complexes[120] in order to design and modulate new and improved anti-tumour 
agents[121]. Gallium nitrate (Ga(NO3)3, Ganite) can suppress the growth of 
subcutaneously implanted tumours and it has completed a phase I clinical trial for 
treatment of children with brain tumours, neuroblastoma, rhabdomyosarcoma, non-
Hodgkin’s lymphoma and refractory solid tumours and phase II trials in patients with 
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relapsed or refractory non-Hodgkin’s lymphoma. Gallium nitrate is also currently in 
phase I clinical trials for cystic fibrosis suffering patients[99],[119]. 
Gallium radioisotopes have been used for decades in diagnostic and medicinal 
chemistry[122] and nowadays their importance is ever increasing with the evolution of 
positron emission tomography (PET) in clinical use for imaging. Radiometal ions must 
be sequestered from aqueous solution by chelators to obviate transchelation and 
hydrolysis. The most typical ligands used to create radiopharmaceutical agents are 
bifunctional chelators (BFCs) (Figure 1.15)[89]. The chelator is tightly bound to the 
radiometal ion, thus, once is injected into a patient, the targeting molecule can 
selectively deliver the isotope without its loss from the radiopharmaceutical agent.  
 
 
Figure 1.15. Illustration of a radiopharmaceutical agent containing a bifunctional chelator (BFCs) conjugated 
to a target molecule (e.g. antibody, peptide, nanoparticle). 
 
Therefore radiopharmaceuticals supply a site-specific radioactive source in vivo for 
imaging or therapy. The radioisotope 67Ga (t1/2 = 3.25 days) has been increasingly used 
for single photon emission computed tomography (SPECT) imaging in chelator-based 
radiopharmaceuticals[122]. 68Ga has suitable properties for high quality emission 
tomography (PET) imaging, including a short half-life (t1/2 = 68 min), decay by 89% 
positron emission and a maximum positron energy of 1.899 keV, as well as the 
availability of a cost-effective generator system  68Ge/68Ga[123],[124].  67Ga is usually used 
as a model for 68Ga in labelling studies experiments because of its longer half-life, 
which makes it more suitable for in vitro assays than 68Ga. The success of a 
radiopharmaceutical is strongly dependent on its high thermodynamic stability and 
kinetic inertness to prevent hydrolytic demetallation and/or transmetallation by 
competitive endogenous molecules in vivo[125]. Specifically, the iron binding protein 
apo-transferrin has high affinity for Ga3+ because of the physical similarities with Fe3+. 
Hence, it is important that the thermodynamic stabilities of the radiometal-chelate 
complexes be higher than those for any endogenous ligands.  
The polydentate aminocarboxylates macrocycles NOTA and DOTA (Figure 1.16) have 
been radiolabelled by coordination with 68Ga and extrafunctionalized with specific 
targeting molecules with promising results[124],[126]. Many attempts to find chelators with 
comparable kinetic inertness and thermodynamic stability have been involved the 
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synthesis of new chelators. A tripodal-based ligand with relevant feature for medical 
applications was synthesized by the group of Santos[125] ((NTP(PrHP)3 Figure 1.9), the 
thermodynamic stability studies of the Ga3+-complexes with the tris-hydroxypyrydinone 
ligand gave evidence of a higher stability compared with that of the Ga3+ complexes 
with the commercially available DOTA, EDTA, DFO, DTPA or even transferrin, 
preventing transmetallation and/or demetallation in vivo. A family of acyclic 
bifunctional chelating ligands were synthesized by the group of Orvig with optimal 
properties for the field of gallium radiopharmaceutical chemistry[127],[128],[129] (Figure 
1.16). H2dedpa ligand and its derivatives, although they are acyclic systems, form more 
stable complexes with Ga and radiolabel with Ga isotopes under mild-room temperature 
conditions and short reaction times, being comparable results with the macrocyclic 
chelate in use NOTA and exceeding the properties of DOTA, and other new Ga3+ 
ligands such as triazacyclononane-phosphinic acid chelators (TRAP) (Figure 
1.16)[130],[131]. 
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1.8. Lanthanides and its applications in bone disorders 
 
There is no known biochemical role of lanthanides in organisms, even though they 
interact with biological materials in specific ways which made them useful probes for 
therapeutic applications. The role of lanthanides in studies of Ca2+ biochemistry was 
first predicted by Williams and Birnbaum[132]. Ln3+ ions are isomorphic replacements of 
Ca2+ ions[133],[134], and rare earth metal ions may be used to probe calcium binding sites 
in proteins by evidences in changes in the absorption spectrum of a lanthanide upon 
binding to a protein (differently from the spectroscopically silent Ca2+ ions, lanthanide 
ions Ln3+ possess useful spectroscopic properties)[134]. The ability of Ln3+ in replacing 
Ca2+ ions resides on similarities in their chemistry. Thus, lanthanide ions form 
complexes primarily electrostatic in nature and analogous to those formed by the 
calcium ions. They have no crystal field stabilization energy (about 4.18 kJ∙mol-1, while 
for transition metals is typically ≥ 418 kJ∙mol-1) and negligible f-orbital-directing steric 
forces. The coordination number varies from 3 to 12. Although Ln3+ and Ca2+ have 
almost the same size, the trivalency in lanthanides confers them a much higher charge to 
volume ratio, so that they usually have much higher affinities than Ca2+ for given 
binding sites. Ca2+ and  Ln3+ share almost the same coordination numbers in protein 
binding sites[132].  
Lanthanides are considered bone-seekers as they have high affinity for bone due to the 
interaction with the inorganic phosphate in hydroxyapatite. Important and interesting 
properties of biological and synthetic hydroxyapatite (Ca5(PO4)3(OH), HAP), the main 
mineral component of bone and dental tissues, are that is a porous structure that is 
constantly being remodelled within the bone cycle, and can undergo substitution of both 
cations (Ca2+) and anions (PO43- and/or OH-)[135],[136],[137],[138]. HAP ceramics are able to 
conduct new bone formation on their surface. In biological systems, the affinity of 
153Sm for Ca2+ in hydroxyapatite is used to treat pain associated with terminal bone 
cancer, whereas Gd3+ and Tb3+ are used as bone-targeting contrast agents. La2CO3 
(Fosrenol) was approved in 2004 for treatment of hyperphosphatemia [139], an electrolyte 
imbalance that results in elevated serum phosphorous levels, and also inhibits osteoclast 
activity while stimulating osteoblast proliferation[140]. Fosrenol acts by binding 
phosphate and reducing its absorption by the formation of insoluble lanthanum 
phosphate complexes (Ksp = 4.0 x 10-23) which can pass through the gastrointestinal 
tract unabsorbed[141]. In vitro experiments show that La3+ binds to phosphate in the pH 
range 3 – 7. However, the low oral bioavailability of Fosrenol related to its strong 
elimination through the GI tract, have stimulated research for new lanthanide 
compounds with an increased oral availability and decreased unwanted effects.  
A series of 3-hydroxy-4-pyridinone ligands and a hexadentate phosphinate-EDTA 
derivative (Figure 1.17) were synthesized and coordinated to lanthanide ions by the 
group of Orvig[142],[143], in order to verify if ion exchange with hydroxyapatite was 
possible. Their complex formation equilibria with La3+ and Gd3+, the extent of 
bioavailability and the cytotoxicity of the lanthanide complexes were studied. The 
introduction of the phosphinate group in the phosphinate-EDTA ligand was selected due 
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to the high affinity in vivo of phosphonate and phosphinate functional groups for bone. 
Low toxicity profiles were found in MG-63 cells (cells derived from a human 
osteosarcoma[144]). Lanthanide complex binding studies with HAP in vitro were made 
under physiological conditions and they show that lanthanide ions interact with HAP, 
but it is not clear if it is a surface interaction or if the Ln3+ is incorporated into the HAP 
crystal lattice[142].  
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 Figure 1.17. A summary of the ligands synthesized and studied with La3+ and Gd3+, for their potential 
application for the treatment of osteoporosis. 
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1.9. Ligands 
 
1.9.1. Bidentate ligand, (5-hydroxy-2-(hydroxymethyl)pyridin-4(1H)-one, P1) 
 
As described in section 1.3.1.5, hydroxypyridinone ligands have been extensively 
studied as candidates for orally active iron chelators since the 1980s. Indeed, the 
European Union approved 3-hydroxy-1,2-dimethylpyridin-4(1H)-one (Deferiprone, 
DFP) as a clinical chelating agent for iron overload diseases in 2000. HPOs can be 
easily functionalized to improve their chelating properties, to change the lipophilicity 
and solubility and to gain additional properties such as fluorescence.  
Scheme 1. Chelating hydroxypyridinones and their abbreviations. 
 
Only a few HPOs derivatives with hydrogen in position 1 are known, and 5-hydroxy-2-
(hydroxymethyl)pyridin-4(1H)-one (P1) (Scheme 1 and 6), with its tautomeric forms, 
has only been considered in computational studies not accompanied by experimental 
studies[145]. Although different authors have debated about tautomeric equilibrium of the 
free DFP ligand and its derivatives, no tautomeric equilibrium in the corresponding 
metal complexes has been experimentally proven. 
The tautomers are usually characterized by different hydrophobicity, pK and structure, 
and therefore different coordination ability. In this respect, the influence of medium 
polarity may be highly significant since a biological system involves either an aqueous 
medium (blood or plasma), or an essentially non-protic medium such as a cell 
membrane or even an enzymatic reaction center.[146] Based on these concerns, we 
considered that metal coordination may be improved in 3,4-hopo with N-H in position 
1. Therefore, in this thesis for the first time a study of 5-hydroxy-2-
(hydroxymethyl)pyridin-4(1H)-one (P1) is presented (a paper on the characterization of 
P1 and of its Fe3+, Al3+, Cu2+ and Zn2+ has been accepted for publication in Dalton 
Transactions)[147], by combining computational, chemical, and biological approaches. 
The use of complementary analytical techniques has allowed us to give evidence of the 
tautomeric changes of P1 as a function of pH, and to determine all of their possible 
forms and properties. We also present the coordination ability of P1 with the Fe3+ and 
Al3+ ions, as well as with the essential Cu2+ and Zn2+ ions, together with biodistribution 
studies on mice to evaluate in vivo its efficacy. 
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1.9.2. Tetradentate (L12-L15 and KβAK) ligands 
 
1.9.2.1.  L12-L15 ligands 
 
Among the tetradentate kojic acid derivatives synthetized in our research group (Figure 
1.8 in section 1.3.1.6), those characterized by the shorter linker present the highest 
values both of pAl and pFe (pM being the parameter generally used to evaluate the 
overall ability of a chelating agent toward a given metal ion, M[148]), i.e. the ligands L1, 
L2, L3 and L8 (Table 1.2). 
 
Table 1.2. pFe and pAl values for L1-L9 ligands. 
 KA L1 L2 L3 L4 L5 L6 L8 L9 
pFe 13.3 23.1 18.9 22.2 18.1 19.3 17.7 20.0 17.7 
pAl 9.1 12.8 11.9 13.9 11.4 11.6 11.8 14.4 10.3 
pM = -log10(Ml) calculated at [M] = 1*10-6 M, [L] = 1*10-5 M and pH = 7.4. 
 
Since L3, bearing a vanillin residue in the linker (Figure 1.8), presents an extremely 
good chelating ability, we synthesized a series of analogous molecules containing the 
different substituents in the linker shown in Scheme 2. These substitutions were 
intended to evaluate how the value of protonation constants can affect the pAl and pFe 
values, being a phenolic group characterized by a pK ∼ 9 and a carboxylic group by a 
pK ∼ 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2. Synthesized ligands L12, L13, L14 and L15. 
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1.9.2.2.  KβAK ligand 
 
Several previous reports have described kojic acid and its derivatives as inhibitors of 
melanin formation, both in vitro and in vivo[149],[150], speculating on a possible role for 
copper coordination mechanisms[151]. In 2011, Fishman et. al. determined a tyrosinase 
structure from Bacillus megaterium (TyrBm) with bound kojic acid, the first tyrosinase 
structure with a bound ligand. The kojic acid molecule occupies identical positions in 
both subunits of TyrBm and it is bound strongly by interactions with Phe, Pro, Asn and 
Arg residues. As opposed to the previously suggested modes for copper complex 
formation, the ligand was oriented with the hydroxymethyl towards the active site at the 
relatively far distance of 7 Å. Hence, the position and orientation of kojic acid causes an 
obstruction of the active site that could lead to inhibition of the tyrosinase enzyme.   
In literature different kojic acid derivatives are reported as tyrosinase inhibitors. These 
studies mainly investigated the ability of the synthesized kojic acid derivatives to 
improve inhibitory properties by converting the methylene hydroxyl group into 
ester[152], hydroxylphenyl ester[153], glycoside[154] and amino acid 
derivatives[155],[156],[157],[158].   
Kojic acid was reported as well as chelating agent for trivalent and bivalent metal 
ions[159],[160],[161],[162]. Encouraged by the promising results obtained in our previous 
reports of L1-L9 kojic acid derivatives (Figure 1.8) [33],[35],[163],[37],[36] , Kojic-βAla-Kojic 
ligand (Scheme 6) was synthesized. We studied Fe3+, Al3+, Zn2+ and Cu2+ complexes 
and compared the results with previously published data. Moreover, the tyrosinase 
inhibition efficacy of the new molecule was evaluated and compared with low effective 
inhibitors of melanin[27-30] in order to know whether two kojic acids were better than 
one and if the length and kind of linker could improve inhibitory activity. 
1.9.3. Hexadentate ligand (SC)  
 
A hexadentate hydroxypyrone ligand, 6,6',6''-(((nitrilotris(ethane-2,1-diyl))tris 
(azanediyl))tris(methylene))tris(3-hydroxy-4H-pyran-4-one) named SC, was 
synthesized to improve the coordination towards Fe3+ and other tripositive metal cations 
(Scheme 3). Complex formation equilibria are presented in section 3.3.5. with Fe3+ and 
Ga3+. 
 
 
 
 
 
 
 
Scheme 3. Reaction scheme for the hexadentate ligand SC. 
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As mentioned in section 1.2, complex formation is entropically favoured by ligands in 
the order hexadentate > tetradentate > tridentate > bidentate. Moreover hexadentate 
ligands can adequately protect the metal ion from deleterious reactions, providing a 
shield of the surface of the metal and avoiding the exposition of the metal to the 
biological environment, with the consequent interactions with molecules that can led to 
the production of ROS. Stability constants and pM values provide a number for the 
direction and magnitude of the equilibrium in a metal-chelate coordination reaction 
under specific conditions, but they do not give any kinetic information such as 
dissociation rate[164],[165]. The rate of dissociation in vivo is a very important factor 
because determines the kinetic inertness of a metal-complex, regardless of 
thermodynamically stability. It is influenced by the highly dilution encountered in vivo, 
when a very tiny concentration of pharmaceutical agent is diluted into the blood pool 
for diagnosis or therapeutic purposes and it will encounter other endogenous ligands 
such as transferrin or ceruloplasmin that will compete for binding the metal and 
disturbing in vivo stability. Due to these kinetic reasons, hexadentate ligands can chelate 
metal ions at low metal concentrations more efficiently than bidentate or tetradentate 
ligands. In fact, considering the dissociation of bidentate (Lb), tetradentate (Lt) and 
hexadentate (Lh) ligands and the equations: 
M(Lb)3 ⇋ M3+ + 3Lb           k'd = [M3+] [Lb]3/[M(Lb)3] 
M(Lt)3/2 ⇋ M3+ + 3/2Lt        k''d = [M3+] [Lt]3/2/[M(Lt)3/2] 
MLh ⇋ M3+ + Lh                 k'''d = [M3+] [Lh]/[MLh] 
 
where k'd, k''d, k'''d are the dissociation equilibrium constants, since the degree of 
dissociation for bidentate ligands depends on [ligand]3, for tetradentate on [ligand]3/2 
and for hexadentate on [ligand], the dilution dependence follows the order hexadentate < 
tetradentate < bidentate.  
 
1.9.4. Losartan and Irbesartan 
 
In section 1.5, the effects of Cu2+ disregulation in cardiovascular complications in 
diabetic patients were outlined, as well as the amelioration of these conditions by 
chelation therapy. In diabetic patients treated with sartans, an improvement of arterial 
complications was found (independently of lowering pressure), related with Cu2+ 
lowered levels[166], raising the possibility that sartans act in this case with a different 
mechanism. Since Losartan and Irbesartan (Scheme 4), registered in the USA and 
Europe for the treatment of cardiovascular disease in diabetic and non-diabetic patients, 
contain several nitrogen atoms at distances consistent with the existence of potential 
Cu2+-binding sites[167], we hypothesized that sartan molecules could demonstrate Cu2+ 
binding properties. For these reasons complex formation equilibria with the essential 
metal ions Cu2+ and Zn2+ were studied, in collaboration with Prof. Garth Cooper from 
the University of Manchester. 
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Scheme 4. Molecular structures of Irbesartan (A) and Losartan (B).  The structural differences between 
molecules are marked in red. 
 
1.9.5. Picolinic acid derivatives ligands (H4pedpa, H6dipedpa) 
 
In the frame of the research by the group of Prof. Chris Orvig on lanthanide metal-based 
complexes for the treatment of bone disorders (section 1.8), during my three month 
period at the University of British Columbia a complete characterization of ligands 
H4pedpa and H6dipedpa (Scheme 5) and of their complexes with La3+ was made. Both 
ligands, bearing phosphonate groups, have high affinity towards bone and in particular 
to HAP. While a lanthanum complex with H4pedpa could potentially be used to treat 
bone disorders such as osteoporosis, H6dipedpa, like its analogous H6phospa[168], could 
demonstrate interesting chelating ability towards the radioisotope 89Zr. Thus it could be 
an alternative to DFO, the only chelator proven to be enough competent for the use with 
89Zr in positron emission tomography (PET) imaging.  
 
 
 
 
 
 
 
 
 
Scheme 5. Acyclic chelators H4peda and H6dipedpa and the recently published and promising H6phospa 
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2. Experimental section 
2.1. Materials and methods 
 
HCl, NaCl, NaOH, ethanol, ethyl acetate, ammonia, benzyl chloride, D2O, DCl, NaOD, 
FeCl3, AlCl3, CuCl2, formaldehyde, 4-formylbenzoic acid, 2-formylbenzoic acid, 4-
hydroxybenzaldehyde, 2-hydroxybenzaldehyde, tris(2-aminoethyl)amine (purity 99%, 
used without further purification) were Sigma Aldrich products, Desferal (DFO) was 
obtained from Biofutura Pharma products, 5-hydroxy-2-hydroxymethyl-pyran-4-one 
(kojic acid) was purchased from Fluka, Standard AAS solutions of Ga3+ and La3+ were 
purchased from Sigma Aldrich. Gallium Citrate 67Ga for biodistribution studies was 
purchased by Mallinckrodt Medical B.V. Potassium Losartan and Irbesartan were 
purchased from TCI Europe. L1-L15, KβAK and SC ligands were synthesized in ours 
laboratories, while H4pedpa and H6dipedpa were synthesized by the PhD student David 
Weekes in the laboratories of Prof. Orvig. 
Fe3+, Al3+, Cu2+ and Zn2+ metal ion standard solutions were prepared by dissolving the 
required amount of chloride salts in pure double distilled water and adding a 
stoichiometric amount of HCl to prevent hydrolysis. The spectrophotometric analysis of 
Fe3+-Desferal complex was used to standardized Fe3+ solution, while EDTA titrations 
were used to standardized Al3+, Cu2+ and Zn2+ solutions. Carbonate-free 0.1 M NaOH 
solution was prepared as reported in a previous papers[169]. 
2.1.1. Elemental analysis 
 
Elemental data were obtained using a Fisons EA1108 CHNS/O. The melting points 
were measured on a Leica Galen III hot stage apparatus and are uncorrected. 
2.1.2. NMR measurements 
 
NMR measurements were performed at the Department of Chemistry and Pharmacy at 
the University of Sassari-Italy, on a Bruker AscendTM 400 MHz spectrometer equipped 
with a 5 mm automated tuning and matching broad band probe (BBFO) with z-
gradients, as previously described.[170],[171],[172] NMR experiments were carried out by 
using 5-7 mM concentration of the ligands in different solvents, D2O, MeOD or DMSO 
at 25˚C in 5 mm NMR tubes. The pH of the solutions was adjusted with diluted DCl 
and NaOD on a pH meter Crison micro TT 2050 pH meter with an electrode Mettler 
Toledo InLab 422. The pD values measured in D2O solutions were converted to the pH 
values by using the deuterium isotopic relation pH = pD–0.4. A stock acidic deuterated 
aqueous solution of ZnCl2 salt was used in the metal-ligand titration analysis. The metal 
ion solution was added to Irbesartan and Losartan ligand solutions (80:20 MeOD:D2O 
solution) and in the case of P1, L1-L8 in water, and the pH was then set to the right 
value just before the acquisition of the spectra. 2-D 1H-13C heteronuclear correlation 
spectra (HSQC) were acquired by using a phase-sensitive sequence employing Echo-
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Antiecho-TPPI gradient selection with a heteronuclear coupling constant JXH = 145 Hz, 
and shaped pulses for all 180° pulses on f2 channel with decoupling during acquisition. 
Sensitivity improvement and gradients in back-inept were also used. Relaxation delays 
of 2s and 90° pulses of about 10 μs were employed in all the experiments. Solvent 
suppression for 1D 1H, 2D 1H-1H TOCSY (total correlation spectroscopy) experiments 
were carried out by using excitation sculpting with gradients. The spin-lock mixing time 
of TOCSY experiments was obtained with MLEV17. 1H-1H TOCSYs were performed 
by using mixing times of 60 ms. A combination of 1D, 2D TOCSY, HSQC experiments 
was used to assign the signals of both free and metal-bound ligands at different pH 
values. All NMR data were processed with TopSpin (Bruker Instruments) software and 
analyzed by Sparky 3.11 and MestRe Nova 6.0.2 (Mestrelab Research S.L.) programs.  
2.1.3. Electrospray ionization-mass spectrometry (ESI-MS) 
 
High-resolution mass spectra were performed in collaboration with the University of 
Wroclaw-Poland using a Bruker MicrO-TOF-Q spectrometer (Bruker Daltonik, 
Bremen, Germany), equipped with an Apollo II electrospray ionization source with an 
ion funnel. The spectra were recorded in the positive ion mode in the range 100 to 1500 
m/z. The instrument parameters were: dry gas–nitrogen, temperature 200 °C, ion source 
voltage 4500 V, collision energy 10 eV. Analyte aqueous solutions (70 μl) were 
introduced at a flow rate of 3 μl/min. Stock solutions were prepared by using 
MeOH/H2O mixture (50/50 v/v) as a solvent. The metal to ligand molar ratio was 1:1. 
The final pH of the solution was 4.0. The instrument was calibrated using the Tunemix 
mixture (BrukerDaltonik, Germany) in the quadratic regression mode. The overall 
charge of the analyzed ion was calculated on the base of distance between isotopic 
peaks. Data were processed by application of the Compass DataAnalysis 4.0 (Bruker 
Daltonik, Germany) program. 
2.1.4. Calorimetry 
 
∆H° e ∆S° values were obtained with calorimetric titrations performed in collaboration 
with the University of Ferrara-Italy in the laboratories of Prof. Maurizio Remelli, on a 
Tronac 450 calorimeter equipped with a 25 mL Dewar titration vessel; the titrant 
solution was added using a 2 mL Hamilton syringe also in the thermostatic bath. A 
warming resistance (about 100 Ω) and a thermistor put into the solution allowed the 
instrument electric calibration and the detection of temperature variations respectively. 
The accuracy was daily checked by titrating a tris(hydroxy methyl)aminomethane 
solution partially neutralized with nitric acid. The thermostatic bath was at 25.00 ± 0.02 
°C. The completely automated system was managed by a PC via Tronac 900 interface. 
The potential difference at thermistor ends was measured by a digital multimeter 
FLUKE 8840A. Home-made programs for the management of the calorimetric system 
and data acquisition and for gross heat correction from non-chemical factors[173] were all 
in BASIC language. The ionic strength was adjusted at 0.1 M with KCl. ΔH° values 
were computed from the calorimetric data by means of the least-squares computer 
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program HypDH[174], which minimizes the function: U = Σwi(Qio – Qic)2, where wi are 
statistical weights and Qio, Qic are the experimental and calculated heats, respectively, 
over n observations. A literature ΔH°w value of 56.4 kJ mol-1, was used in the 
calculations[175]. From experimental ΔH° values the corresponding ΔS° values were 
computed by means of the Gibbs-Helmholtz equation: -ΔG° = -ΔH° + TΔS°, where the 
free energy variation was calculated by the corresponding cumulative constants (β), 
given by potentiometry:  
-ΔG° = 2.303 RT log β. 
2.1.5. X-ray diffraction (XRD) studies 
 
Crystallographic studies were performed at the University of Granada-Spain in the 
laboratories of Dr. Duane Chosquesillo and Prof. Juan Niclós-Gutiérrez. Crystals of L1 
ligand suitable for XRD were grown by slow evaporation of a solution of the compound 
(5 mg, in water:ethanol 70:30) placed in an opened vessel in air at room temperature. 
Single crystals of P1 were grown by slow evaporation of a methanol solution (30 mg in 
3mL at 50 ºC). Crystals from L13 and L14 ligands were furthermore obtained, and their 
relative data analysis are being processed. The single crystal was protected at inert 
conditions in perfluoropolyether, mounted on MiTeGen Micromount and used for data 
collection on a Bruker D8 Venture diffractometer (100 K, MoKα). The data were 
processed with APEX2[176] and corrected for absorption using SADABS[177]. The 
structure was solved by direct methods[178], which revealed the position of all non-
hydrogen atoms. These atoms were refined on F2 by a full-matrix least-squares 
procedure using anisotropic displacement parameters. All hydrogen atoms were located 
in difference Fourier maps and included as fixed contributions riding on attached atoms 
with isotropic thermal displacement parameters 1.2 (C−H) or 1.5 (O−H) times those of 
the respective atom.  
2.1.6. Potentiometry 
 
The potentiometric studies of protonation and complex formation equilibria were 
performed with the use of thermostatted glass cell equipped with a magnetic stirrer, a 
Metrohm LL UNITRODE glass electrode, Metrohm 691 pH-meter, a Dosimat 665 
Metrohm titrator, and under the flow of Argon. Titrations were performed at 25.0 °C 
using 0.1 M NaOH and 0.1 M NaCl as an ionic strength buffer. The electrode was 
calibrated daily for hydrogen ion concentration by HCl/NaOH titration in the above 
experimental conditions and the results were analyzed with Gran procedure[179]. 
Working ligand concentrations were: 1 mM (L7, L12-L15, SC, KβAK, H4pedpa and 
H6dipedpa), 0.4 mM (L1, L6), 0.5 mM (L2-L5) 0.8 mM (L8) and 0.5 mM (losartan and 
irbesartan) in 30:70 and 80:20 MeOH/H2O mixtures, depending on ligand solubility in 
water. Potentiometric data were processed by Hyperquad2013 program[180].  
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2.1.7. Spectrophotometry UV-Vis 
 
UV-Visible studies were carried out on a Varian Cary 50 UV/Vis Spectrophotometer. 
Ligand protonation equilibria were studied by titrating 20 mL of 0.5 mM ligand 
solutions[181] with 0.1 M NaOH at 0.1 M NaCl ionic strength using a joined 
potentiometric-spectrophotometric procedure. Spectra were recorded in the 200–400 nm 
spectral range with a 0.2 cm path length fiber optic. Fe3+ complex formation studies 
were made with the use of 0.5 mM ligand concentration and metal to ligand molar ratio 
1:1. The Vis spectra were recorded in the 300-800 nm range using a 1 cm path length. 
Because of the completely filled d shell of the Ga3+ ion, it was not possible to use 
spectrophotometric measurements in the visible region of the spectra, so were studied 
the variations in the ultraviolet spectra of the chelate and the free ligand vs. pH. The 
Al3+, Cu2+ and Zn2+ complexes were studied with the use of only potentiometric 
method; 0.5mM ligand concentration and metal to ligand molar ratio 1:1. The obtained 
spectrophotometric data were processed by HypSpec program[182]. 
2.1.8. Spectrofluorimetry  
 
Fluorescence spectra of losartan and irbesartan molecules were recorded on Varian Cary 
Fluorimeter. Ligand working concentrations were 0.032 mM in 30% and 80% 
methanol/water solutions. Batch measurements at variable pH were performed by 
adding proper amounts of HCl and NaOH. UV-Vis spectra at different pH revealed an 
isosbestic point at 280 nm, so this wavelength was chosen for excitation. Emission 
spectra were registered in the 290-490 nm spectral range.  
2.1.9. EPR spectroscopy 
 
EPR spectra were recorded in collaboration with the University of Wroclaw-Poland, at 
77 K on a Bruker ELEXSYS E500 CW-EPR spectrometer equipped with an NMR 
teslameter (ER 036TM) and frequency counter (E 41 FC) at X-band frequency.  The 
solutions for EPR measurements were prepared in water by adding ethylene glycol 
(30%) as a cryoprotectant. The experimental spectra were simulated by using WINEPR 
Simfonia 1.26 program and Spin (EPR OF S>1/2) program by Dr. Andrew Ozarowski, 
National High Field Magnetic Laboratory, University of Florida. 
2.1.10. DFT calculation 
 
Theoretical calculations for P1 ligand were performed under the supervision of Prof. 
Massimiliano Arca, at Density Functional Theory (DFT) level[183] with the Gaussian 09 
package of programs (Rev. A.02)[184] on a E4 workstation equipped with four quad- 
core AMD Opteron 2.2 MHz processors and 16 Gb of RAM and running the 64 bit 
version of the Ubuntu 12.04 Linux operating system. Barone and Adamo’s mPW1PW 
hybrid functional was adopted,[185] along with the Schäfer, Horn, and Ahlrichs double-ζ 
plus polarization all-electron basis sets[186] (BS) for all atomic species. The geometry of 
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the compounds was optimized with tight SCF convergence criterion and fine numerical 
“pruned” integration grids (75 radial shells and 302 angular points per shell). The nature 
of the minima of each optimized structure was verified by harmonic frequency 
calculations. NBO charges distributions[187] and Wiberg[188] bond indices were 
calculated at the optimized geometries. Solvation calculations were carried out in the 
gas phase and water, implicitly taken into account by means of the polarizable 
continuum model (PCM) in its integral equation formalism variant (IEF-PCM).[189] The 
programs Gaussview 5.0.8,[190] and Molden 5.2.4[191] were used to investigate the charge 
distributions and optimized geometries. 
2.1.11. Partition coefficients  
 
P1 and DFP octanol/water partition coefficients (log P) were calculated at 25 °C, as the 
logarithm of the ratio of their concentrations in n-octanol phase and in aqueous phase 
(Tris, pH = 7.4), using the well-established ‘‘shake flask” method[31]. Each compound 
was added to a premixed suspension, containing 3 mL of n-octanol and 3 mL of the 
aqueous phase, and stirred for 4 h. The species concentration in the aqueous layer was 
evaluated by spectrophotometry with a Perkin Elmer Lambda 35 spectrophotometer, 
using a thermostated 1 cm path length cell, on the benzenoid bands of the compounds (λ 
= 280–290 nm). The measurements were done in triplicate and repeated three times. 
2.1.12. Biodistribution studies 
 
Biodistribution studies were performed by Prof. L. Gano at Campus Tecnológico e 
Nuclear, Instituto Superior Técnico, Universidade de Lisboa, Portugal. 67Ga-citrate 
injection solution was prepared by dilution of commercial 67Ga citrate solution with 
saline to obtain a final radioactive concentration of 5 -10 MBq/100 µL. Biodistribution 
studies were carried out in groups of 3 female Balb-C mice, weighing ca. 20-22 g 
(randomly bred, Charles River, from CRIFFA, France). Mice were intravenously 
injected with 100 µL (5 -10 MBq) of 67Ga citrate via the tail vein immediately followed 
by intraperitoneal injection of 0.35 µmol of each ligand (P1 and DFP as a control) in 
100 µL saline. Animals were maintained on normal diet ad libitum and were sacrificed 
by cervical dislocation at 1h and 24 h post-administration. The administered radioactive 
dose and the radioactivity in sacrificed animals were measured in a dose calibrator 
(Aloka, Curiemeter IGC-3, Aloka, Tokyo, Japan). The difference between the 
radioactivity in the injected and in sacrificed animal was assumed due to the whole 
body excretion. Tissue samples of main organs were then removed for counting in a 
gamma counter (Berthold LB2111, Berthold Technologies, Germany). Radioactivity 
remaining in the carcass was measured in the dose calibrator and expressed as percent 
of injected activity (%I.A.). Biodistribution results were expressed as percent of injected 
activity per gram of organ (%I.A./g) and presented as mean values ± SD.  
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2.1.13. Enzyme extraction, purification and tyrosinase activity 
 
The mushroom tyrosinase (EC 1.14.18.1) from Agaricus bisporus was purified as 
previously described[192]. Tyrosinase inhibitory activity was determined by a 
spectrophotometric method. The compound solution was prepared in 10% DMSO 
solution. Each sample was diluted in a test tube with 0.05 M sodium phosphate buffer 
(pH 6.8). This was followed by the addition of 0.04-0.35 mL (S)-2-Amino-3-(3,4-
dihydroxyphenyl)propanoic acid (L-DOPA, 10 mM) solution (in 10 mM acetic acid) 
and 0.034 mL mushroom tyrosinase (200 units/mL). The 2.000 mL solution was mixed, 
incubated for 10 min at 250C and the absorbance measured at 476 nm. The experiment 
was repeated with different inhibitor concentrations: 0.069, 0.139 and 0.279 mM. The 
absorbance of the same mixture without inhibitor was used as control with the addition 
of 10% DMSO water solution for its inhibitory effect. The percent inhibition of 
tyrosinase activity was calculated using the equation below: 
% inhibition = (A-B)/A x 100 
where A represents the absorbance at 476 nm without the test sample, and B represents 
the absorbance at 476 nm with the test sample at the same substrate concentration.  
In order to calculate IC50 values, 2 mM stock solutions of tyrosinase inhibitors (kojic 
acid and KβAK) were prepared in 10% ethanol/water mixture. IC50 values were 
determined after addition of various inhibitors amounts to enzyme assays to determine a 
range of inhibitors needed to encompass the IC50 value.  Each 1 mL assay contained a 
fixed amount of enzyme, inhibitor, 3 mM L-DOPA (final concentration), and 100 mM 
phosphate buffer (final concentration) pH 6.5. The inhibition was also characterized in 
terms of an IC50 value by using GraFit Version 7.0.3 program (Erithacus Software Ltd., 
Horley, Surrey, UK) based on the following equation: 
𝑦𝑦 = 𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅
1+�
𝑥𝑥
𝐼𝐼𝐼𝐼50
�
𝑆𝑆 + Background 
where Range is the maximum y range, and s is a slope factor. The x axis represents the 
concentration of analyte. Data fitted to this equation are displayed with a 
logarithmically scaled x axis.  
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2.2. Synthesis of ligands 
2.2.1. P1 
 
Synthesis of 5-hydroxy-2-(hydroxymethyl)pyridin-4(1H)-one (P1) 
5-hydroxy-2-(hydroxymethyl)pyridin-4(1H)-one was obtained from kojic acid (KA), 
following a standard synthetic procedure, previously described for the preparation of 
other pyridinones[31]. The first step involved the protection of the 5-hydroxyl group of 
KA with a benzyl group, by reaction with benzyl chloride and formation of 5-
(benzyloxy)-2-(hydroxymethyl)-4H-pyran-4-one. This was converted in the 
corresponding pyridinone, 5-benzyloxy-2-(hydroxymethyl)-pyridin-4(1H)-one, by 
reaction with an ammonia aqueous solution under reflux (Michael addition, ring 
opening/closure, and dehydration). The benzyl protecting group was then removed by 
catalytic hydrogenolysis providing the final product P1. 
Scheme 6. Synthesis of P1. 
 
5-Benzyloxy-2-(hydroxymethyl)-4H-pyran-4-one 
Sodium hydroxide aqueous solution 11 M (10 mL) was added to 100 mL of a solution 
of KA (14.2 g, 100 mmol) in MeOH and the mixture was heated under reflux. Benzyl 
chloride (12.75 mL, 111 mmol) was added dropwise, and the reaction mixture was 
refluxed overnight. Once the reaction finished (checked by TLC; eluent: DCM/MeOH, 
1:0.75), the mixture was cooled to room temperature. The precipitate was filtered and 
washed with an ethylic ether/petroleum ether mixture to obtain a light brown solid 
(18.016 g, 77% yield); M.p. 129 -131 °C (lit. value 129-130°C[193] and 132°C[194]). 1H 
NMR (300 Hz, MeOD), δ (ppm): 8.01 (s, 1H, 6-HPy), 7.44–7.32 (m, 5H, HPh), 6.51 (s, 
1H, 3-HPy), 5.02 (s, 2H, CH2-Bz), 4.41 (s, 2H, CH2-OH). 
5-Benzyloxy-2-(hydroxymethyl)-pyridin-4(1H)-one   
5-Benzyloxy-2-(hydroxymethyl)-4H-pyran-4-one (6.25 g, 26.91 mmol) was dissolved 
in methanol (25 mL) and then 25% ammonia aqueous solution (57.5 mL) was added. 
The mixture was refluxed in oil bath for 7 hours and the progress of the reaction was 
monitored by TLC (eluent: DMC/MeOH 6:0.75 solvent mixture). The reaction mixture 
was concentrated in a rotary evaporator to obtain a pale brown solid residue, which was 
recrystallized from ethanol/ethyl ether, leaving the pure target compound as beige 
product (5.659 g, 90% yield); M.p. 224 °C (lit. value 225-226 °C[193]). 1H NMR (300 
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Hz, DMSO), δ (ppm): 11.3 (s, 1H, NH), 7.42 -7.30 (m, 5H, HPh), 6.11 (s, 1H, 6-HPy), 
5.70 (s, 1H, 3-HPy), 5.00 (s, 2H, CH2-Bz), 4.33 (s, 2H, CH2-OH). 
5-Hydroxy-2-(hydroxymethyl)pyridin-4(1H)-one (P1) 
5-Benzyloxy-2-(hydroxymethyl)-pyridin-4(1H)-one (2.542 g, 10.99 mmol) was 
dissolved in methanol (200 mL) and 10% Pd/C (0.258 g) was added. The suspension 
was stirred for 4 h under H2 atmosphere (2 bar). Afterwards the mixture was filtered and 
the solvent evaporated. Final recrystallization from EtOH/Et2O afforded the pure 
product a pale brown color (1.065 g, 70% yield); M.p. 245-247 °C. 1H NMR (300 Hz, 
MeOD), δ (ppm): 7.48 (s, 1H, 6-HPy), 6.44 (1s, 1H, 3-H-Py), 4.55 (s, 2H, CH2-OH). 
13C NMR (400 Hz, D2O), δ (ppm): 171.73 (C=O), 147.43 (C-OH), 145.65 (2-C-Py), 
121.71 (6-C-Py), 111.09 (3-C-Py), 59.52 (CH2OH). Elemental analysis (%) calculated 
for (C6H7NO3 0.1H2O): C 50.40; H 5.08, N 9.80%; found: C 50.43, H 5.12, N 9.65%. 
2.2.2. L12 
 
2-{bis[3-hydroxy-6-(hydroxymethyl)-4-oxo-4H-pyran-2-yl]methyl} benzoic acid 
0.3970 g (3.53 mmol) of dimethylamine and 0.5255 g (3.5 mmol) of 2-formylbenzoic 
acid were dissolved in 2 mL of EtOH and stirred at room temperature for 30 min. The 
solution was added dropwise into 20 ml ethanolic solution of kojic acid 1.0015 g (7.05 
mmol). The reaction was carried out at room temperature for 24h; then the mixture was 
kept at -5C for 2h and the excess of substrate was filtered. The solvent was evaporated 
under reduced pressure. After extracting the sample using a saturated sodium carbonate 
solution, the water fraction was acidified with 2M HCl and above pH 3 a white 
precipitate appeared. The product was then filtered and washed with ethyl acetate and 
cold ethanol. Melting point 225ºC, Analytical data: 60.58 % yield, ESI–MS Found: 
415.066 m/z; calculated 415.066 m/z for (C20H16O10-H)-, 1H NMR (D2O, 500 MHz) δ 
4.31 (s, 4H, CH2-OH), 6.49 (s, 2H), 6.71 (s, 2H), 7.28 (d, 1H), 7.41 (m, 2H), 7.67 (d, 
1H). 
2.2.3. L13 
 
4-{bis[3-hydroxy-6-(hydroxymethyl)-4-oxo-4H-pyran-2-yl]methyl} benzoic acid 
0.4045 g (3.27 mmol) of dimethylamine and 0.50315 g (3.35 mmol) of 2-formylbenzoic 
acid were dissolved in 2 mL of EtOH and  stirred at room temperature for 30 min. The 
solution was added dropwise into 20 ml ethanolic solution of kojic acid 1.0004 g (7.04 
mmol). The reaction was carried out at room temperature for 24h; then the mixture was 
kept at -5C for 2h and the excess of substrate was filtered. The solvent was evaporated 
under reduced pressure. After extracting the sample using a saturated sodium carbonate 
solution, the water fraction was acidified with 2M HCl. The reaction product was then 
filtered and washed with ethyl acetate and cold ethanol. Melting point 250ºC, Analytical 
data: 62.67 % yield, ESI–MS Found: 417.074 m/z; calculated 417.082 m/z for 
(C20H16O10+H)+, 1H NMR (D2O, 500 MHz) δ 4.34 (s, 2H), 6.21 (s, 1H), 6.49 (s, 2H), 
7.40 (d, 2H), 7.87 (d, 2H). 
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2.2.4. L14 
 
2,2'-[(2-hydroxyphenyl)methanediyl]bis[3-hydroxy-6-(hydroxymethyl)-4H-pyran-
4-one] 
0.4049 g (3.60 mmol) of dimethylamine and 0.4327 g (3.54 mmol) of 2-formylbenzoic 
acid were dissolved in 2 mL of EtOH and stirred at room temperature for 30 min. The 
solution was added dropwise into 20 ml ethanolic solution of kojic acid 1.0106 g (7.11 
mmol). The reaction was carried out at room temperature for 24h; then the mixture was 
kept at -5C for 2h and the excess of substrate was filtered. The solvent was evaporated 
under reduced pressure. After extracting the sample using a saturated sodium carbonate 
solution, the water fraction was acidified with 2M HCl. The reaction product was then 
filtered and washed with ethyl acetate and cold ethanol. Melting point 255ºC, Analytical 
data: 69.38 % yield, ESI–MS Found: 389.076 m/z; calculated: 389.082 m/z for 
(C19H16O9+H)+, 1H NMR (D2O, 500 MHz) δ 4.33 (s, 4H), 6.29 (s, 1H), 6.50 (s, 2H), 
6.89 (m, 2H), 7.11 (d, 1H), 7.22 (t, 1H). 
2.2.5. L15 
 
2,2'-[(4-hydroxyphenyl)methanediyl]bis[3-hydroxy-6-(hydroxymethyl)-4H-pyran-
4-one] 
0.4124 g (3.67 mmol) of dimethylamine and 0.4280 g (3.5 mmol) of 2-formylbenzoic 
acid were dissolved in 2 mL of EtOH and stirred at room temperature for 30 min. The 
solution was added dropwise into 20 ml ethanolic solution of kojic acid 1.0842 g (7.6 
mmol). The reaction was carried out at room temperature for 24h; then the mixture was 
kept at -5C for 2h and the excess of substrate was filtered. The solvent was evaporated 
under reduced pressure. After extracting the sample using a saturated sodium carbonate 
solution, the water fraction was acidified with 2M HCl. The reaction product was then 
filtered and washed with ethyl acetate and cold ethanol. Melting point 285ºC, Analytical 
data: 71.81 % yield, ESI–MS Found: 389.078 m/z; calculated 389.078 m/z for 
(C20H16O10+H)+, 1H NMR (D2O, 500 MHz) δ 4.36 (s, 4H), 6.07 (s, 1H), 6.48 (s, 2H), 
6.82 (d, 2H), 7.22 (d, 2H).  
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2.2.6. KβAK 
 
The synthesis was performed according to a recently described method[195](Scheme 7).  
 
 
Scheme 7. Synthesis of (5-hydroxy-4-oxo-4H-pyran-2-yl)methyl 3-({[(5-hydroxy-4-oxo-4H-pyran-2 
yl)methoxy]carbonyl}amino)propanoate (Kojic-βAla-Kojic, KβAK). 
 
Synthesis of (5-hydroxy-4-oxo-4H-pyran-2-yl)methyl 3-({[(5-hydroxy-4-oxo-4H-
pyran-2 yl)methoxy]carbonyl}amino)propanoate (Kojic-βAla-Kojic, KβAK) 
Kojic acid (5.4 g, 38 mmol) and Tos-OSu (5.6 g, 21 mmol)[196],[197] were suspended in 
40 mL of dioxane followed by dropwise addition of triethylamine (8 mL). After stirring 
the reaction mixture at 65ºC for 1 h, the solvent was evaporated under reduced pressure. 
After extracting the sample using a saturated sodium carbonate solution, the water 
fraction was acidified with HCl. The reaction product was extracted with ethyl acetate 
and dried over MgSO4. The solvent was then evaporated and further purified by 
preparative HPLC according to the procedure described in below in this section. Sample 
identity and purity were confirmed by NMR, ESI-MS (Electrospray Ionization-Mass 
Spectrometry) and HPLC. 
Analytical data: 92% yield, ESI–MS Found: 382.0810 m/z; calculated 382.0769 m/z for 
(C16H15NO10)+, 1H NMR (DMSO – d6, 500 MHz) δ 2.50 (t, 2H, J = 6.6Hz), 3.18 (q, 2H, 
J = 6.4Hz, J=12.72Hz), 4.78 (s, 1.8H), 4.87 (s, 2H), 6.30 (s, 1H), 6.39 (s, 1H), 7.50 (t, 
0.8H, J = 5.5Hz), 7.99 (m, 2H). 13C NMR (DMSO-d6, 500 MHz) δ 33.64, 36.41, 61.2, 
61.3, 111.9, 112.5, 139.7, 139.8, 146.0, 155.1, 161.4, 162.5, 170.5, 173.6.  
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Synthesis of 1-{[(4-Methylphenyl)sulfonyl]oxy}pyrrolidine-2,5-dione (Tos-OSu) 
The protocol used for the synthesis of Tos-OSu was similar to that previously described 
in the literature[196],[197]. Briefly, N-Hydroxyimide (93 mmol) and tosyl chloride (100 
mmol) were dissolved in tetrahydrofuran (100 mL) and triethylamine (14.7 mL) was 
then added over 20 min. After 40 min, the solvent was removed in vacuo and 100 mL of 
5% hydrochloric acid was added. The product was filtered off, washed twice with water 
and crystallized from ethyl acetate to give Tos-OSu. Analytical data: 92% yield, ESI–
MS Found: 292.02 m/z; calculated 292.03 m/z for (C11H11NO5S +Na)+, 1H NMR 
(CDCl3, 500 MHz) δ 2.44 (s, 3H), 2.76 (s, 4H), 7.35 (d, 2H, J = 8.4 Hz), 7.87 (d, 2H, J = 
8.4 Hz). 13C NMR (CDCl3, 500 MHz) δ 21.8, 25.4, 129.6, 130.3, 131.3, 147.3, 168.7. 
 
Purification of Kojic-βAla-Kojic 
Preparative reversed-phase HPLC was performed on a Tosoh TSKgel ODS-120T 
column (21.5 mm × 300 mm) (Tosoh, Tokyo, Japan) using the same solvent system, 
gradient 0.5% min-1 and a flow rate of 7 mL min-1. The crude product was analyzed by 
analytical HPLC using a Thermo separation HPLC system with UV detection (210 nm) 
on a Vydac Protein RP C18 column (250×4.6 mm, 5 mm) (Grace, Deerfield, IL, USA), 
with a gradient elution of 0-80% B in A (A = 0.1% TFA in water; B = 0.1% TFA in 
acetonitrile - H2O, 4:1) for 45 min (flow rate 1 mL mL-1, rt). 
2.2.7. SC  
 
6,6',6''-(((nitrilotris(ethane-2,1-diyl))tris(azanediyl))tris(methylene))tris(3-
hydroxy-4H-pyran-4-one) 
Kojic acid (1.0 g, 7.04 mmol) was suspended in 20 mL ethanol followed by dropwise 
addition of tris(2-aminoethyl)amina (350 μL, 2.32 mmol) solved in CHCl3 (2 mL). After 
stirring the reaction mixture at room temperature for 1 h, the precipitate was filtered and 
washed with ethyl acetate. Sample identity and purity were confirmed by NMR and 
elemental analysis. Analytical data: 98.5% yield, 1H NMR (D2O, 500 MHz) δ 2.83 (t, 
6H, J = 2.81 Hz), 3.09 (t, 6H, J = 3.09 Hz), 4.49 (s, 6H), 6.49 (s, 3H), 7.82 (s, 3H). 13C 
NMR (D2O, 500 MHz) δ 39.84, 53.86, 62.92, 112.94, 145.16, 168.24, 184.01, 199.25. 
Elemental analysis (%) calculated for (C24H36N4O12∙3H2O): C 50.35; H 6.34, N 9.79 %; 
found: C 50.65, H 6.17, N 9.27 %. 
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3. Results and discussion 
3.1. Structural studies 
3.1.1. P1 Crystal structure[147] 
 
The bond lengths and angles in the molecule P1 (Figure 3.1) have commonly 
encountered values (Table A5). The substituents at C4 and C5 are almost coplanar with 
the aromatic ring. In contrast, the torsion angle N1–C2–C7–O8 [-31.0(2)º] reveals a 
noticeable twisting for the C2 hydroxymethyl group towards the aromatic ring plane. 
 
 
 
Figure 3.1. Ball and stick structure and atom labelling scheme of P1. 
The crystal packing of P1 features infinite one-dimensional zig-zag chains along c axis, 
built up by classical hydrogen bonding interactions: N1-H1A⋅⋅⋅O4c and O5-H5A⋅⋅⋅O8a 
(operators for generating equivalent atoms: a, -x+1/2, -y+1, z-1/2; c, -x+1/2, -y+1, 
z+1/2, with with R (10)22  hydrogen-bonding patterns (Figure 3.2a).  
 
 
Figure 3.2. Crystal packing of P1 seen along the a (b) and b (a) directions. 
Each molecule forms an additional hydrogen bond O8-H8A⋅⋅⋅O4b (b, -x+1, y+1/2, -
z+1/2) with a molecule of a neighbouring chain to give an infinite three-dimensional 
network (Figure 3.2b). Hence, the O4-carbonyl atom acts twice as H-acceptor whereas 
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the O8-H8A alcoholic moiety plays both H-donor and H-acceptor roles. The structural 
comparison of P1 with kojic acid,[198] shows that the O-heterocyclic atom of kojic acid 
does not act as H-acceptor in its crystal. In clear contrast, the isolobal N1-H1A group of 
P1 (replacing the O-heterocyclic donor of the kojic acid) acts as an H-donor for 
intermolecular interactions. In addition, the torsion angle O1–C2–C7–O8 [–167.8(2)˚] 
in KA shows that the hydroxymethyl substituent is oriented in the opposite direction 
respect to KA. These data will be of importance in the following considerations of 
tautomeric forms.  
 
3.1.2. L1 Crystal structure[199] 
 
The asymmetric unit of L1 ligand consists of one half-molecule. The molecule is 
completed by a two-fold symmetry element (Figure 3.3A) and exhibits two symmetry 
related intra-molecular H-bonds involving each OH phenol-like group as donor and the 
corresponding O keto–kojic group as acceptor (O5-H⋯O4 (2.750(3) Å, 112.00°). These 
interactions seem favoured by the almost coplanar array of each hydroxyl groups and its 
pyranone ring, forming a torsion angle O2-C3-C4-O3 of only 1.88°. The two pyranone 
rings of the kojic are planar and define a dihedral angle of 74.76(2)°. This molecular 
structure is close to that previously reported for L8[163] (Figure 3.3B, where the kojic 
moieties define a dihedral angle of 85.02º) but in the L1 molecule there is not the 
disorder reported for a hydroxymethyl group of L8. It is noteworthy that in the L1 
ligand the KA units are turned in opposite direction, while in L8 the KA units are turned 
in the same direction. 
 
Figure 3.3. Asymmetric unit in the crystal of ligand L1 (A) and L8 (B). Intra-molecular H-bonding 
interactions are plotted as dash line. 
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In the crystal of L1, inter-molecular hydrogen bonds involving the keto-phenol moiety 
and the hydroxymethyl group (O(5)-H(5)···O(9), 2.687(3) Å, 153.2°; O(9)-H(9)···O(4) 
2.653(3) Å, 170.3° (graph set R44(14), Figure 3.4A) associate adjacent molecules to 
generate a densely packed three-dimensional network (Figure 3.4B). 
 
 
Figure 3.4. (A) Detail of the graph set R44(14) involving O-H···O contacts in L2. (B) View in the ab plane of the 
H-bonded 3D network of the crystal of L2. 
3.1.3. L13 Ligand structure 
 
In Figure A the structure of the L13 ligand is reported, which remarks that the 
intermolecular H bonds form a tridimensional network. These hydrogen bonds take 
place between the OH group of one KA unit and the carbonyl group of a second ligand, 
and between the OH group of the second KA unit and the CH2OH group of a third 
ligand. A further point to be remarked is that the presence of a substituent on the linker 
moves the two kojic units in the same direction, as already observed in the L2, L3 and 
L8 ligand structures[35],[163]. 
 
Figure A. Detail of the network structure showing the O-H···O contacts in L13. 
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3.2. Protonation equilibria studies 
3.2.1. P1 Ligand[147] 
 
The protonation equilibria of P1 have been examined with different techniques. 
Potentiometric-spectrophotometric measurements gave evidence of three different 
deprotonation steps according to the sequence (1). 
 
H3L+ ⇋ H2L⇋ HL- ⇋ L2-  (1) 
 
The loss of each proton markedly affects UV absorption spectra (Figure 3.5 and Figure 
A1), and three different pH regions (3 – 4.6, 7.3 – 10.5, and 10.6 – 13.2) relative to each 
single equilibrium can be identified, characterized by different bands and well defined 
isosbestic points. These features allowed the evaluation of the protonation constants 
(Table 3.1); the related speciation plot is presented in Figure 3.6A with superimposed 
the heights of UV bands, obtained by spectral decomposition. The trend of 1H NMR 
signals of protons H3, H6 and H7 vs pH (Figure 3.6B, Figure A2 and Table A6) 
confirms the deprotonation sequence (1). 
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Figure 3.5. UV spectra collected during potentiometric titration of the ligand, CL 4.95 x 10-4 M, using a 0.2 cm 
optical path length. A pH 2.98-4.59, B 7.29-10.52, C pH 10.64-13.22; D Absorptivity spectra of the ligand in the 
acidic and basic forms. 200-340 nm spectral range. 
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Figure 3.6. A) Normalized heights of the peaks at 248 nm(blue), 273nm (red) and 307 nm (violet), obtained by 
spectral decomposition, superimposed to the speciation plot of ligand. B) Normalize chemical shifts of H6 (●), 
H3 (■) and H7 (Δ) proton, superimposed to the speciation plot of ligand. 
The first deprotonation (pH 2-5) mainly affects proton H3, suggesting that the proton is 
lost from the protonated oxygen in position 4. The signal of H6 reflects this effect 
though in a minor extent. The second step (pH 7.3 - 10.5), related to the deprotonation 
of the 5-hydroxy group, mainly reflects on H6 chemical shift. The last deprotonation ( 
pH > 10.6) affects predominantly H7 signals of methylene group, which could be 
implied in a hydrogen bond between the OH group and the now deprotonated nitrogen 
atom. The high pK of this last dissociation suggests a keto-enol tautomer transition with 
dissociation from the hydroxyl group. 
 
Table 3.1. Protonation constants for P1 at 25°C, 0.1 M KCl ionic strength, obtained using HyperQuad2013 
program.[200] Standard deviations on the last figure in brackets. The literature values for DFP (Scheme 1, HL' 
in the neutral form) and 3,4-hopo are reported for comparison. 
Species P1 Log K Species 
DFP 
Log K[201] 
3,4-hopo  
Log K[202] 
H3L+ 3.37(7) H2L'+ 3.66(1) 3.34(1) 
H2L 9.00(1) HL' 9.82(2) 9.01(1) 
HL– 12.16(1)  - - 
 
The log K 9.00 and 3.37 are almost equal to those of 3,4-hopo[202], and somewhat lower 
than those of DFP (Table 3.1).[201] Conversely, the loss of a third proton is a new 
feature, which implies an equilibrium with a catechol-like molecule that loses its proton 
at basic pH values (log K 12.16). The deprotonation at the ring NH group of DL-α-
amino-β-(6-oxo-1,6-dihydro-pyridin-6yl)propanoic acid (Stunzi et al.)[203] is 
characterized by a log K value of 11.8, similar to that of 2-hydroxypyridine (11.7).[204] 
The ESI-MS measurements in D2O give evidence of the exchange of four labile protons 
with deuterium. The spectrum of ligand in D2O solution (Figure A3) shows five signals 
of different intensities. The most intense signals at 145.070 m/z and 146.076 m/z 
correspond to [C6H5D3O3N]+ and [C6H4D4O3N]+ deuterated on two or three oxygen 
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atoms and on a single nitrogen atom.  The less intense signals at 142.050, 143.057 and 
144.063 m/z match with the simulated spectra of [C6H8O3N]+, [C6H7DO3N]+ and 
[C6H6D2O3N]+. The ESI-MS signals of free ligand at different pH values (1.68, 6.13, 
11.5 and 13.7, Table A7) show that the molecular weight of the ligand does not change 
during the first (140.032 m/z) and third (139.032 m/z) deprotonation in negative mode 
spectrum, and does not present positively charged signals at basic pH. The presence of a 
peak at 139.032 m/z, a sticking peculiarity observed in aqueous solutions at pH >11.5, 
further confirms the last deprotonation process shown in Sequence 1.  
The deprotonation sequence of P1 has been also investigated at DFT level by 
calculating the electronic energies of the possibly protonated forms of the ligand at their 
ground state optimized geometry. Based on the results recently published on related 
systems, DFT calculations were performed by using the mPW1PW hybrid 
functional[185] and Schäfer, Horn, and Ahlrichs double-ζ plus polarization all-electron 
basis sets (BS) for all of the atomic species.[186] In particular, the fully protonated 
cationic ligand H3L+, the three possible isomers of the neutral and monoanionic forms 
(H2L and HL–, respectively), and the completely deprotonated dianion L2– were 
optimized, both in the gas phase and in water, implicitly taken into account by using the 
integral equation formalism of the polarizable continuous model (IEF-PCM) within the 
self-consistent reaction field (SCRF) approach (Scheme 8).[189] 
 
Scheme 8. Lewis structures of the differently protonated forms of P1 optimized at the DFT level. 
A comparison of the metric parameters optimized for the neutral isomer H2La in the gas 
phase with the corresponding structural data (see section 3.1.1) shows very good 
agreement between the two sets of data, the principal bond distances being varied by 
less than 0.05 Å (Table A8). No significant changes in the optimized structural 
parameters were observed upon considering implicit solvation in the calculations, all the 
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bond lengths and angles differing by less than 0.01 Å and 2°, respectively for all of the 
eight forms of the ligand considered here. All of the compounds show a completely 
planar structure, except the hydroxymethyl substituent, whose orientation depends on 
the protonation pattern of the ligand. In particular, in the species where N1 is 
deprotonated (H2Lb, HLa–, HLc–, and L2–), the O8-H8 hydroxyl group is coplanar with 
the heterocyclic ring, and H8 is oriented towards N1 (C2-C7-O8-H8 dihedral angle ∼ 
0.0°), so that a hydrogen bond interaction can be observed between the two atoms 
(N1···H8 distance in the range 1.663-1.907 Å; Figure A4 for H2Lb). A Second-Order 
Perturbation Theory Analysis (SOPTA) of Fock matrix in NBO basis allows for 
evaluation of the energy ESOPTA of the interaction between the lone pair (LP) localized 
on N1 and the unfilled natural orbitals of the O8-H8 hydroxyl group in the range 
between 10.3 and 35.0 kcal/mol depending on the species. On the other hand, in the 
forms of the ligand showing N1 protonated (namely H2La, H2Lc, and HLb–), in 
agreement with what was found experimentally for H2La, the O8-H8 moiety lies outside 
the plane described by the rest of the molecule, the N1-C2-C7-O8 and C2-C7-O8-H8 
dihedral angles being in the ranges –23.0/–40.8 and –49.2/–78.8°, respectively (Table 
A8 and Figure A4 H2La and H2Lc). Finally, in H3L+, although the C7 hydroxyl group is 
coplanar with the heterocyclic ring, H8 is oriented opposite to N1 (C2-C7-O8-H8 
dihedral angle ∼180.0°). An analysis of the total electronic energies calculated for the 
three possible neutral tautomeric forms of the ligand suggests the tautomer H2La to be 
the most stable (H2Lb and H2Lc being less stable by about 7 and 5 kcal/mol, 
respectively). This agrees with a first deprotonation of the ligand concerning H4, as 
hypothesized based on spectroscopic evidences, and with the X-ray diffraction analysis 
discussed above. In agreement with experimental data, H2La is stabilized by a hydrogen 
bond (O4···H5 distance = 1.885 Å; Figure A4), the interactions between the LP 
localized on O4 and the unfilled natural orbitals of the O5-H5 hydroxyl group being 
calculated in ESOPTA = 10.6 kcal/mol. 
As far as the monoanionic forms of the ligand are concerned, the isomers HLa– and HLc–
were calculated to be more stable than HL–b by 12 and 15 kcal/mol, respectively, thanks 
to the formation of two different hydrogen bonds, one involving the N1 atom and the 
hydroxymethyl pendant, and the other the C4–O4 and C5–O5 groups (O5···H4 distance 
in HLa– = 1.684 Å; O4···H5 distance in HLc– = 1.775 Å; ESOPTA ∼27 and 18 kcal/mol for 
HLa– and HLc–, respectively). This accounts for the mechanism suggested by 
experimental data for the second deprotonation of the ligand, which should involve the 
O5-H5 hydroxyl group, then followed by a rearrangement leading from the pyridinone 
HLb– to the catechol-like tautomer HLa–.  
Each technique has given evidence of tautomeric forms, and together they provided a 
complete description of the deprotonation paths. As long as third deprotonation was not 
observed for 3,4-hopo, we believe that –CH2OH in the position 2 is important for the 
tautomer change of the molecule. 
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3.2.2. L12 Ligand 
 
The protonation equilibria of L12 (Scheme 2) have been studied by potentiometry, UV-
Vis spectrophotometry, 1H-NMR spectroscopy and calorimetry. Protonation constants 
of L12 were determined by simultaneous potentiometric-spectrophotometric 
titrations[205]. Since L12 is constituted by two units of kojic acid joined by a methylene 
bridge substituted with a benzoic acid, three protonation equilibria were observed when 
a L12 solution 5.49x10-4 M was potentiometrically titrated with NaOH 0.1 M, at ionic 
strength 0.1 M NaCl and 25 ºC (Figure 3.7). The log K values for the four examined 
ligands L12-L15 are reported in Table 3.2, together to the literature values for L2 and 
L3 ligands[35] in order to have a complete picture of the effects of the substituents. The 
thermodynamic parameters ∆G, ∆H and T∆S have been also reported in Table 3.2, 
evaluated from calorimetric measurements.  
 
Table 3.2. Protonation constants values and thermodynamic parameters ∆G, ∆H and T∆S for L12-L15 ligands. 
Ligand log K 
- ∆ G0 
(kJ mol-1) 
- ∆ H0 
(kJ mol-1) 
T∆S0 
(kJ mol-1) 
L12 
9.57 (3) 54.6 (1) 18.8 (6) 35.8 (6) 
7.44 (2) 42.4 (1) 12.1 (9) 30.3 (9) 
3.49 (1) 19.9 (1) -1.3 (8) 21.2 (8) 
L13 
9.24 (2) 52.7 (1) 15.1 (6) 37.6 (6) 
7.04 (3) 40.2 (1) 11.3 (6) 28.9 (6) 
4.14 (1) 23.6 (1) 1.3 (4) 22.3 (4) 
L14 
10.10 (3) 57.6 (1) 25 (1) 33 (1) 
8.57 (1) 48.9 (1) 20 (1) 29 (1) 
6.91 (1) 39.4 (1) 13.8 (8) 25.6 (8) 
L15 
9.98 (2) 56.9 (1) 14.6 (6) 42.3 (6) 
8.47 (2) 48.3 (1) 16.7 (9) 31.6 (9) 
6.78 (1) 38.7 (1) 11.7 (8) 27.0 (8) 
L2[35]  
10.58 (3) 60.4 (2) 0 (1) 60 (1) 
8.92 (2) 50.9 (1) 14 (1) 37 (1) 
6.95 (1) 39.6 (1) 12 (2) 28 (2) 
L3[35] 
10.18 (2) 58.1 (3) 12 (1) 46 (1) 
8.84 (1) 50.4 (1) 16 (1) 34 (1) 
7.21 (1) 41.1 (1) 12 (1) 29 (1) 
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Figure 3.7. Potentiometric titration of L12 with NaOH 0.1M, NaCl 0.1M, 25ºC. 
 
The carboxylic group deprotonation in L12 takes place with pK1 = 3.49, lower than that 
of the two OH groups in KA moieties, pK2 = 7.44 and pK3 = 9.57.  
The UV-Vis spectra were registered during the simultaneous potentiometric-
spectrophotometric titration (0.2 cm path length) at 4.86 ∙10-4 M ligand concentration. 
The four absorptivity spectra obtained by SPECFIT and HypSpec programs are 
presented in Figure 3.8. An easy attribution of the protonation steps that involves the 
OH group of KA moieties can be done on the basis of the characteristic spectra of 
KA[33], where the L- and LH species are characterized by UV bands at 315 nm (ε = 5900 
M-1 cm-1) and 270 nm (ε = 8700 M-1 cm-1), respectively, with a sharp isosbestic points at 
242 nm and 290 nm (Figure A5). 
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Figure 3.8. Absorptivity spectrum of L12 ligand. 
 
LH3 species of L12 has a maximum at 279 nm with ε = 13330 mol-1∙L∙cm-1, LH2- 
species has a maximum  at 279 nm with ε = 12500 mol-1∙L∙cm-1, LH2- species has two 
maxima at 281 nm ε = 7390 mol-1∙L∙cm-1 and 324 nm ε = 6390 mol-1∙L∙cm-1 and L3- 
species has one maximum at 335 nm ε = 10100 mol-1∙L∙cm-1.  
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The trends of the peak heights after decomposition of the spectra in the Gaussian 
components[206], are in agreement with the speciation plots calculated by Hyss program 
with the pK values in Table 3.2 and (Figure 3.9). 
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Figure 3.9. Speciation curves of ligand L12, with the overlapping trends of the heights of UV bands at 279 nm 
(+), 324 nm (◊) and 335 nm (Δ), obtained by spectral decomposition of the spectra in Figure 3.8 with the 
Specpeak program[206]. 
On the basis of the spectral changes observed during ligand spectrophotometric-
potentiometric titration, the values pK2 = 7.44 and pK3 = 9.57, can be attributed to the 
two OH groups in KA moieties, while the first deprotonation, almost 
spectrophotometrically silent, is attributed to the carboxylic acid in the benzene ring. 
Twenty two 1H-NMR spectra in the pH range 1.4-13.05 were collected for L12 ligand 
(Figure A6). The variation of intrinsic chemical shifts (Table 3.3 and Figure 3.10) in the 
deprotonation steps allow to further define the deprotonation sequence obtained by UV-
vis spectra, and to give evidence of some related structural rearrangements. 
 
LH3 ⇋ LH2- ⇋ LH2- ⇋ L3- 
Table 3.3. Intrinsic chemical shifts of the different protons in L12 ligand in the different protonated species, 
calculated with HypNMR, and variations of the intrinsic chemical shifts connected to each deprotonation step. 
Species E F G L M N P 
L3- 6,50 6,33 4,20 6,94 7,24 7,23 7,28 
LH2- 6,27 6,42 4,38 7,27 7,29 7,29 7,35 
LH2- 6,66 6,48 4,32 7,25 7,32 7,34 7,45 
LH3 6,76 6,49 4,29 7,29 7,52 7,45 7,88 
Δδ E F G L M N P 
LH2-→L3- -0,23 0,10 0,17 0,33 0,04 0,06 0,07 
LH2-→LH2- 0,39 0,05 -0,05 -0,02 0,04 0,05 0,11 
LH3→LH2- 0,10 0,01 -0,03 0,04 0,20 0,11 0,42 
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Figure 3.10. Chemical shifts of L12 ligand as a function of pH. 
 
 
The first step due to the loss of a proton from the carboxylic group strongly affects P 
and M protons, and in a smaller amount N and E protons. The protons in ortho and para 
with respect to COOH are those mainly affected, and the formation of a hydrogen bond  
COO-..…HO requires a conformational change that affects the E proton on the linker 
(Figures 3.10 and 3.11). This is supported by the comparison of thermodynamic 
protonation data of Table 3.2  with the corresponding parameters reported in the 
literature for free benzoic acid under similar experimental conditions (pK = 3.99, -∆H° 
= 0.87 kJ·mol-1, T∆S° = 21.9 kJ·mol-1[207]): the protonation of the carboxylic group of 
L12 is characterized by less favorable ∆G° and T∆S° values; the ∆H° value becomes 
endothermic, in agreement with the suggested break of the H-bond requested for 
carboxylate protonation. 
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Figure 3.11. Hydrogen bond formation COO-..…HO after the first deprotonation of the carboxylic group. 
 
The second step, the deprotonation of the OH group of one KA moiety, affects proton 
E, F and P. The proton F in the KA ring, in meta with respect to the OH group, is only 
slightly affected by its deprotonation. The remarkable change in the intrinsic chemical 
shift of E could derive from the breaking of COO-..…HO hydrogen bond and the 
formation of a new one O-..…HO between the two KA units. The breaking of the COO-
..…HO hydrogen bond also affects the resonance of P, no more involved in hydrogen 
bonding (Figure 3.12). 
 
 
Figure 3.12. Hydrogen bond formation O-..…HO between the two KA units. 
 
The third step involves the deprotonation of the OH group on the second KA unit. The -
O-..…HO hydrogen bond is no more possible, and the molecule rearranges to form a new 
hydrogen bond involving the hydroxymethyl group. This reverses the chemical shift of 
E proton, and affects the resonances of G and L protons (Figure 3.13). The described 
pattern of H-bond formation and re-organization is the same already observed for bis-
kojic acid derivatives containing a vanillin molecule in the linker[35] and the calorimetric 
data are in good agreement with those measured for the latter ligands. 
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Figure 3.13. Hydrogen bond formation after the third deprotonation of L12. 
 
 
3.2.3. L13 ligand  
 
L13 differs from L12 ligand only for the position of the carboxylic group in the benzene 
ring (Scheme 2). Three protonation constants were evaluated from the potentiometric 
titration data relative to a L13 solution 5.01x10-4 M titrated with NaOH, at 0.1 M NaCl 
ionic strength and 25 ºC (Figure 3.14). 
 
LH3 ⇋ LH2- ⇋ LH2- ⇋ L3- 
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Figure 3.14. Potentiometric titration of L13 with .NaOH 0.1 M, NaCl 0.1 M, 25ºC. 
 
UV-Vis spectra, collected during the simultaneous potentiometric-spectrophotometric 
titration (0.2 cm path length) of a 3.01 ∙10-4 M ligand solution allowed the evaluation by 
SPECFIT and HyperSpec programs of the four absorptivity spectra in Figure 3.15.  
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As in the case of L12, the attribution of the protonation steps involving the OH group of 
KA moieties, to the second (pK2 = 7.04) and to the third deprotonations (pK3 = 9.24) can 
be done. The first deprotonation spectrophotometrically silent takes place on the 
carboxylic group (pK1 = 4.14). 
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Figure 3.15. Absorptivity spectra of the four different protonated forms of L13 calculated on the whole spectra 
(pH 3.93-11.12)[180]. 
 
The trends of the peak heights, after decomposition of the spectra in the Gaussian  
components, overlap the speciation plots calculated by Hyss program with the log K 
values in Table 3.2 (Figure 3.16). 
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Figure 3.16. Speciation plots of L13ligand, with the overlapping trends of the heights of UV bands at 276 nm 
(+), 325 nm (◊) and 340 nm (Δ), obtained by spectral decomposition of the spectra in Figure 2.15 with the 
Specpeak program[206]. 
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Table 3.4. Intrinsic chemical shifts of the different protons in L13 ligand in the different protonated species, 
calculated with HypNMR, and variations of the intrinsic chemical shifts connected to each deprotonation step. 
Species E F G I L 
L3- 6,43 6,34 4,28 7,72 7,21 
LH2- 6,07 6,42 4,36 7,75 7,31 
LH2- 6,20 6,49 4,35 7,76 7,36 
LH3 6,22 6,49 4,34 7,93 7,43 
Δδ E F G I L 
LH2-→L3- -0,36 0,08 0,07 0,03 0,10 
LH2-→LH2- 0,13 0,07 -0,01 0,02 0,05 
LH3→LH2- 0,02 0,00 -0,01 0,17 0,07 
 
    
 
 
      
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17. Chemical shifts of L13 ligand as a function of pH. 
In the case of 1H-NMR measurements, the first deprotonation step, due to the loss of a 
proton from the carboxylic group, strongly affects I and, in a smaller amount, L protons. 
The ortho and para protons with respect to COOH are those mainly affected, and no 
hydrogen bond  COO-..…HO- formation is observed (Figures 3.17 and 3.18 and Table 
3.4). Contrarily to what discussed for L12, in the case of L13 all the thermodynamic 
parameters referring to carboxylate protonation are very similar to those reported for 
 
O
O
OH
OH
HO
HO
OHO
0 4 8 12
pH
6
6.2
6.4
6.6
C
he
m
ic
al
 S
hi
ft
E
F
0 4 8 12
pH
7
7.2
7.4
7.6
7.8
8
C
he
m
ic
al
 S
hi
ft
I
L
0 4 8 12
pH
4.2
4.25
4.3
4.35
4.4
C
he
m
ic
al
 S
hi
ft
G
F 
E 
L 
I 
G 
59 
 
free benzoic acid, in agreement to the observation that no H-bond is possible between 
the carboxylate group and the rest of the molecule. 
 
Figure 3.18. L13 ligand after the loss of the H on the carboxylic group. 
 
In the second step E proton is the most affected, suggesting that the deprotonation  of –
OH group leads to the hydrogen bond OH----O between the two units of KA, which 
affects F and E protons (Figure 3.19). 
 
Figure 3.19. Hydrogen bond OH----O between the two units of KA  after the second deprotonation of L13 
ligand. 
 
The hydrogen bond between the two KA moities breaks when the third deprotonation 
occurs. This last step involves the deprotonation of the second OH group. Two 
hydrogen bond are possible, between –COO- and CH2OH in one KA unit, and –O- in the 
same unit with CH2OH in the second unit. These imply a large torsion of the E protons , 
and the large ∆δ of F, G and L protons (Figure 3.20). The similarity between the 
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thermodynamic parameters refferring to the second and the third proton dissociation 
from L13 and L12 justify the hypothesis that the behaviour of the two ligands, 
concerning the H-bonds formation, is also similar (Table 3.2). 
 
 
Figure 3.20. Hydrogen bond formation after the third deprotonation of L13 ligand. 
 
3.2.4. L14 Ligand 
 
The protonation equilibria of L14 were studied both by a potentiometric/UV-Vis 
spectrophotometric titration and by 1H-NMR titration. L14 is characterized by two KA 
units joined by a linker bearing a benzene ring with a phenolic group in ortho position. 
Three protonation constants were estimated when a L14 solution 7.96x10-4 M was 
potentiometrically titrated with NaOH, at 0.1 M NaCl ionic strength and 25ºC (Table 
3.2 and Figure 3.21). 
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Figure 3.21. Potentiometric titration of L14 with NaOH 0.1M, NaCl 0.1M, 25ºC. 
 
The absorptivity spectra collected during the simultaneous potentiometric-
spectrophotometric titration (in 0.2 cm path length, at 3.65∙10-4 M ligand concentration) 
are presented in Figure 3.22. They show that the bands of the fully protonated species 
LH3 are similar to those of the protonated LH species of KA, differing only in the 
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wavelength of the maximum, now shifted from 270 nm to 280 nm (ε = 18309 M-1∙cm-1). 
The intensity of this band decreases during the first deprotonation (red spectra), with the 
contemporary appearance of a new band at 326 nm (ε = 9129 M-1∙cm-1) with sharp 
isosbestic points at 242 nm and 302 nm. This permit to attribute the first deprotonation 
with pK1 = 6.91to the OH group in one of the two KA moieties. 
During the second deprotonation (blue curves) a further decrease on the band at 280 nm 
and an increase of that at 326 nm take place with pK2 = 8.57, attributable to the second 
unit of kojic acid in the ligand. 
Finally, when the deprotonation of the phenolic group takes place, (pK3 = 10.10), the 
band at 326 is shifted to higher wavelengths where reach the maximum for the fully 
deprotonated species at 330 nm (ε = 14397 M-1∙cm-1). 
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Figure 3.22. Absorptivity spectrum (A) collected during the spectrophotometric titration of L14 (CL = 3.65∙10-4 
M, 0.2 cm optical path length), and selected absorptivity spectra (B) in the pH range 5.90-10.71. 
 
The trends of the peak heights after decomposition of the spectra in the Gaussian 
components overlap the speciation plots in Figure 3.23. 
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Figure 3.23. Speciation curves of ligand L14, with the overlapping trends of the heights of UV bands at 280 nm 
(+), 326 nm (◊) and 330 nm (Δ), obtained by spectral decomposition of the spectra in Figure 2.22 with the 
Specpeak program. 
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The variation of intrinsic chemical shifts (Table 3.5 and Figure 3.24) in the various 
deprotonation steps allow to better define the deprotonation sequence attributed by UV-
Vis spectra, and to give evidence of some related structural rearrangements. 
 
LH3 ⇋ LH2- ⇋ LH2- ⇋ L3- 
 
Table 3.5. Intrinsic chemical shifts of the different protons in L14 ligand in the different protonated species, 
calculated with HypNMR, and variations of the intrinsic chemical shifts connected to each deprotonation step. 
Species E F G I L M N 
L3- 6,32 6,34 4,29 6,99 6,53 7,05 6,64 
LH2- 6,20 6,37 4,38 7,32 6,88 7,17 6,87 
LH2- 6,09 6,45 4,35 7,15 6,86 7,20 6,85 
LH3 6,30 6,50 4,33 7,12 6,89 7,23 6,91 
Δδ E F G I L M N 
LH2-→L3- -0,11 0,03 0,09 0,34 0,34 0,12 0,23 
LH2-→LH2- -0,11 0,07 -0,04 -0,17 -0,02 0,02 -0,02 
LH3→LH2- 0,21 0,05 -0,02 -0,04 0,04 0,03 0,06 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.24. Chemical shifts of L14 ligand as a function of pH. 
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The first and the second deprotonation, as inferred from the UV-Vis spectra, take place 
from the OH groups of the KA units, also in agreement with the thermodynamics 
parameters of Table 3.2.  The first deprotonated –O- can form hydrogen bonds either 
with the OH group of the phenol in the linker (Figure 3.25A), or with the OH group in 
the second KA unit (Figure 3.25B). The ∆δ of N proton supports, the first hypothesis, 
also confirmed by the relevant ∆δ of E proton, which in this case undergoes a strong 
rotation. Calorimetric data support the formation of a H-bond although they cannot give 
any hints on which one of the two hypotheses is the most likely. 
 
Figure 3.25.Two hypothesis of hydrogen bond formation after the first deprotonation of L14 ligand. 
 
After the second deprotonation an opposite chemical shift takes place on E proton, 
presumably due to the formation of a hydrogen bond OH----O with the till protonated 
phenolic OH (or with the CH2OH on the second KA unit), (Figure 3.26). 
 
 
Figure 3.26. Second deprotonation of L14 ligand. 
 
The third deprotonation affects the intrinsic chemical shifts of all the protons in the 
phenolic unit, and of the E proton. In theory the formation of hydrogen bond is possible 
between the phenolate group and one CH2OH group of the kojic moiety (Figure 3.27); 
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however, the thermodynamic parameters do not support this suggestion. In fact, the 
formation of a H-bond which favors the –OH deprotonation would be reflected in lower 
pKa and -∆H° values of L14 with respect to free phenol (pKa = 9.86, -∆H° = 21.3 kJ 
mol-1).[207] 
     
Figure 3.27. Hydrogen bond between -O- from the phenolic group and CH2OH on one of the KA units after the 
third deprotonation of L14 ligand. 
 
3.2.5. L15 Ligand 
 
The protonation equilibria of L15 were studied by potentiometric titration, simultaneous 
potentiometric- spectrophotometric titration and 1H-NMR spectra collected at different 
pH values and calorimetric titration. L15 differs from L14 for the phenolic group in para 
position.  
Also in this case three protonation constants were calculated from potentiometric data 
obtained when a L15 solution 7.96·10-4 M was titrated with NaOH, at 0.1 M NaCl ionic 
strength and 25 ºC (Table 3.2 and Figure 3.28). 
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Figure 3.28. Potentiometric titration of L15 with NaOH 0.1 M, NaCl 0.1 M, 25ºC. 
The absorptivity spectra calculated from the spectra collected during a titration (0.2 cm 
path length) of a 4.79 ∙10-4 M ligand solution are presented in Figure 3.29. The band of 
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the fully protonated species at 280 nm (ε = 19965 M-1∙cm-1) decreases during the first 
deprotonation (red spectra), with the contemporary appearance of a new band at 334 nm 
(ε = 4154 M-1∙cm-1), with sharp isosbestic points at 242 nm and 302 nm. This permit to 
attribute the first deprotonation with  pK1 = 6.78 to the OH group in one of the two KA 
moieties. 
During the second deprotonation (blue curves) a further decrease on the band at 280 nm 
and an increase of that at 334 nm take place. This deprotonation with pK2 = 8.47 is 
attributed to the second unit of KA unit. 
The deprotonation of the phenolic group (pK3 = 9.98) shifts the band at 334 to higher 
wavelengths, and the maximum for the fully deprotonated specie occurs at 340 nm (ε = 
15762 M-1∙cm-1). 
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Figure 3.29. Absorptivity spectra (A) collected during the spectrophotometric titration of L15 ligand solution 
CL = 4.79∙10-4 M, 0.2 cm optical path length, and selected absorptivity spectra (B) in the pH range 5.54-10.27. 
The trends of the peak heights, after decomposition of the spectra in the Gaussian 
components[206], follow the speciation plots in Figure 3.30. 
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Figure 3.30. Speciation plots of ligand L15, with the overlapping trends of the heights of UV bands at 280 nm 
(+), 326 nm (◊) and 334 nm (Δ), obtained by spectral decomposition of the spectra in Figure 2.29 with the 
Specpeak program. 
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Table 3.6. Intrinsic chemical shifts of the different protons in L15 ligand in the different protonated species, 
calculated with HypNMR, and variations of the intrinsic chemical shifts connected to each deprotonation step. 
Species E F G I L 
L3- 6,26 6,32 4,31 6,91 6,50 
LH2- 6,17 6,37 4,33 7,11 6,78 
LH2- 5,94 6,44 4,37 7,19 6,80 
LH3 6,07 6,48 4,35 7,21 6,82 
Δδ E F G I L 
LH2-→L3- -0,09 0,04 0,03 0,20 0,28 
LH2-→LH2- -0,23 0,07 0,03 0,08 0,01 
LH3→LH2- 0,12 0,04 -0,01 0,03 0,02 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.31. Chemical shifts of L15 ligand as a function of pH. 
 
As far as regards NMR data, the first and the second deprotonations, as in the case of 
L14, take place from the OH groups of the KA units. The first deprotonated –O- can 
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form hydrogen bonds only with the OH group in the second KA unit (Table 3.6, Figures 
3.31 and 3.32).  
 
Figure 3.32. Hydrogen bond -OH----O between the two KA units of L15. 
 
After the second deprotonation an opposite chemical shift takes place on E proton, due 
to the formation of a hydrogen bond OH----O with the CH2OH on the second KA unit 
(Figures 3.31 and 3.33). 
 
Figure 3.33. Hydrogen bond OH----O with the CH2OH on the second KA unit after the second deprotonation 
of L15 ligand. 
The third deprotonation affects the intrinsic chemical shifts of all the protons in the 
phenolic unit, and of the E proton. The only hydrogen bond possible is that of O- group 
in the KA unit with one CH2OH group (Figures 3.31 and 3.34). Calorimetric data 
support the above hypotheses on the protonation path of L14. 
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Figure 3.34. Hydrogen bond OH----O with the CH2OH on the second KA unit after the third deprotonation of 
L15 ligand. 
Different remarks can be done: 
The carboxylic group deprotonation in L12 and L13 take place, as expected, at lower 
pH values than that of the phenolate group in each KA moiety, while those of the OH 
group in the aromatic ring in L14 and L15 take place with well distinct higher pK’s 
values (about 1.5 units) than that of the more basic OH groups in KA units (Table 3.7). 
 
Table 3.7. Ionization constants for L12-L15 ligands. 
pK L12 L13 L14 L15 
pK1 3,49 (3) 4,14 (2) 6,91 (3) 6,78 (2) 
pK2 7,44 (2) 7,04 (3) 8,57 (1) 8,47 (2) 
pK3 9,57 (1) 9,24 (1) 10,1 (1) 9,98 (1) 
 
The negative charge assigned to the L12 molecule by the deprotonation of carboxylic 
group increases the basicity of phenolates leading to an increase on the first log K with 
respect to L14 of about 1 unit, and of about 0.5 units on the second. The analogous 
variation for the ligands L13 and L15 with the acidic group in para position in the 
aromatic ring are about 0.5 and 0.2 log K units. This difference can be explained by a 
further contribute, besides that of negative charge, related to the formation of a 
hydrogen bond between the orto COO- and OH group that delays the loss of the 
involved proton. This is also substantiated by the lower log K value for the ortho 
carboxylic group whose deprotonation is favored by the hydrogen bond stabilization. 
An analogous trend was observed for the log K’s of L2 and L3[35], even if the OCH3 
always in orto with respect to OH group made it more basic for its marked inductive 
effect. 
More complex is the formation of hydrogen bonding in the case of an OH group in the 
aromatic ring. In fact, after the first deprotonation that now happens on OH group of 
KA unit, the hydrogen bond formation can occur either on the protonated OH in the 
aromatic ring (Figure 3.25A), and on the OH group in the second KA unit (Figure 
3.25B). Presumably, they take place contemporary in different extent.   
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3.2.6. KβAK Ligand[1] 
 
The KβAK ligand (Scheme 7) has three potential protonation sites and indeed was 
determined three protonation constants from combined potentiometric-UV titration data 
calculated by HypSpec software[180] (Table 3.8). In Figure 3.35, the four absorptivity 
spectra are reported, each representing a differently protonated form. The [LH3]+ band 
has the highest intensity at 268 nm (ε=10998 M-1cm-1). The first deprotonation at pH 2.9 
can be attributed to nitrogen atom and does not significantly change the spectrum. The 
[LH2] band displays maximum intensity at 268 nm and does not differ in shape from the 
band of the fully protonated ligand. The two kojic acid units are separated by the 
hydrophobic linker and ligand is not symmetric; each kojic unit deprotonates at 
different pH levels: 7.15 and 8.44. The [LH]- and [L]2- bands are different:  [LH]- band 
presents two maxima at 250 nm (ε=6400 M-1cm-1) and 317 nm (ε=5403 M-1cm-1); the 
[L]-2 band has a maximum absorptivity at 317 nm (ε=8218 M-1cm-1). The charge of the 
molecule depends on the pH of the solution (Figure 2.36); negatively charged forms are 
in equilibrium at neutral pH.  
 
Table 3.8. Protonation constants of the new ligand KβAK calculated with HyperQuad2013 program at 25°C 
and 0.1 M KCI ionic strength using the ligand concentration 5∙10−4 M. a Standard deviation values were 
calculated by the HyperQuad2013 program. 
 
Specie Log β Log K 
LH- 8,44(4)a 8,44(4) 
LH2 15,59(4)a 7,15(4) 
LH3+ 18,5(1)a 2,9(1) 
 
 
Figure 3.35. Absorptivity spectrum of the KβAK ligand using the HypSpec program, 0.2 cm path length and 
ligand concentration 5∙10-4 M. 
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Figure 3.36. Speciation plots of the ligand calculated with the log β values shown in Table 3.8, using 5∙10-4 M 
ligand concentration. 
The first and second protonations attributed to the kojic acid units differ significantly 
from the kojic acid protonation constant (7.70[33]). This is due to the formation of the 
intramolecular hydrogen bonds previously reported by our group for kojic acid 
derivatives[33],[35],[163],[37]. 
3.2.7. SC Ligand 
 
Simultaneous potentiometric-spectrophotometric titrations[35] and 1H-NMR spectra 
collected at different pH values gave evidence of six different protonation equilibria for 
SC ligand (Scheme 3).  
The absorption spectra collected during the potentiometric-spectrophotometric titration 
(0.2 cm path length) on 2.47∙10-4 M ligand solution are presented in Figure 3.37A. From 
the UV spectra, an easy attribution of the protonation steps that involves the OH group 
of KA moieties can be done on the basis of the characteristic spectra of the KA[33] as 
outlined above for the tetradentate KA derivatives L12-L15. The absorption band of the 
fully protonated species LH63+ at 271 nm decreases during the first deprotonation, with 
the contemporary appearance of a new band at 315 nm, with sharp isosbestic points at 
242 nm and 290 nm. This permit to attribute the first deprotonation with pK1 = 6.72 to 
the OH group in one of the three KA moieties (Table 3.9). The second deprotonation 
takes place with pK2 = 7.7, attributable to a second KA unit. When the third 
deprotonation occurs with pK3 = 8.11, the trend of the heights of the peaks in Figure 
3.37B, show that the characteristic band of the fully deprotonated kojic acid has not 
entirely reached its maximum at 320 nm. This suggests the presence of a micro-
equilibrium between the loss of the proton from the last KA unit and the loss from a NH 
proton. 
71 
 
During the fourth deprotonation, the band at 320 nm reaches its maximum. The last two 
deprotonations (protons from NH groups) do not significantly change the spectra. 
 
Table 3.9. Protonation constants of the new ligand SC calculated with HyperQuad2013 program at 25°C and 
0.1 M KCI ionic strength using the ligand concentration 2.47∙10−4 M. 
Species LH2- LH2- LH3 LH4+ LH52+ LH63+ 
Log K 10.97 9.62 9.00 7.95 7.84 7.02 
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Figure 3.37. A) Absorbance spectrum of the new SC ligand using the HypSpec program, 0.2 cm path length 
and 2.47∙10-4 M ligand concentration; B) Speciation plots of SC ligand, with the overlapping trends of the 
heights of UV bands at 271 nm (■), 320 nm (+), obtained by spectral decomposition of the spectra with the 
Specpeak program.  
The variation of intrinsic chemical shifts (Table 3.10) in the deprotonation steps allow 
to better define the deprotonation sequence attributed by UV-Vis spectra. The most 
affected nuclei for the first three deprotonations are Ha and Hb. In particular the 
variation of intrinsic chemical shift of Ha after the third deprotonation involves the 
equilibria between the loss of the proton from the OH group in the KA moiety and that 
from a NH group in the linker. Chemical shifts follow the trend of chemical shift 
simulated with potentiometric data (Figure 3.38). 
 
Table 3.10. Intrinsic chemical shifts of the different protons in L15 ligand in the different protonated species, 
calculated with HypNMR program, and variations of the intrinsic chemical shifts connected to each 
deprotonation step. 
 
Species Ha Hb Hc Hd He 
L3- 7,64 6,34 4,36 2,61 2,45 
LH2- 7,65 6,35 4,36 2,72 2,52 
LH2- 7,63 6,35 4,39 2,93 2,70 
LH3 7,71 6,37 4,33 2,94 2,67 
LH4+ 7,78 6,42 4,49 3,13 2,88 
LH52+ 7,95 6,48 4,36 2,99 2,73 
LH63+ 8,01 6,51 4,43 3,08 2,81 
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Δδ  Ha Hb Hc Hd He 
LH2-→L3- 0,01 0,01 0,00 0,10 0,07 
LH2-→LH2- -0,01 0,00 0,03 0,21 0,18 
LH3→LH2- 0,07 0,02 -0,06 0,01 -0,03 
LH4+→LH3 0,07 0,04 0,16 0,19 0,21 
LH52+→LH4+ 0,17 0,06 -0,13 -0,14 -0,15 
LH63+→LH52+ 0,07 0,03 0,07 0,09 0,08 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.38. Chemical shifts of SC ligand as a function of pH. 
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3.2.8. Losartan and Irbesartan ligands 
 
The study of the acid–base behavior is of great relevance in pharmacology. This is 
particularly true in the case of antihypertensive drugs, in which the examination of acid-
base properties helps in the understanding of physiological mechanisms in which their 
receptor antagonists is implied.[208] Regularly assumed cardiovascular drugs are more 
and more formulated into controlled-release forms, where the knowledge of dissociation 
constants is of great importance.[209] Moreover Losartan and Irbesartan solubility is 
related to the protonation state of the molecules. The water solubility is drasticaly 
lowered in acidic pH. The highest water solubility of Losartan determined 
spectrophotometrically at 280 nm at pH 3 was 5.72·10-5 M, while that of Irbesartan 
4.64·10-4 M. Irbesartan is more water soluble than Losartan at the acidic pH of stomach 
and this could be the reason why the overall bioavailability of Irbesartan (60-80%[210]) is 
higher than that of Losartan (33%[211]). 
Losartan and Irbesartan contain both acidic and basic centers, the first on the tetrazole 
ring, the second on the imidazole in Losartan, and on the 5-oxo-imidazole in Irbesartan. 
A number of protonation constants are reported in literature, without any mention 
neither to the experimental conditions in which they were determined, nor to the used 
techniques (Losartan 2.36 and 5.55[212], 4.9[213], 5.6[214] and Irbesartan 4.5[215]).  
Reliable data are presented by Tosco et al.,[216] who evaluated potentiometrically in co-
solvent mixtures of variable composition the pKa values of both groups. These values 
plotted against the mixture composition allow to extrapolate the values in water and to 
compare them with those of some tetrazole ligands reported in literature (tetrazole 
4.89,[217] methyltetrazole 5.50,[218] and 5-phenyl-1H tetrazole 4.38[219]). Their results 
demonstrate that the acidity of the tetrazole moiety increases with aromatic 5-
substitution, reflecting a larger delocalization of the negative charge on the aromatic 
moiety, together with the influence of the electron withdrawing substituent. 
Consequently, the first dissociation can be attributed to the imidazole ring and the 
second to the tetrazole ring.[216] 
Potentiometry and spectrophotometry are the most adequate and versatile techniques for 
the study of equilibrium constants in homogeneous phase.[220],[221] The low drug 
solubility in water at acidic pH prevented potentiometric studies in aqueous solution. 
The ligand protonation studies were thus performed in 30:70 and 80:20 MeOH/H2O 
mixtures, being methanol effects on pKa values extensively studied.[222]  
Irbesartan and Losartan are biprotic ligands and deprotonate in the same manner. In the 
30:70 MeOH/H2O mixtures (Table 3.11) Irbesartan loose imidazole proton with pKa1 
3.59, while Losartan with pKa1 2.95. After the first deprotonation, ligands exist in the 
zwitterionic form because of the negative charge on the tetrazole nitrogen. The tetrazole 
ring of Irbesartan deprotonates with pKa2 5.03, while that of Losartan with pKa2 4.5. 
According to the plot of psKa vs. weight-% of MeOH[216], the higher %MeOH the lower 
pKa1 and the higher pKa2. Indeed, in 80:20 MeOH/H2O (Table 3.11), pKa1 of Losartan is 
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2.56, while pKa2 5.07. In the case of Irbesartan, pKa1 became lower (3.25), while pKa2 
remains almost unchanged (4.98). At physiological pH ligands exist in anionic form.  
Irbesartan and Losartan contain a complicated molecular structure and two protonation 
equilibria can be monitored spectrophotometrically with close dissociation constants. 
Both molecules exhibit quite similar absorption bands, and the spectral range from 240 
to 310 nm, with an isosbestic point at ~280 nm, was selected as the most convenient for 
an estimation of protonation constants.  
Table 3.11. Dissociation constants determined potentiometrically at 250C and 0.1 M NaCl ionic strength.  
 Irbesartan Losartan 
 30:70 MeOH/H2O 
80:20 
MeOH/H2O 
30:70 
MeOH/H2O 
80:20 
MeOH/H2O 
pKa1 3.6(1) 3.25(1) 3.06(7) 2.56(1) 
pKa2 5.0(1) 4.98(1) 4.38(4) 5.07(1) 
 
The pKa values calculated with HypSpec[182] program slightly differ, and are much less 
reliable than those potentiometrically determined in Table 3.11. Their low reliability 
depends on the slight variation with pH presented by the absorptivity spectra of 
Irbesartan and Losartan shown in Figure 3.39.  
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Figure 3.39. Absorptivity spectrum of the irbesartan (A 30% and B 80% methanol/water solution) and 
losartan (C 30% and D 80% methanol/water solution) using the HypSpec program, 0.2 cm path length and 
ligand concentration 0.5mM. 
 
The presence of different fluorescent groups (fluorophores) as biphenyl[223] and 
imidazole[224] allowed the study of the emission properties of both Irbesartan and 
Losartan from pH 1 to pH 7. In the pH range 1-2 the maximum of fluorescence peak 
shifts towards higher energy both in 30:70 (Figure 3.40A and 3.41A) and 80:20 
MeOH/H2O (Figure 3.40D and 3.41C) solutions. In the pH range 2-7, upon excitation at 
280 nm in 30:70 MeOH/H2O solution both drugs show an emission band centered at 
376 nm (Figure 3.40B and Figure 3.41B), that in 80:20 MeOH/H2O is shifted to 370 nm 
(Figure 3.40E and Figure 3.41D) due to the polarity decrease of the solvent.  
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Figure 3.40. Fluorescence spectra of Irbesartan in 30% methanol/water (A-C) and 80%methanol/water (D-F) 
solution in pH dependent titration.  
 
Figure 3.41. Fluorescence spectra of Losartan in 30% methanol/water (A,B) and 80%methanol/water (C,D) 
solution in pH dependent titration. 
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The plot of the fluorescence intensity at fixed wavelength (from pH 2 to pH 7) 
superimposed to the speciation plot obtained from the potentiometric results (Figure 
3.42) shows that the fluorescence emission is always related to the imidazole 
deprotonation. The deprotonation imidazole has a quenching effect in Losartan and a 
slight increasing effect in Irbesartan. The anionic form of both drugs is not fluorescent 
and its presence lowers the fluorescence intensity, mainly in the case of Losartan. The 
fluorescence intensity of Irbesartan is increasing in the pH range 2-3.6 (Figure 3.42, A 
~15% of intensity in 30:70 MeOH/H2O and Figure 3.42, B ~40% of intensity in 80:20   
MeOH/H2O solutions) and decreases in the pH range 3.8-7, while the fluorescence 
intensity of Losartan gradually decreases in the pH range 2-7 both in 30:70 MeOH/H2O 
(Figure 3.42, C) and 80:20 MeOH/H2O solutions (Figure 3.42, D). 
 
 
Figure 3.42. The fluorescence intensity at 376 nm (A,C) and 370 nm (B,D), normalized to the scale 0–100% (+), 
and species concentration as a fraction of the total acid concentration (solid lines) for Irbesartan (A,B) and 
Losartan (C,D). The charges are omitted for the simplicity.  
In the previous studies of Jiménez et al.[208] spectrofluorimetry was wrongly used for the 
pKa determination. Their studies made in 5% methanol revealed only one pKa value for 
each molecule and attributed pKa values of Losartan 3.15±0.07 and Irbesartan 
4.70±0.06 to the tetrazole group.  
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3.2.9. Picolinic acid derivatives 
 
Potentiometric titrations of ligands H4pedpa and H6dipedpa were carried out using 1·10-
3 M ligand solutions at 0.16 M NaCl ionic strength and 25 ºC. In order to calculate the 
more acidic protonation constants from the phosphonate groups, which may not be 
calculated on the bases of potentiometric titration[53], 1H-NMR and 31P-NMR titrations 
were performed.  
H4pedpa ligand, gave evidence of five different deprotonation steps according to the 
sequence:  
H5L+ ⇋ H4L ⇋ H3L- ⇋ H2L2- ⇋ HL3- ⇋ L4-   
 
The more acidic logKa at 1.7 was calculated on the basis of 1H NMR and 31P H NMR 
titrations, and the remaining constants were calculated by fitting the potentiometric data 
using HyperQuad2013 program. These constants are presented in Table 3.12, and the 
speciation plot calculated with the fitted protonation constants is shown in Figure 3.43.  
 
Table 3.12. Protonation constants for H4pedpa at 25°C, 0.16 M NaCl ionic strength, obtained using 
HyperQuad2013 program.[200] Standard deviations on the last figure in brackets.  
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Figure 3.43. Speciation plots of the ligand calculated with the log β values shown in Table 3.12, using 1∙10-3 M 
ligand concentration. 
Species log β log K 
LH3- 8.43 (2) 8.43 
LH22- 14.71 (3) 6.28 
LH3- 18.21 (4) 3.5 
LH4 20.72 (7) 2.51 
LH5+ 22.46 1.7 
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Considering that simple phosphonate moieties, e.g. methylphosphonic acid, possess two 
protonation sites, with log KHL ~ 7.5 and log KH2L ~ 2.2[225], and that in α-
aminophosphonates and β-derivatives log Ks vary in the range 5.0-6.5 and 0.5-1.5 for 
the first and second protonation, respectively, the protonation constants calculated for 
H4pedpa (log K = 1.7 and log K = 6.28), can be attributed to the phosphonate moiety. 
Thus, the introduction of the amino group leads to the decrease of log K’s of 
phosphonate group, being log K values for the amino function in α- and β-
aminophosphonates in the range 9.5-10.5 and 10.0-11.0 respectively.  
Moreover, 1H NMR and 31P NMR titrations gave evidence of the deprotonation steps 
(Table 3.13 and Figure 3.44). The nuclei H4, H5 and P are the most affected at pH 
between 8 and 9, so the potentiometrically calculated log K = 8.43 is attributable to the 
deprotonation of the amino function. An easy attribution can be made on the basis of the 
Δδ values for each deprotonation step (Table 3.13 red values). Thereby, the first 
deprotonation with pK = 1.7, is attributable to the more acidic phosphonate proton and 
the second and third deprotonations to the carboxylic groups on the pyridine ring with 
pK = 2.51 and 3.5. 
In Figure 3.44 the chemical shifts follow the trend of calculated chemical shifts. 
 
Table 3.13. Intrinsic chemical shifts of the different protons in H4pedpa ligand in the different protonated 
species, calculated with HypNMR program, and variations of the intrinsic chemical shifts connected to each 
deprotonation step. 
Species H1 H2 H3 H4 H5 H6 
L4- 7,55 7,55 7,22 3,92 3,03 1,78 
LH3- 7,61 7,61 7,27 4,62 3,65 2,07 
LH22- 7,68 7,68 7,31 4,59 3,61 2,23 
LH3- 7,84 7,83 7,49 4,69 3,68 2,22 
LH4 7,92 7,86 7,51 4,68 3,72 2,14 
LH5+ 7,88 7,82 7,50 4,68 3,70 2,38 
 
Δδ (ppm) H1 H2 H3 H4 H5 H6 
LH3-→ L4- -0,06 -0,06 -0,05 -0,69 -0,62 -0,29 
LH22-→ LH3- -0,07 -0,07 -0,04 0,02 0,05 -0,16 
LH3- → LH22- -0,16 -0,15 -0,18 -0,10 -0,07 0,00 
LH4→ LH3- -0,08 -0,03 -0,02 0,02 -0,04 0,09 
LH5+ → LH4 0,04 0,04 0,01 0,00 0,02 -0,24 
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Figure 3.44. Chemical shifts of H4pedpa ligand as a function of pH. 
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Potentiometric and 1H-NMR and 31P-NMR titrations of H6dipedpa ligand were carried 
out and gave evidence of the eight different deprotonation steps according to the 
sequence: 
 
H8L2+ ⇋ H7L+ ⇋ H6L ⇋ H5L- ⇋ H4L2- ⇋ H3L3- ⇋ H2L4- ⇋ HL5- ⇋ L6-   
 
In this case the two more acidic log K’s from the phosphonate groups were calculated 
from 1H NMR titrations and the others were calculated by fitting the potentiometric 
data, were the LH82+ and LH7+ species were considered as strong acids. The calculated 
protonation constants are reported in Table 3.14 and the speciation plots are presented in 
Figure 3.45. 
Table 3.14. Protonation constants for H6dipedpa at 25°C, 0.16 M NaCl ionic strength, obtained using 
HyperQuad2013 program.[200] Standard deviations on the last figure in brackets.  
Species log β log K 
LH5- 10.95 (3) 10.95 
LH24- 20.07 (3) 9.12 
LH33- 27.31 (3) 7.24 
LH42- 33.22 (3) 5.91 
LH5- 37.24 (4) 4.02 
LH6 39.45 (1) 2.21 
LH7+ 41.25 (5) 1.8 
LH82+ 41.95 (7) 0.7 
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Figure 3.45. Speciation plots of the H6dipedpa ligand calculated with the log β values shown in Table 3.14, 
using 1∙10-3 M ligand concentration. 
In this case it was difficult to attribute the deprotonation sites on the basis of the Δδ 
values, as nuclei may be affected not only by the deprotonations but also by their 
structural rearrangements due to hydrogen bonding. Nonetheless the first two 
deprotonations are attributed to the most acidic protons on phosphonate groups (pK 0.7 
and 1.8), the last two deprotonations are attributed to the amino functions (pK 9.12 and 
10.95). Carboxylic groups on the pyridine ring deprotonate at pK 2.21 and 4.02 
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respectively while the more basic protons on phosphonate moieties are lost at pK 5.91 
and 7.24. In Figure 3.46 the chemical shifts follow the trend of chemical shift simulated 
with potentiometric data.  
 
Table 3.15. Intrinsic chemical shifts of the different protons in H6dipedpa ligand in the different protonated 
species, calculated with HypNMR program, and variations of the intrinsic chemical shifts connected to each 
deprotonation step. 
Species H1 H2 H3 H4 H5 H6 H7 
L6- 7,66 7,66 7,24 3,47 2,25 2,59 1,57 
LH5- 7,68 7,68 7,26 3,80 2,73 2,92 1,62 
LH24- 7,70 7,70 7,29 4,06 3,08 3,13 1,73 
LH33- 7,70 7,70 7,31 3,98 3,05 3,08 1,84 
LH42- 7,87 7,77 7,44 4,40 3,51 3,33 1,97 
LH5- 7,99 7,91 7,57 4,57 3,68 3,44 2,01 
LH6 8,13 8,29 7,80 4,83 3,92 3,67 2,20 
LH7+ 8,03 7,90 7,64 4,60 3,86 3,58 2,03 
LH82+ 7,82 8,13 7,43 4,89 3,59 3,44 2,59 
Δδ (ppm) H1 H2 H3 H4 H5 H6 H7 
LH5- → L6- -0,02 -0,02 -0,02 -0,33 -0,48 -0,33 -0,05 
LH24-→ LH5- -0,02 -0,02 -0,04 -0,26 -0,36 -0,21 -0,11 
LH33- → LH24- 0,01 0,01 -0,01 0,08 0,03 0,06 -0,10 
LH42- → LH33- -0,17 -0,08 -0,13 -0,42 -0,46 -0,26 -0,13 
LH5- → LH42- -0,12 -0,14 -0,13 -0,18 -0,17 -0,11 -0,04 
LH6 → LH5- -0,15 -0,37 -0,23 -0,26 -0,24 -0,22 -0,18 
LH7+→ LH6 0,10 0,39 0,16 0,23 0,06 0,09 0,16 
LH82+ → LH7+ 0,21 -0,23 0,21 -0,29 0,27 0,14 -0,56 
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Figure 3.46. Chemical shifts of H6dipedpa ligand as a function of pH. 
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3.3. Complex-formation equilibria studies 
 
3.3.1. Complex formation equilibria of P1 ligand[147] 
 
3.3.1.1. Complex formation equilibria with Fe3+ 
 
The iron complex formation was studied by potentiometric-spectrophotometric 
combined titrations, ESI-MS and NMR. Some spectra collected during a Fe3+-P1 
titration are presented in Figure 3.47, representative of the transformations that occur 
with pH. Up to pH 2 a new band centred at 550 nm increases in intensity (Figure 
3.47A), due to the formation of a [FeLH]2+ complex from the colourless hexaaquo-iron 
species. In the pH range 2-3 (Figure 3.47B) a new band appears at 500 nm with a clear 
isosbestic point at 585 nm, related to the formation of a [FeL2H2]+ complex. By 
increasing the pH a new band forms at 460 nm related to the neutral [FeL3H3] complex, 
with an isosbestic point at 488 nm. The behaviour up to pH 5 is similar to that of 
deferiprone that presents in sequence similar bands due to the formation of 1:1, 1:2 and 
1:3 complexes[201]. 
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Figure 3.47. Spectra obtained by increasing pH values of Fe3+-P1 system (25˚C, 0.1 M KCl ionic strength, P1 
concentration 4.9 × 10-4 M, 1:3 Fe/L molar ratio, optical path length 1 cm). These spectra were divided in 
different pH ranges to remark the transformations there occurring. 
 
A different behaviour is featured by P1 at pH > 5: first a new band appears at 445 nm 
with a clear isosbestic point at 464 nm, that at pH > 9 further transforms into a new 
band at slightly higher wavelength, with an isosbestic point at 485 nm. These last 
transformations, taking into account the potentiometric results, are related to the loss of 
a proton from the neutral species modelled as FeL3H3 (possibly corresponding to 
Fe(HL)3) giving a negatively charged complex modelled as [FeL3H2]–, and then of two 
further protons to give the [FeL3]3– complex. Such changes were observed above pH 7 
by Scarrow et al. for 3,2-hopo, but not for 3,4-hopo[202]. The first isosbestic point of 
tris(3,2-hopo) iron complex at 494 nm was attributed by the authors to the mono-
deprotonation with pK value of 9.04. A second deprotonation occurred around pH 11. It 
has to be remarked that, while DFP and P1 iron complexes are well soluble in the pH 
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range 2-11, the neutral tris(hydroxypyridinonato) iron complexes with the three hopo 
ligands studied by Scarrow et al.[202] are quite insoluble. The negative charge in the 
complexes of P1 with general model [FeL3H3–n]n– further contributes to increase their 
solubility. The stability constants of the Fe3+-P1 complexes obtained by the 
spectrophotometric-potentiometric results are reported in Table 3.16, and the related 
speciation plot in Figure 3.48. 
 
Table 3.16. Metal-ligand complex formation constants at 25˚C, 0.1 M KCl ionic strength, obtained using 
HyperQuad2013 program.[200]  Standard deviations on the last figure in brackets. 
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Figure 3.48. Speciation plots of P1 complexes with Fe3+ at 1 µM metal ion concentration and 10 µM ligand 
concentration (log β in Table 3.16). 
The pFe3+ value 22.0 of P1-iron complexes is noticeable higher than that of deferiprone 
(20.6)[201], 3,4-hopo (20.6)[202] and 3,2-hopo (16.3)[202]. This is due on one side to the 
loss of the nitrogen proton from the complex with model FeL3H3, with corresponding 
Model Fe
3+ Al3+ 
Logβ           pK Logβ              pK 
[MLH]2+ 25.92(9)  23.32(9)  
[ML2H2]+ 49.12(1)  45.18(6)  
ML3H3 71.43(6)   65.25(7)  
[ML3H2]– 65.33(3)     6.1 58.30(4)       6.95 
[ML3]3– 46.03(5)   9.65 38.41(5)       9.95 
pM 22.0 15.1 
Model Cu
2+ Zn2+ 
Logβ            pK Logβ            pK 
[MLH]+ 21.78(7)  18.79(6)  
ML2H2 41.42(7)  36.70(4)  
[ML2H]– 34.21(5)     7.21 26.02(9)   10.68 
[ML2]2– 24.68(5)     9.53 ----  
pM 10.1 6.3 
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tautomeric change to the catechol form, and on the other to the protonation constant of 
the OH group lower in P1 than in deferiprone. 
The ESI-MS data confirm the potentiometric-spectrophotometric results. Positively 
charged complexes form at acidic pH: [FeL2H2]+ (336.004 m/z), [FeL2H2+Cl-+K+]+ 
(409.940 m/z) and [FeL3H3+K+]+ (515.002 m/z), while at neutral and basic pH 
[FeL2H2]+ (336.004 m/z), [FeL3H3+Na+]+ (499.029 m/z) and [FeL3H3+K+]+ (515.002 
m/z), complexes are present. At basic pH also, the formation of negatively charged 
complex [FeL2]- (333.998 m/z) is observed (Figure A7 and Table A9). 
The interaction of P1 with Fe3+ ions has been followed by NMR at two different pH 
values. In Figure 3.49 the aromatic region of 1H NMR spectra of P1 is reported. The 
spectra were obtained by using sub-stoichiometric amounts of Fe3+ ions, from 0:1 till to 
0.2:1 metal to ligand molar ratio at pH 7 and 11.5. Both aromatic protons, H3 and H6, 
are affected by the interaction with Fe3+ ions.  
In the aromatic region of 1H NMR spectra, at pH 7, a selective broadening of signals 
was evidenced and both aromatic protons, H3 and H6, were affected by the interaction 
with Fe3+ ions. In particular, the H6 proton is the most affected suggesting the 
involvement in the coordination of the deprotonated oxygen in the position 5 to give a 
FeL3H3 species.  
 
Figure 3.49. Stacked aromatic region of 1D 1H NMR spectra of P1 by increasing sub-stoichiometric amounts of 
Fe3+, at pH 7 (left) and pH 11.5 (right) at 25 °C. 
 
Ga3+ ions have been used as a diamagnetic probe for the paramagnetic Fe3+ ions, in 
order to prevent the NMR paramagnetic line broadening. The aromatic region of 1H 
NMR spectra obtained by adding incremental amounts of Ga3+ ions to P1 solution at 
neutral pH shows that, similarly to Fe3+, H6 and H3 were the most affected protons by 
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metal coordination, giving however in this case an upfield and a downfield shift, 
respectively (Figure A8). 
The spectra obtained at pH 11.5 (Figure 3.49) confirm that the deprotonation of the 
pyridine nitrogen protons affects, after Fe3+ coordination, in the same way H3 as well as 
H6, suggesting the deprotonation of both oxygen atoms at pH > 11 without any 
hydrolysis of the complex. These features are in agreement with the proposed scheme of 
tautomerism. For Ga3+-P1 system, the signals H3 and H6 were affected, also at high pH, 
in a similar way to that of Fe3+-P1 (Figure A9). 
DFT calculations were recently used by our group to investigate the relative stabilities 
of Al3+ and Fe3+ complexes featuring the 2,2'-[(2-hydroxy-3-
methoxyphenyl)methanediyl]bis [3-hydroxy-6-(hydroxymethyl)-4H-pyran-4-one] and 
2,2'-[(4-hydroxy-3-methoxyphenyl)methanediyl]bis[3-hydroxy-6-hydroxymethyl)-4H-
pyran-4-one] ligands[35]. Encouraged by these results, we optimized the structures of the 
complexes Fe(HL)3 and [FeL3]3– at the same level of theory as free ligand. In both cases, 
the 3d5 Fe3+ metal ion has been considered to assume a high-spin configuration (spin 
sextet state). In the neutral complex, the metal ion is chelated by the three HL– ligands 
in an only slightly distorted octahedral fashion (O4-Fe-O13 angle = 96.15°; Figure 
3.50). The three ligand units show corresponding bond lengths and angles, with barely 
distinguishable Fe–O (“hydroxy”) and Fe–O (“keto”) lengths in the complex (Fe-O4 
and Fe-O5 distances = 2.082 and 1.994 Å, respectively, in the gas phase). A comparison 
of the metric parameters optimized for Fe(HL)3 in the gas phase (Figure 3.50 and Table 
A10) with the corresponding ones determined by X-ray diffraction for the neutral 
complexes Fe(P2)3, isolated in Fe(P2)3·3H2O[226], and Fe(P3)3[227] show a very good 
agreement between the experimental and calculated sets of data [P2 = 3-hydroxy-6-
hydroxymethyl-1-methylpyrid-4-onato; P3 = 1,2-dimethyl-3-hydroxypyrid-4-onato; 
average structural Fe–O distances: 2.007 and 2.018 Å; C–O: 1.314 and 1.320 Å; O–Fe–
O, 81.27° and 80.91 for Fe(P2)3 and Fe(P3)3, respectively; average calculated Fe–O 
distances: 2.039 Å; C–O: 1.275 Å; O–Fe–O, 79.29° for Fe(HL)3. 
 
Figure 3.50. Ball and stick drawing of the DFT-optimized molecular structure of the neutral complex Fe(HL)3 
(purple = Fe; red = O; grey = C; blue = N; white = H). 
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By complete deprotonation of the complex Fe(HL)3, the anionic species [FeL3]3– is 
ideally obtained. As expected, the coordination environment at the high-spin central 
metal ion is not changed as compared to the corresponding neutral complex, with only a 
marginal elongation of the Fe–O and C–O distances [average optimised Fe–O distances: 
2.056 Å; C–O: 1.287 Å; O–Fe–O, 78.77°; corresponding average structural metric 
parameters for trianionic tris-catecholate Fe3+ complexes: Fe–O, 2.01(3) Å; C–O, 
1.33(2) Å; O–Fe–O, 80(1)°], reflecting an unchanged pattern of bond orders at the iron 
centre [average Wiberg[188] bond index: 0.332 and 0.331 for FeL3H3 and [Fe(L)3]3–, 
respectively]. As observed for the free ligand, the deprotonation of the N-heterocycles 
results in the formation of hydrogen bonds between the nitrogen atoms and the 
hydroxymethyl pendants (distance N···H(O) = 1.724 Å).  The SOPTA allows 
evaluating the energy of the non-bonding hydrogen interaction in 13.1 kcal/mol for each 
ligand in the gas phase. This stabilization, amounting to about 40 kcal/mol, might be at 
the origin of the stability of such trianionic complex. 
 
3.3.1.2. Complex formation equilibria with Al3+ 
 
Aluminium with P1 forms [AlLH]2+, [AlL2H2]+ and AlL3H3 complexes. Analogous but 
weaker to those with iron. The first deprotonation of                                                                                                                                                                                                                        
AlL3H3 complex occurs with pK 6.95 and other two protons are lost together with pK 
9.9 (Table 3.16, Figure 3.51). The pAl3+ of the formed aluminium complexes is similar 
to that of DFP (Table A11). 
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Figure 3.51. Speciation plots of P1 complexes with Al3+ at 25 0C, 0.1 M KCl ionic strength, 0.5 mM ligand 
concentration and  1:3 Al3+/ligand molar ratio. 
The ESI-MS spectra both at neutral and basic pHs show the signals of [AlL2]- (305.030 
m/z), [AlL2H2]+ (307.056 m/z), [AlL3H3+H]+ (448.101 m/z), [AlL3H3+Na]+ (470.074 
m/z) and [AlL3H3+K]+ (486.049 m/z) complexes (Figure A10 and Table A12). 
The interaction of Al3+ ions with P1 has been studied in the pH range 2.2 -10.7 by 
NMR. The stacked aromatic region of 1D 1H NMR spectra of P1:Al3+ system at 3:1 
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molar ratio is reported in Figure 3.52. At pH 2.2, new signals from two species labeled 
as A and B besides the free ligand signals are shown in Figure 3.52. The specie A can 
be attributed the 1:1 complex and is not present at pH 3.6. The species B has maximum 
at pH 4.4 and exists till pH 6.9; this species, in agreement with the potentiometric 
results, can be identified as [AlL2H2]+ species. The third species (species C), present in 
3.6-10.7 pH range, can be identified as AlL3 in all the different protonation states. The 
different degree of the protonation for all of the complex species does not influence the 
coordination mode of the ligand towards Al3+ ions. 
At lower pH (2.2 -5.4) the signals in 12.4-12.1 ppm range are observed. The position of 
chemical shift for these protons strongly suggest that they are located on nitrogen 
atoms.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.52. Stacked aromatic region of 1D 1H NMR spectra of P1:Al3+ system, 3:1 molar ratio, with changing 
the pH. Arrows indicate the position of H6 and H3 proton signals in the free status of the ligand. 
 
3.3.1.3. Copper complexes 
 
P1 ligand forms with copper ions a [CuLH]+ complex from pH 2, replaced by CuL2H2 at 
pH 5. CuL2H2 loses a proton forming the [CuL2H]- complex with pK 7.21. A second 
deprotonation takes place with pK 9.53 (Table 3.16 and Figure 3.53). The pCu2+ value 
of the formed copper complexes is similar to that of DFP and 3,4-hopo (Table A11). 
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Figure 3.53. Speciation plots of P1 complexes with Cu(II) at 25 0C, 0.1 M KCl ionic strength, 0.5 mM ligand 
concentration and  1:2 Cu(II)/ligand molar ratio. 
In the ESI-MS spectra at neutral and basic pH the signals of [CuL2H]- (341.989 m/z), 
[CuL2H2+H]+ (344.002 m/z), [CuL2H2+Na]+ (365.985 m/z) and [CuL2H2+K]+ (381.963 
m/z) are observed (Table A13 and Figure A11). 
3.3.1.4. Zinc complexes 
 
P1 forms similar Zn2+ complexes to those with Cu2+, though the zinc complexes are 
weaker. [ZnLH]+ species forms from pH 4, reaching its maximum at pH ∼ 6 while the 
species [ZnL2H2] appears and becomes predominant at pH 9. This last complex 
deprotonates at pH > 10 (Table 3.16 and Figure 3.54), similarly to Zn-DFP complexes, 
suggesting the formation of a hydroxo complex [ZnL2OH]- (pK 11.25[228]). The pZn2+ 
value of the formed complexes is similar to that of 3,4-hopo (Table A11). 
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Figure 3.54. Speciation plots of P1 complexes with Zn2+ at 25 0C, 0.1 M KCl ionic strength, 0.5 mM ligand 
concentration and  1:2 Zn2+/ligand molar ratio. 
 
The ESI-MS spectra at neutral pH show only one signal attributed to [ZnL2H2+K]+ 
(382.970 m/z) (Figure A12). 
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The complexation ability of the ligand towards Zn2+ ions can be followed by 1H NMR 
spectroscopy.[185],[189] The stacked aromatic region of 1D 1H NMR spectra for P1:Zn2+ 
system at 2:1 molar ratio as a function of pH (from 2.8 to 11.5) is reported in Figure 
3.55. The H6 and H3 chemical shifts can be observed compared to those of the free 
ligand.  No zinc interaction with the ligand is observed until pH 4, as expected from 
potentiometric results. At higher pH values, changes in the chemical shift values, 
∆δ = δZn- δfree, have been determined. A dynamic equilibrium between [ZnLH]+ and 
ZnL2H2 species has been detected, forming faster than the NMR timescale. This results 
in an average signal for H6 and H3, deriving from both complexes. [ZnLH]+ is present 
in the pH range 4-9, with a maximum at pH ~ 6.5, in agreement with potentiometric 
data, even though its signals overlap those of the ZnL2H2 species. Both species are 
present until pH 9, where ZnL2H2 complex becomes predominant. By increasing the pH 
from 9.8 to 11.5, no changes in the chemical shifts of H6 and H3 protons for [ZnL2H]- 
species have been detected, except for a slight broadening of the signals, confirming the 
presence of Zn complexes together with Zn hydroxides. 
 
Figure 3.55. Stacked aromatic region of 1D 1H NMR spectra for P1:Zn2+ system, 2:1 molar ratio, as a function 
of pH. Arrows indicate the position of H6 and H3 proton signals in the free status of the ligand. 
 
It has to be remarked that the pAl3+, pCu2+, pZn2+ calculated for P1 complexes are 
almost equal to those for deferiprone and 3,4-hopo (see Table A11), in contrast with the 
net increase relative to iron complexes. This behaviour drives us to define P1 as an iron 
chelator more selective than deferiprone. 
 
93 
 
3.3.2. Complex formation equilibria of L12-L15 ligands 
3.3.2.1. Complex formation equilibria with Fe3+ 
 
The complex formation equilibria were studied using constant ligand concentration and 
1:1, 1:2 and 1:3 Fe3+/ligand molar ratios. The strong visible bands of Fe3+ complexes 
allow the study of complex formation equilibria by simultaneous potentiometric-
spectrophotometric measurements. The spectra were recorded in the 300–700 nm range, 
after addition of known volumes of NaOH solution to the ligand/iron solution (0.5 cm 
path length, concentrations of L12-L15 ligands between 1.12·10-4 M to 4.29·10-4 M), at 
25 ºC and 0.1M NaCl ionic strength. Basic titrations of all ligands gave precipitation, 
and in the case of L12 and L13 ligands, precipitation occurred even at pH > 1.3 and 3.0 
respectively, with complete dissolution of precipitate at higher pH values. Since 
complex formation was almost complete when Fe3+ and ligands were mixed, additional 
spectra were collected in the range 0-2 by adding hydrochloric acid until the 
disappearance of the band of complexes. Some of the collected spectra are reported on 
Figure 3.56. These spectra collected at acidic pH values look similar (wavelength of 
maxima and absorptivity)  to those measured for the 1:2 Fe3+ complex with kojic 
acid[33], so we hypothesized the formation of Fe2L2H2 complex. The heights of the peak 
at around 500 nm was calculated by spectral decomposition, and its trend with pH 
allowed to estimate the stability constant of the complex formed in the pH range 0-2, 
successively refined with HypSpec program (Table 3.17).  
The potentiometric data were then elaborated with HyperQuad2013 program, taking the 
value of the stability constant of the  Fe2L2H2 complex constant. This treatment allowed 
to determine the existence of the complexes reported in Table 3.17, and the related 
formation constants. The calculated speciation plots are shown in Figure 3.57. 
 
Table 3.17. Stability constants of metal complexes calculated with HyperQuad program at 25°C and 0.1 M 
NaCI ionic strength using the ligand concentration 1.12∙10−4  to 4.29∙10−4 M and metal to ligand molar ratio 
1:1. Charges are omitted for simplicity. Protonation constants of the ligands and overall stability constants (log 
βpqr) of the metal complexes were calculated by using eqs: pM + qH + rL = MpHqLr, βpqr =([MpHqLr])/( 
[M]p[H]q[L]r). 
 
 
 
Model log β L2 pK L2 log β L3 pK L3 log β L12 pK L12 log β L13 pK L13 log β L14 pK L14 log β L15 pK L15
Fe2L 26.86 --- --- --- --- --- --- --- --- --- --- ---
Fe2L2H2 --- --- --- --- 47.72 (3) --- 47.42 (4) --- 59.78 (5) --- 57.39 (2) ---
Fe2L2H 49.57 --- --- --- 44.23 (6) 3.49 -- 3.09 55.42 (6) 4.36 53.15 (6) 4.24
Fe2L2 47.43 2.14 48.82 --- 40.09 (3) 4.14 41.60 (5) 50.61 (5) 4.81 48.41 (5) 4.74
Fe2L2H-1 43.91 3.52 45.97 2.85 34.31 (4) 5.78 36.28 (5) 5.21 44.95 (4) 5.66 41.13 (4) 7.28
Fe2L2H-2 --- --- 42.29 3.68 28.13 (3) 6.18 30.06 (4) 6.25 37.14 (3) 7.81 --- ---
Fe2L2H-3 --- --- --- --- --- --- 22.42 (4) 7.66 --- --- --- ---
Fe2L2H-4 --- --- --- --- --- --- 12.35 (6) 10.07 --- --- --- ---
pFe 18.9 22.2 17.1 18.7 20.4 18.7
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All complexes are dimers of general formula [Fe2L2Hr]; when r is negative, the species 
are actually hydroxo complexes.  
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Figure 3.56. Some spectra of the titration of: a) Fe3+:L12 1:1 Me/L molar ratio [L12] = 2.83·10-4 M, b) Fe3+:L13 
1:1 Me/L molar ratio [L13] = 3.96·10-4 M, c) Fe3+:L14 1:1 Me/L molar ratio [L14] = 1.12·10-4 M, c) Fe3+:L15 
1:1 Me/L molar ratio [L15] = 4.29·10-4 M. 
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Figure 3.57. Speciation plots of L12-L15 complexes calculated on the basis of stability constants reported in 
Table 3.17, using ligand concentrations between 1.12·10-4 M to 4.29·10-4 M and metal to ligand molar ratio 1:1, 
overlapping the heights of the peaks calculated by spectral decomposition using Specpeak program[206]. 
Charges are omitted for simplicity. 
 
The calculated speciation plots shown in Figure 3.57 and the pK sequence for the loss 
of the protons from the Fe2L2H2 complex (Table 3.17) permit some considerations. 
Starting from L12, the initial [Fe2L2H2]2+ complex can be hypothesized as a dinuclear  
complex in which each Fe3+ ion is coordinated by two KA units from two different 
ligands through the two oxygen atoms (carbonyl and deprotonated OH group) as shown 
in Scheme 9A. Each iron atom is presumably hexacoordinated, with the coordination 
completed by two water molecules. This complex loose the protons from the two 
carboxylic groups with pK 3.49 and 4.14, the first equal to the pK of the free ligand and 
the second slightly higher, even if the positive charge of the entire molecule should have 
lowered these values. The complete formation of the neutral complex Fe2L2 between pH 
4 and 5 determines its precipitation. At higher pH values two of the coordinated water 
molecules loose one proton with very similar pK values 5.78 and 6.18, leading to the re-
dissolution of the precipitate. The complex [Fe2L2H-2]2- is the prevailing species at 
physiological pH, and the corresponding pFe3+ value was estimated 17.1. 
The coordination scheme of L13 with Fe3+ is similar to that of L12, but the two 
carboxylic protons are lost together with pK 3.09, which is lower than the 
corresponding values for L12. This is in line with what expected from the positive 
charge of the entire molecule that favours the deprotonation of the carboxylic groups. 
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Furthermore the neutral complex Fe2L2 with L13 loses up to four protons from the 
coordinated water molecules, the first two with pK 5.21 and 6.25 and the second two 
with pK 7.66 and 10.07. The prevailing species at pH 7.4 is always [Fe2L2H-2]2- (Figure 
3.57), but accompanied by a non-negligible amount of the [Fe2L2H-3]3- species, and this 
determines the higher pFe3+ value 18.7 (Table 3.17). 
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Scheme 9. Hypothesized coordination scheme of L12-L15 ligands with Fe3+. 
 
The behaviour of L14 and L15 is only apparently similar to that of L12 and L13 
(Scheme 9B). The deprotonation of the coordinated water molecules takes place with 
lower pK values (4.26 and 4.81 for L14, and 4.24 and 4.74 for L15), since the starting 
molecule is now positively charged. The following pKs (two for L14 and one for L15) 
are difficult to be attributed, being equally possible that the proton is lost from further 
coordinated water molecules or from the phenolic group on the linker. We trust in the 
quantum chemical calculations in progress to clarify this point. The prevailing species at 
pH 7.4 is the negative [Fe2L2H-1]- species in the case of L14 (Figure 3.57), which 
determines a very interesting pFe3+ value 20.4 (Table 3.17). In the case of L15 the 
neutral species Fe2L2 is that prevailing at physiological pH for the higher pK value, and 
this determines a lower pFe3+ value 18.7. 
The ESI-MS measurements support the previous statements. In fact for the FeCl3/L12 
system (Figure A46), the presence of dinuclear iron complexes with positive charges is 
confirmed by the signals at m/z 466.973, 475.976, 484.991 and 493.980 assigned to 
[Fe2(L12ox)H2]2+, [Fe2(L12ox)H2+H2O]2+, [Fe2(L12ox)H2+2H2O]2+ and 
[Fe2(L12ox)H2+3H2O]2+ Figure A46A) respectively. The same system in negative mode 
ESI-MS (Figure A47) shows the presence of dinuclear [Fe2(L12ox)2H2+3Cl]- complex 
(m/z 1040.870). The reaction between FeCl3 and L13 is characterized by the presence of 
signal deriving from the complexes with 2:2 stoichiometry (Figure A48): 
[Fe2(L13)2H2]2+ (m/z 469.995), [Fe2(L13)2H2+H2O]2+ (m/z 478.998) and 
[Fe2(L13)2H2+2H2O]2+ (m/z 488.004). The ESI-MS spectrum of Fe/L15 solution (Figure 
A49) confirms the formation of iron dinuclear complexes. The signals at m/z 441.991, 
A B 
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450.998 and 460.004 can be assigned to [Fe2(L15)2H2]2+, [Fe2(L15)2H2+H2O]2+ and 
[Fe2(L15)2H2+2H2O]2+ respectively (Figure A49A).  
 
3.3.2.2. Complex formation equilibria with Al3+ 
 
The ligands L12-L15 form with aluminium ion complexes similar to those observed 
with iron, but of lower stability. This implicates that the complexation happens at higher 
pH values than with iron, so with L12 at low pH a mononuclear complex [AlL2H2]- is 
initially formed in which one Al3+ ion is coordinated by two KA units of two different 
ligands, being the two COOH already deprotonated and the two remaining OH groups 
on the non-coordinating KA moieties till protonated (Scheme 10A). This molecule 
binds at pH 5 a second aluminium ion giving the neutral binuclear complex Al2L2 
(Figure 3.58). In the case of L13 the first formed complex is [Al2L2H]+ till protonated on 
a carboxylic group. All the binuclear complexes at increasing pH form hydroxo-
complexes in a similar fashion as that observed with iron ions (Scheme 10B). The 
prevailing species at physiological pH are [Al2L2H-1]-  and  [Al2L2H-2]2- in different 
ratios and the pAl3+ values are 12.7 and 12.2 for L12 and L13 respectively (Table 3.18).   
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Scheme 10. Hypothesized coordination scheme of L12-L13 ligands with Al3+. 
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A behavior analogous to that observed with iron is presented by L14 and L15 (Scheme 
11). The prevailing species at pH 7.4 are also in this case [Al2L2H-1]-  and  [Al2L2H-2]2- 
in different ratios and the pAl3+ values are 13.2 and 13.3 for L14 and L15 respectively, 
higher than the corresponding values with L12 and L13, as with iron.    
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Scheme 11. Hypothesized coordination scheme of L14-L15 ligands with Al3+. 
 
 
Table 3.18. Logβ complex formation constants of Al3+ with L12-L15 ligands. 
Model log β L12 log β L13 log β L14 log β L15 
Al2L2H2 --- --- 48.58 (6) 48.6 (1) 
Al2L2H --- 34.96 (6) 43.65 (6) 43.0 (2) 
Al2L2 30.81 (4) 30.26 (6) 37.57 (7) 37.73 (8) 
Al2L2H-1 --- 24.57 (5) 30.45 (5) 29.7 (1) 
Al2L2H-2 18.09 (4) 17.08 (7) --- --- 
Al2L2H-3 9.89 (5) 8.90 (6) --- --- 
AlL2H2 35.95 (5) --- --- --- 
pAl 12.7 12.2 13.2 13.3 
H-n are referred to hydroxo complexes. 
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Figure 3.58. Speciation plots of L12-L15 complexes calculated on the basis of stability constants reported in 
Table 3.18, using a ligand concentration 5 × 10−4 M and metal to ligand molar ratio 1:1 . Charges are omitted 
for simplicity. 
These findings are substantiated by ESI-MS results. In ESI-MS  spectrum of L12 ligand 
with Al3+ ions (Figure A50) in positive mode, we can observe an intense signal at 
441.035 m/z corresponding to [Al2(L12)2H2]2+ complex (Figure A50A) and a lower 
intensity signal at 440.027 m/z corresponding to [Al2(L12ox)2H2]2+ complex (Figure 
A50B). Each of the dinuclear complexes is present in mono- and bis-hydrated form 
represented by the signals at 450.041 m/z (attributed to [Al2(L12)2H2+H2O]2+ complex), 
459.045 (attributed to [Al2(L12)2H2+2H2O]2+ complex), 449.033 m/z (attributed to 
[Al2(L12ox)2H2+H2O]2+ complex) and 458.038 m/z (attributed to 
[Al2(L12ox)2H2+2H2O]2+  complex). The dinuclear aluminium complexes can be 
observed as well in negative mode ESI-MS spectrum (Figure A51). The signals at 
474.999, 915.036, 933.022 and 951.009 m/z can be attributed to [Al2(L12)2+2Cl]2- 
(Figure A51A), [Al4(L12)4+2Cl]2-, [Al4(L12)4+2Cl+2H2O]2- and 
[Al4(L12)4+2Cl+4H2O]2- (Figure A51B) respectively. 
The ESI-MS spectra of the reaction mixture of AlCl3/L13 is characterized by the 
presence of two major peaks (Figure A52) at m/z 441.029 and 459.040, attributed to the 
dinuclear [Al2(L13)2H2]2+ and [Al2(L13)2H2+2H2O]2+ complexes respectively (Figure 
A52A). Electrospray ionization with tandem mass spectrometry (MS/MS) spectrum of 
the [Al2(L13)2H2]2+ complex shows that the dinuclear complex is degraded into 
mononuclear [Al(L13)H]+ (m/z 459.040) complex (Figure A53A).  
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The ESI-MS spectrum of Al3+ complexes with L14 ligand shows four different species 
(Figure A54). The major signals, at m/z 413.038, 422.044 and 431.049 came from the 
dinuclear complex with stoichiometry [Al2(L14)2H2]2+ and its adducts with water, 
[Al2(L14)2H2+H2O]2+ and [Al2(L14)2H2+2H2O]2+ (Figure A54A). The charged hydrates 
are stable in vacuum when using relatively in-source collision energy (10 eV). The low 
intensity signal at m/z 607.077 can be attributed to [Al2(L14)3H5]2+ complex (Figure 
A54B). The electrospray ionization with tandem mass spectrometry (MS/M) spectrum 
of [Al2(L14)2H2]2+ (Figure A55) shows the presence of  stable hydrated dinuclear 
complexes [Al2(L14)2H2+H2O]2+ and [Al2(L14)2H2+2H2O]2+  with the signals at m/z 
422.049 and 431.056 respectively.   
 
3.3.2.3. Complex formation equilibria with Cu2+ 
 
In the acidic pH range 2-3 copper forms with L12 and L13 ligands [Cu2LH]2+ binuclear 
complexes, in which a ligand molecule binds two copper ions, one with each KA 
moiety. This complex transforms in a [Cu2L2H]- and then in a [Cu2L2]2- complex with 
pK’s 5.31 and 5.95. These values appear too high (~2 units higher than in the free 
ligand) to be attributed to the deprotonation of a carboxylic group, even also taking into 
account the negative charge of the entire molecule. A further possibility is that in 
[Cu2L2H]- one copper ion is coordinated by two KA units and the second by one, being 
the remaining till protonated on the OH group (Scheme 12B). This complex transforms 
with pK 5.31 and 5.55 for L12 and L13 respectively in the [Cu2L2]2-. This complex 
loses two further protons from the coordinated water molecules with pK 6.31 and 9.31 
for L12, and one proton at 6.19 for L13 (Scheme 12C). The prevailing species at pH 7.4 
is the [Cu2L2H-1]3- complex that determines pCu2+ values 11.1 and 9.9 for L12 and L13 
respectively (Figure 3.59  and Table 3.19). 
 
Table 3.19. Logβ complex formation constants of Cu2+with L12-L15 ligands. 
Cu log β L12 log β L13 log β L14 log β L15 
CuLH2 --- --- 25.34 (5) 24.9 (1) 
CuLH --- --- --- --- 
Cu2LH 22.62 (4) 20,89 (4) --- --- 
Cu2L2H2 --- --- 44.84 (2) 45.14 (6) 
Cu2L2H 35,10 (2) 32,31 (3) 38.68 (3) --- 
Cu2L2 29,79 (1) 26,36 (5) 31.89 (5) 33.14 (7) 
Cu2L2H-1 23,48 (3) 20,17 (3) 21.3 (1) 23.8 (2) 
Cu2L2H-2 14,17 (2) --- --- --- 
pCu 11.1 9.9 10.2 10.9 
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Scheme 12. Hypothesized coordination scheme of L12-L13 ligands with Cu2+. 
The L14 and L15 ligands form with copper the [CuLH2]+ complex in which Cu2+ is 
coordinated by one KA unit being protonated the second KA unit and the phenolic 
group on the linker. This transforms in the Cu2L2H2 neutral complex that loses a proton 
from the coordinated water molecule with pK 6.16 and 6.00 for L14 and L15 
respectively, then from the phenolic groups with pK 6.79 and 6.00 the first, and 9.34 
and 10.6 the second, always for L14 and L15 respectively (Scheme 13). The prevailing 
species at pH 7.4 are [Cu2L2H]- and [Cu2L2]2- for L15, determining the pCu2+ values 
12.2 and 10.9 respectively, always higher for the ortho substituent as in L12 and L13 
Figure 3.59 and Table 3.19). The phenolic ligands in this case are better ligands than the 
carboxylic ones. 
 
 
 
 
 
 
 
 
 
Scheme 13. Hypothesized coordination scheme of L14-L15 ligands with Cu2+. 
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Figure 3.59. Speciation plots of L12-L15 complexes calculated on the basis of stability constants reported in 
Table 3.19, using a ligand concentration 5 · 10−4 M and metal to ligand molar ratio 1:1. Charges are omitted 
for simplicity. 
The ESI-MS spectra of the reaction mixture of CuCl2/L12 (Figure A56) is characterized 
by the presence of few peaks:  475.974 m/z attributed to overlapping signals of 
[Cu(L12ox)H2]+ and [Cu2(L12ox)2H4]2+ and 493.990 m/z attributed to 
[Cu(L12ox)H2+H2O]+ complex.  
The presence of mononuclear and dinuclear copper/L13 complexes is confirmed by the 
signals at m/z 477.986 and 954.960 (Figure A57). The overlapping signals at m/z 
477.986 are assigned to [Cu(L13)H2]+ and [Cu2(L13)2H4]2+ complexes respectively 
(Figure A57A). The signal at m/z 954.960  corresponds to the [Cu2(L13)2H]+ specie 
(Figure A57B). 
The ESI-MS spectrum of Cu2+ complexes with L14 ligand shows high intensity signal 
of free ligand at m/z 389.076 and lower intensity signals of the Cu/L14 complexes 
(Figure A58). As long as the sample preparation and ESI-MS measurements conditions 
were the same for of metal/L14 solution, it can be concluded that the affinity of ligand 
toward copper ions is lower than that toward aluminum ions. The signal at m/z 449.991 
can be attributed to two overlapping species [Cu(L14)H2]+ and [Cu2(L14)2H4]2+ (Figure 
A58A). The low intensity signals at m/z 838.061  and 898.972 show the presence of 
[Cu(L14)2H5]+ (Figure A58B) and [Cu2(L14)2H3]+ (Figure A58C) complexes 
respectively. 
103 
 
The ESI-MS spectrum of Cu2+ complexes with ligand L15 (Figure A59) is similar to 
that of Cu2+ complexes with ligand 14, which indicates the formation of similar 
complexes. However, the intensity of the peak corresponding to [(L15)H3+H]+ at m/z 
389.078 is lower, indicating that ligand 15 has a higher tendency to form copper 
complexes. The presence of [Cu(L15)H2]+  and [Cu2(L15)2H3]2+ is marked by the 
overlapping signals at  m/z 449.995 (Figure A59A) . The low intensity signals at m/z 
898.983 and 920.976 are attributed to [Cu2(L15)2H3]+ (C38H29Cu2O18) and 
[Cu2(L15)2H2+Na]+ complexes (Figure A59B). 
 
3.3.2.4. Complex formation equilibria with Zn2+ 
 
The first complex formed with Zn2+ with L12 and L13 is the dinuclear complex 
[Zn2LH]2+ in which each metal ion is coordinated by one KA unit on the same 
molecule, being the carboxylic group till protonated (Scheme 19A). This complex 
transforms with L12 in a [Zn2L2]2- species coordinated by two KA units being the 
carboxylic groups deprotonated (Scheme 14B). In L13 instead it transforms in a 
[Zn2L2H]- complex, and then in a [Zn2L2]2- form with pK 6.1. This value is too high to 
be attributable to a carboxylic group, even taking into account the negative charge on 
the molecule. So a form as that reported in Scheme 14C can be hypothesized, in which 
both carboxylic groups are deprotonated and one Zn2+ ion is coordinated by two KA 
moieties, and the second by only one KA unit, being the second not implied in bonding 
and till protonated. The pK 6.1 thus corresponds to the loss of this proton, with the 
bonding of zinc by the second KA unit.  
 
Table 3.20. Logβ complex formation constants of Zn2+ with L12-L15 ligands. 
Model log β L12 log β L13 log β L14 log β L15 
Zn2LH 19.3 (2) 18.61 (9) --- --- 
Zn2L2H2 --- --- 40.0 (1) 38.3 (1) 
Zn2L2H --- 27.2 (1) --- 30.8 (1) 
Zn2L2 23.5 (1) 21.13 (8) 27.1 (2) --- 
Zn2L2H-1 16.0 (1) 12.2 (1) --- --- 
pZn* 7.5 6.8 7.7 6.4 
H-n are referred to hydroxo complexes. 
 
A final deprotonation occur both in L12 and L13 giving the hydroxo-complex [Zn2L2H-
1]3- with pK 7.5 and 8.9 for L12 and L13 respectively. 
The prevailing species at pH 7.4 are with L12 [Zn2L2]2- and [Zn2L2H-1]3- in similar 
amounts, giving a pZn2+ 7.5, and [Zn2L2]2- with L13 giving a lower pZn2+ 6.8 (Figure 
3.60 and Table 3.20). 
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Scheme 14. Hypothesized coordination scheme of L12-L13 ligands with Zn2+. 
 
The first formed complex with the ligands L14 and L15 is the neutral complex 
[Zn2L2H2] that in the case of L14 loses two protons from the coordinated water 
molecules with pK 6.5 (Scheme 15), 0.4 units lower than in the free ligand, and in L15 
only one proton with pK 7.5. Deprotonation of phenolic protons were not observed at 
high pH values. At pH 7.4 the species [Zn2L2]2- exists in L14, and [Zn2L2H2] and 
[Zn2L2H]- in L15, giving respectively the low pZn2+ values 7.7 and 6.4 (Figure 3.60 and 
Table 3.20). 
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Scheme 15. Hypothesized coordination scheme of L14-L15 ligands with Zn2+. 
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Figure 3.60. Speciation plots of L12-L15 complexes calculated on the basis of stability constants reported in 
Table 3.20, using a ligand concentration 5 × 10−4 M and metal to ligand molar ratio 1:1 . Charges are omitted 
for simplicity. 
For the reaction between ZnCl2 and L12 (Figure A60 and Figure A61), ESI-MS spectra 
are characterized by the presence of signal deriving from the positively and negatively 
charged mononuclear complexes:  [Zn(L12ox)H2]+ (m/z = 476.972, Figure A60A), 
[Zn(L12)H2]+ (m/z = 478.979, Figure A60A) and [Zn(L12)]- (m/z = 477.096, Figure 
A61A), [Zn(L12)H+Cl]- (m/z = 512.952, Figure A61B), [Zn(L12)H2+2Cl]- (m/z = 
548.920).  
The ESI-MS spectra of ZnCl2/L13 system confirm the formation of mononuclear and 
dinuclear zinc complexes (Figure A62). The signal at m/z 478.988 is attributed to 
overlapping mono e dinuclear [Zn2(L13)2H4]2+, [Zn(L13)H2]+ complexes (Figure 
A62A). The signals at m/z 496.998 and 514.977 are assigned to [Zn(L13)H2+H2O]+ and 
[Zn(L13)H2+2H2O]+ complexes respectively (Figure A62B). The signals at m/z 496.998 
and 514.977 corresponds to [Zn(L13)H2+H2O]+ and [Zn(L13)H2+2H2O]+ complexes 
(Figure A62C). 
The ESI-MS spectrum of Zn2+ complexes with ligand 14 (Figure A63), shows intense 
signal of free ligand at m/z 389.075 and low intensity signal at m/z 450.990. This signal 
is assigned to overlapping complexes with the stoichiometry [Zn2(L14)2H4]2+ and 
[Zn(L14)H2]+  respectively (Figure A63A).  
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Electrospray ionization with tandem mass spectrometry (MS/MS) spectrum of the 
[Zn2(L14)2H4]2+ complex shows the formation of hydrated mononuclear complex 
[Zn(L14)H2+H2O]+ with the signal at m/z 469.004. 
The spectrum of L15 with Zn2+ solution (Figure A64) shows the presence of free ligand 
intensive signal at m/z 389.079 and low intensity signals of the mono e dinuclear 
complexes. The signal at m/z 450.995 can be attributed to two overlapping Zn(L15)H2]+ 
and [Zn2(L15)2H4]2+ complexes (Figure A64A), while the signals at m/z 469.006 and 
486.977 can be assigned to [Zn(L15)H2+H2O]+ and [Zn(L15)H2+2H2O]+ (Figure A64) 
respectively. The m/z values of the molecular ions are in excellent agreement with the 
calculated masses. 
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3.3.3. Complex formation equilibria of L1-L8 ligands[199] 
 
Here is presented the complete characterization of the complex formation equilibria of 
copper and zinc with the ligands L1-L8 (Scheme 9, previously studied in our research 
group with Al3+ and Fe3+ metal ions[33]), together with a speciation study, showing the 
degree at which the studied ligands interfere on the homeostatic equilibria of these two 
essential metal ions. 
 
 
Scheme 16. Molecular structures of L1-L8 ligands. 
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Ligand protonation constants were previously studied and the logβ and logK values are 
summarized in Table 3.21.[33],[35],[163],[37],[36] 
Table 3.21. Protonation constants of kojic acid (KA) and L1-L8 ligands. [33] 
 KA L1 L2 L3 L4 L5 L6 L7 L8 
logK1 7.70 9.48* 10.58 10.18 9.19* 9.01* 8.52* 8.49* 9.49* 
logK2  6.59* 8.92* 8.84* 7.51* 7.61* 7.81* 6.02 6.69* 
logK3   6.95* 7.21* 4.38 3.35 5.49   
logK4       1.97   
logβ1 7.70 9.48 10.58 10.18 9.19 9.01 8.52 8.49 9.49 
logβ2  16.07 19.50 19.02 16.70 16.62 16.33 14.51 16.18 
logβ3   26.45 26.23 21.08 19.97 21.82   
logβ4       23.79   
*logK attributed to the protonation of –OH groups of kojic acid units on the base of spectrophotometric 
evidence. 
 
The biskojic acid derivatives are symmetric molecules, nevertheless two KA units do 
not lose their protons contemporary and pKs are different than those of free KA. As 
remarked in the previous works the pK’s for the deprotonations of the two kojic units 
present an opposite trend: the first one takes place at a lower and the second at higher 
pK values with respect to that of KA (Figure 3.61).  
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Figure 3.61. Comparison of pK values of kojic acid units of L1-L8 ligands. (●) pK of kojic acid, (Χ) basic pK, 
(■) acidic pK. 
 
The presence of two kojic units with two -OH groups leads to a stabilization of the first 
deprotonation through hydrogen bond, in which the proton is shared between the two –
O- groups. The formation of this hydrogen bond favours the lowering of the first pK and 
proportionally the increase of the second one (Figure 3.61). 
L1 and L8 ligands are two similar kojic acid derivatives, differing by the presence of a 
methyl group in the linker that determines the different crystal structures of protonated 
forms described in section 3.1.2. This difference between L1 and L8 in the solid state 
exists also in solution, as remarked by different NMR trend of the –CH2- and –CH3 
signals in L1 and L8 as a function of pH. The first[33] changes noticeably during the first 
deprotonation due to the bond rotation to allow the hydrogen bond formation, while –
CH3 signal in L8 is practically unaffected by this deprotonation.    
Previously studied iron complex formation constants are summarized in Table 3.22. The 
ligands L1-L3 and L8, with a single carbon in the linker between two KA units, form 
the most stable iron complexes of 2:2 stoichiometry (pFe3+ ≥20). The ligands L4-L6, 
with longer linker containing nitrogen, form 2:3 complexes of lower stability.  
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Table 3.22. logβ complex formation constants of FeIII with KA and L1-L8 ligands. [199] 
Model KA L1 L2 L3 L4 L5 L6 L7 L8 
Fe2L 
  26.86       
FeLH3       25.25   
FeLH2     22.21 21.9    
FeLH  18.1       18.4 
FeL 8.5         
Fe2L2H4          
Fe2L2H   49.57       
Fe2L2  38.14 47.43 48.82     41.11 
Fe2L2H-1  35.05 43.91 45.97     38.97 
Fe2L2H-2 
 30.37  42.29      
Fe2L3H4     69.1  70.3   
Fe2L3H3     66.10 67.2 66.2   
Fe2L3H2     61.6 64.1 61.2   
Fe2L3H     56.19 59.9    
Fe2L3 
    49.75 53.5 49.4  55.08 
FeL2H2        33.0  
FeL2H        28.2  
FeL2 17.04 31.66      22.6  
FeL2H-1  22.83      15.7  
FeL2H-2 
 13.94        
FeL3 24.15       27.1  
pFe* 13.3 23.1 18.9 22.2 18.1 19.3 17.7 16.7 20.0 
* Negative logarithm of the concentration of the free FeIII in solution, calculated for total [ligand] = 10−5M and total 
[iron] = 10−6M at pH 7.4.  
H-n are referred to hydroxo complexes. 
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3.3.3.1. Complex formation equilibria with Cu2+ and Zn2+ 
 
The protonation constants pKs of L1 and L8 are similar[33], nevertheless their  
complexes with copper ions are different (Figure 3.62A and 3.62B, Table 3.23). L1 
forms a mononuclear complex [Cu(L1)H]+ from pH 2, followed by dinuclear complexes 
[Cu2(L1)2H]+, [Cu2(L1)2] and [Cu2(L1)2H-1]- starting from pH 3. The hydroxyl group of 
one of the ligand molecules deprotonates at pH 5.97. As shown in Figure 3.62, 
[Cu2(L1)2H]+, [Cu2(L1)2] and [Cu2(L1)2H-1]- species are in equilibrium around pH 6. 
The [Cu2(L1)2H-1]- and [Cu(L1)H-1]2- complexes are the products of the hydrolysis of 
[Cu2(L1)2] complex above pH 6. With regard to L8, it forms from pH 3 only a dinuclear 
complex stable even at basic pH, in which both ligand molecules are completely 
deprotonated. The orientation of two KA in the same direction in the L8 ligand leads to 
the direct formation of dinuclear complexes. It is likely, that the presence of 
hydrophobic methyl group in the linker leads to different coordination geometries of 
dinuclear complex and  lowers the access of water in the coordination core preventing 
the hydrolysis of the [Cu2(L8)2] complex. L8 forms dinuclear complexes more stable 
than corresponding L1 complexes, as previously observed for iron complexes (Table 
3.62). 
 
 
Figure 3.62. Speciation plots of L1 (A and C) and L8 (B and D) complexes calculated on the basis of stability 
constants reported in Table 3.23 (copper) and Table 3.24 (zinc), using a ligand concentration 4∙10−4 M (L1), 
8∙10−4 M and metal to ligand molar ratio 1:1. Charges are omitted for simplicity. 
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Table 3.23. Logβ complex formation constants of Cu2+ with KA and L1-L8 ligands. 
Model KA L1 L2 L3 L4 L5 L6 L7 L8 
Cu2L       16.04(2)   
CuLH2          
CuLH  15.4(1)   16.78(4) 16.0(1)  13.50(4)  
CuL 6.6         
CuLH-1  3.22(7)   1.79(4) 2.49(7)  -0.91(5)  
CuLH-2        -12.10(2)  
Cu2L2H3    52.0(7)      
Cu2L2H2   47.34(9) 47.4(4)      
Cu2L2H  30.57(9) 41.0(2) 41.1(3) 32.3(2) 32.1(1)    
Cu2L2  24.6(1) 32.6(2) 32.5(5) 27.81(7) 27.7(1) 23.63(8)  26.9(1) 
Cu2L2H-1  18.1(1)    20.1(1)    
CuL2H2        26.43(4)  
CuL2H        20.33(4)  
CuL2  11.8       13.43(1)  
pCu* 7.3 9.4 10.2 10.5 10.4 10.0 8.5 7.2 8.8 
* Negative logarithm of the concentration of the free Cu2+ in solution, calculated for total [ligand] = 10−5M and total 
[iron] = 10−6M at pH 7.4.  
H-n are referred to hydroxo complexes. 
 
Although L1 and L8 coordinate Zn2+ ions in the same mode (Figure 3.62C and 3.62D, 
Table 3.24), the stability of the L8 complexes is higher (Table 3.24). [ZnLH]+ 
complexes form with both ligands, from pH 3. They transform in [Zn2L2] complexes, 
from pH 5. The zinc dinuclear complexes are weaker than copper dinuclear complexes 
and hydrolyze at pH higher than 6. It is likely that the higher stability of L8 complexes 
with respect to those of L1 depends on the contribution both of inductive and 
conformational effects of methyl group in the linker. 
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Table 3.24. Logβ complex formation constants of Zn2+ with KA and L1-L8 ligands. 
Model KA[229]* L1 L2 L3 L4 L5 L6 L7 L8 
ZnLH2    24.63(6)       
ZnLH  14.60(8) 18.80(7) 18.7(1) 16.49(6)  15.12(7) 12.3(1) 14.77(5) 
ZnL 4.9      8.68(5)   
ZnLH-1       -0.74(6)   
ZnLH-2        -12.86  
Zn2L2H   34.99(8) 33.0(3)      
Zn2L2  20.4(2) 27.5(2) 22.9(2) 25.1(1) 20.6(9)   21.1(1) 
Zn2L2H-1  13.3(1)   15.7(2) 15.6(9)   14.0(2) 
ZnL2H        17.5(1)  
ZnL2 9.1       9.92(6)  
pZn** 6.1 6.6 7.6 7.9 8.8 7.1 7.8 6.1 6.8 
* Studies made at 210C degrees.  
** Negative logarithm of the concentration of the free Zn2+ in solution, calculated for total [ligand] = 10−5M and total 
[iron] = 10−6M at pH 7.4.  
H-n are referred to hydroxo complexes. 
 
Similarly to L8, other two biskojic derivatives, L2 and L3, form directly dinuclear 
complexes from pH 3 (Figure 3.63A and 3.63B, Table 3.23). In [Cu2L2H2] complexes, 
Cu2+ ions are coordinated to kojic units, being orto-vanillin and vanillin on the linker 
still protonated. These groups do not contribute to metal ion coordination and 
deprotonate at pH 6.3 and 8.4 in the case of orto-vanillin, and at pH 6.3 and 8.6 in the 
case of vanillin. The difference of Cu2+ coordination between these two ligands is that 
L3 forms [Cu2(L3)2H3]+ complex where one of the hydroxyl group of kojic acid remain 
protonated until pH 4.6. It is due to the pK1 of L3 (7.21) higher than that of L2 (6.95). 
In the consequence pCu2+ of L3 (10.5) results slightly higher than that of L2 (10.2) 
(Table 3.23). 
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Figure 3.63. Speciation plots of L2 (A and C) and L3 (B and D) complexes calculated on the basis of stability 
constants reported in Table 3.23 (copper) and Table 3.24 (zinc), using a ligand concentration 5 × 10−4 M and 
metal to ligand molar ratio 1:1 . Charges are omitted for simplicity. 
Zinc coordination by L2 and L3 is weaker than that of copper (Figure 3.63C and 3.63D, 
Table 3.24). From pH 3 mononuclear complexes [Zn(L2)H2]+ and [Zn(L2)H] are 
forming, while formation of  [Zn(L3)H] species appears from pH 4. The zinc(II) ion is 
bound in [Zn(L2)H2]+ complex only to one KA unit, while the second KA unit remains 
protonated until pH 5.83 when [Zn(L2)H] is forming. [Zn2(L2)2H]- is a dominant 
species at pH 7. Although the hydroxyl group of o-vanilin in the linker do not 
participate the metal coordination it deprotonates at pH 7.49 thus lower than pK3 of free 
ligand. The possible explanation may the formation of hydrogen bond between 
deprotonated hydroxyl group of the linker and –CH2OH of kojic acid. [Zn2(L2)2]2- 
complex does not hydrolyze even at pH 10. L3 forms directly [Zn(L3)H] from pH 4. 
Such complexes are replaced by dinuclear complexes [Zn2(L3)2H]- from pH 5. The 
hydroxyl group of vanillin in the linker do not participate the metal coordination and 
deprotonate at pH 10.1 (pK3 10.18). The lack of hydrolysis of dinuclear complexes of 
L2 and L3 may be explain by the limited access of water molecule into the coordination 
core, due to the hydrophobic linker between two KA units. 
Similarly to L1, L4 and L5 ligands forms from pH 3 [CuLH] complexes, but the 
remaining proton is bound to the nitrogen (Figure 3.64A and 3.64B, Table 3.23). From 
pH 3.5 the dinuclear [Cu2L2H]+ complexes  are formed.  The proton of [Cu2L2H]+  
complexes is bound to the nitrogen, which do not coordinate metal ion, and dissociate at 
pH ~4. At basic pH occurs the hydrolysis of the dinuclear complexes, that leads to the 
115 
 
decomposition of the complexes. The [Cu2(L5)2] complexes are weaker than [Cu2(L4)2] 
and hydrolyze at lower pH. Such an important difference in the complex stability might 
be explained by the opposite inductive effects of methyl group in L4, and of benzyl 
group in L5. 
 
Figure 3.64. Speciation plots of L4 (A and C) and L5 (B and D) complexes calculated on the basis of stability 
constants reported in Table 3.23 (copper) and Table 3.24 (zinc), using a ligand concentration 5·10-4M and 
metal to ligand molar ratio 1:1. Charges are omitted for simplicity. 
Regarding zinc(II) complexes only L4 forms mononuclear [ZnLH] species (Figure 
3.64C, Table 3.24). The dinuclear complex of L4 is stronger than that of L5 and 
hydrolyze at basic pH, while [Zn2(L5)2] complex hydrolyze at pH 6 (Figure 3.64D).  
L6 ligand contains two piperazine nitrogen atoms in the linker, which is the longest 
linker among ligands presented here (Scheme 8). One ligand molecule coordinates two 
metal ions in the acidic pH (Figure 3.65A). From pH 5 the dinuclear species [Cu2(L6)2] 
forms and is stable even at pH 10. The formation of dinuclear complex [Zn2(L6)2] was 
not observed (Figure 3.65B). L6 forms only mononuclear species [Zn(L6)H]+ from pH 
4 that deprotonates at pH 6.4, while at pH 9.4 the hydrolysis of the complex starts. 
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Figure 3.65. Speciation plots of L6 complexes with copper (A) and zinc (B) calculated on the basis of stability 
constants reported in Table 3 and 4, using a ligand concentration 4·10−4 M and metal to ligand molar ratio 1:1. 
Charges are omitted for simplicity. 
L7 ligand, a step-product in the synthesis of L5, contains only one kojic acid unit and 
has one nitrogen atom in the linker (Scheme 8). As L5, it forms mononuclear 
[Cu(L7)H]2+ complexes with copper ions from pH 3 (Figure 3.66A), but weaker than 
that of L5. The explanation is the pK=9.49 of KA unit, which is higher than that of KA 
unit of L5 (7.61).  From pH 5, two L7 ligands coordinate one copper ion in the 
[Cu(L7)2H2]2+ complexes. The nitrogen atoms do not coordinate metal and deprotonate 
at pH 6.1 and 6.9. The [Cu(L7)2] complex hydrolyze at basic pH.   
 
Figure 3.66. Speciation plots of L7 complexes with copper (A) and zinc (B) calculated on the basis of stability 
constants reported in Table 3.23 and 3.24, using a ligand concentration 1 × 10−3 M and metal concentration 5 × 
10−4 M. Charges are omitted for simplicity. 
L7 ligand forms from pH 3 weak [Zn(L7)H]2+ complexes, which transforms into 
[Zn(L7)2H]+ complex at pH 5. Similar to copper complexes, nitrogen atom does not 
coordinate zinc ion and deprotonates at pH 7.51. The stability constants of 1:1 and 1:2 
(metal to ligand molar ratio) L7 complexes and higher than that of KA acid [229] (Table 
3.24).  
 
The biskojic ligands: L8, L2 and L3 do not have nitrogen in the linker and form directly 
dinuclear complexes with Cu2+ ions at pH 3. L1, in contrary to L4 and L5, does not have 
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nitrogen in the linker but forms, as they do, first mononuclear 1:1 and then 2:2 
complexes. It is likely that the stoichiometry of the formed complexes depends on the 
orientation of the kojic acid units. The ligands with the limited torsion angles due to 
short and hydrophobic linker have KA units in the same direction (L2, L3 and L8) and 
form directly 2:2 complexes with both KA units deprotonated. The ligands with lower 
steric effects form first 1:1 and then 2:2 complexes.  
 
3.3.3.2. UV-Vis studies 
 
The Cu2+ complex formation was studied by UV-Vis spectrophotometry. The UV 
spectrum from 230 to 370 nm of KA [33] and L7 [163] in the pH range 2-10 were 
previously reported and there is no absorption of the free ligands above 370 nm. The 
formation of [Cu(KA)]+ in acidic pH is marked on the absorptivity spectrum by a 
maximum at 780 nm. The band  at ~400 nm, assigned as the charge transfer 
O(phenol)→Cu2+ transition [230], confirm the metal coordination to the pair of O-donor 
atoms, the carbonyl and the vicinal hydroxyl groups of KA (Figure 3.67A). Above pH 5 
the [Cu(KA)2] complex precipitates.  
 
 
Figure 3.67. UV-Vis spectra of Cu/kojic acid (A) system (1:2 metal/ligand molar ratio) and Cu/L7 (B) system 
(1:2 metal/ligand molar ratio). 
The spectra of copper(II)/L7 system at low pH are the same as spectra of [CuKA]+ 
(Figure 3.67B). It confirms the formation of [Cu(L7)H]2+ complex and the metal 
coordination only by KA unit. The formation of [Cu(L7)2H2]2+ and [Cu(L7)2H]+ 
complexes is marked by the hypsochromic shift of the absorptivity maximum from 780 
to 750 nm. The absorptivity of [Cu(L7)2H2]2+ complex is twice of that of [Cu(L7)H]+. 
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3.3.3.3. EPR studies 
 
Due to solubility reasons, only L4, L5 and L7 Cu2+ complexes have been studied in 
water solution by EPR spectroscopy. L4 and L5 ligands show similar behavior towards 
Cu2+ ions. The EPR parameters of the complex with ligand L4, observed in the frozen 
solution at pH ~3, correspond to mononuclear (S=1/2) species with Cu2+ ions, i.e. 
[CuLH]+ (Table 3.25), (g = 2.366, A = 134.65 G) which are in agreement with an 
axial local symmetry of the Cu2+ center. By increasing the pH above 4, a new EPR 
spectrum of distinctly different form appears. It exhibits the lines corresponding to 
triplet transitions between S=1 levels splitted in Zero Magnetic Field (ZFS) (Figure 
3.68), due to anisotropy of spin-spin interaction in the formed dinuclear complexes.  
 
 
Figure 3.68. The frozen solution EPR spectra (exp) of Cu2+/L4 system and simulated (sim) using the spin 
Hamiltonian parameters given in the text. In the inset a multiplied magnified fragment portion of the 
spectrum is shown; (pH 4.32, 77 K; [Cu2+] = 3·10-3 M, metal to ligand ratio of 1:2). The stars indicate the 
signals due to S=1/2 mononuclear species. 
The formation of dimeric species, predicted by potentiometric data analysis, is also 
evidenced by the hyperfine splitting (hs) due to the interaction of the unpaired electron 
with two Cu2+ nuclei  (∑I = 2 x 3/2) that leads to seven hs lines, A = 73 G, which 
appears about half of A value for S = 1/2 Cu2+ species. The characteristic hyperfine 
splitting is seen for the two different resonance transitions: the “forbidden“ (∆Ms = 2, at 
~1500 G) and the “allowed” (∆Ms =1, ~2400 G). The calculated theoretical spectrum 
(sim) gave the best fit to the experimental spectrum using the S=1 spin Hamiltonian 
parameters, gx = gy= g⊥= 2.07, gz = g =2.38, A = 73 G and |D|=0.049cm-1. The g 
tensor components suggest similar coordination sphere to that proposed in the 
mononuclear complex. A relatively small D value allows to assume that ZFS originates 
mainly from magnetic dipole-dipole interactions dominating strongly the exchange 
coupling anisotropy and D = Ddip. Hence using the point-dipole model it is possible to 
calculate an approximate value of Cu-Cu distance in the dinuclear species of about 4 
Å[231],[232],[233]. The g and A tensors parameters, g = 2.38 , g⊥ = 2.087 and A = 135-140 
G are very similar to those assigned to the species observed at low  pH.  
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Table 3.25. Spectroscopic characteristic of Cu2+ complexes.  
Ligand Species EPR 
  A g g⊥ 
L4 [CuLH]+ 134.65 2.37 2.09 
 [Cu2L2H]+ 73 2.38 2.07 
 [Cu2L2] 73 2.38 2.07 
 [CuLH-1]- 160.10 2.29 2.09 
 
L5 
 
[CuLH]+ 
 
133.50 
 
2.37 
 
2.09 
L7 
[Cu2L2H]+ 
[Cu2L2H-1]- 
 
[CuLH]2+ 
[CuL2H2]2+ 
[CuL2H]+ 
[CuL2] 
75 
75 
 
133.50 
151.80 
151.80 
151.80 
2.38 
2.38 
 
2.37 
2.32 
2.32 
2.32 
2.07 
2.07 
 
2.09 
2.09 
2.09 
2.09 
[Cu2+] = 3·10-3 M, Cu2+ to ligand ratio of 1:2; for Cu2+aq A = 119.4, g = 2.42. 
No dinuclear complexes were observed for L7 ligand. The presence of [Cu(L7)H]2+ and 
[Cu(L7)2Hx]n+ forms was confirmed by EPR spectra, indicating tetragonal coordination 
around Cu2+ ion (Figure 3.69, Table 3.25).  
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Figure 3.69. EPR spectra of Cu2+/L7 species depending on pH at 77 K; [Cu2+] = 3·10-3 M, metal to ligand ratio 
of 1:2. 
3.3.3.4. ESI-MS studies 
 
In order to confirm speciation studies, mass spectrometry was used as a complementary 
technique. It is a powerful tool providing qualitative information on metal complexes 
formed in solution. This method can be successfully applied to determine the metal-to-
ligand stoichiometry directly from the m/z values. ESI-MS spectra of copper complexes 
of L4, L5 and L7 confirm formation of complexes of various stoichiometries. The ESI-
MS spectra of the reaction mixture of Cu(ClO4)2/L4 (Figure A13) is characterized by 
the presence of few major peaks, attributed to the mononuclear [Cu(L4)H]+ (m/z 401.03) 
and [Cu(L4)+2Na++Cl-]+  (m/z 480.97) species, and dimeric [Cu2(L4)2H]+ (m/z 803.03) 
and [Cu2(L4)2+Na]+ (m/z  825.01) complexes. The signal at m/z 432.49 corresponds to 
[Cu3(L4)2]2+ species, and the peak at m/z 762.10 indicates the formation of 
[Cu(L4)2H2+Na+]+ complex. None of these species was detected by potentiometric 
studies. A comparison between experimental and simulated signals showed an excellent 
agreement. 
For the Cu(ClO4)2/L5 system (Figure A14), the presence of mononuclear and dinuclear 
copper complexes is confirmed by the signals at m/z 477.05, and 955.07 assigned to 
[Cu(L5)H]+ and [Cu2(L5)2H]+, respectively. The signals at m/z 508.51, 892.16 
correspond to the [Cu3(L5)2]2+ and [Cu(L5)2H3]+ species. 
For the reaction between Cu(ClO4)2 and L7 (Figure A15), ESI-MS spectrum is 
characterized by the presence of signal deriving from the complexes with 1:1, [Cu(L7)]+ 
(m/z 337.04) and [Cu(L7)H+ClO4-]+ (m/z 437.00), and 1:2 [Cu(L7)2H]+ (m/z 612.17) 
stoichiometry.  
The ESI-MS spectra of the reaction mixture of Zn(ClO4)2/L1 is characterized by the 
presence of few major peaks (Figure A16), attributed to the mononuclear [Zn(L1)H]+ 
(m/z 340.97), [Zn(L1)2H3]+ (m/z 655.04) and [Zn(L1)2H2+Na+]+ (m/z 677.02), and 
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dinuclear [Zn2(L1)2H]+ (m/z 718.95), [Zn2(L1)2+Na+]+ (m/z  740.93), 
[Zn2(L1)2H2+ClO4-]+ (m/z 820.90) and [Zn2(L1)3H3]+ (m/z 1015.00) complexes. The 
signal at m/z 391.94 corresponds to [Zn3(L1)2]2+ species, the peak at m/z 1078.91 
indicates the formation of [Zn3(L1)3H]+ complex.  
The presence of mononuclear and dinuclear zinc/L2 complexes is confirmed by the 
signals at m/z 481.02, 899.10 and 921.09 assigned to [Zn(L2)H]+, [Zn(L2)2H3]+ and 
[Zn(L2)2H2 + Na+]+ respectively (Figure A17). The signals at m/z 513.98 and 963.02  
correspond to the [Zn3(L2)2]2+ and [Zn2(L2)2H]+ species. 
For the reaction between Zn(ClO4)2 and L3, ESI-MS spectrum (Figure A18) is 
characterized by the presence of signal deriving from the complexes with 1:1, 
[Zn(L3)H]+ (m/z 481.02) and 1:2 [Zn(L3)2H3]+ (m/z 899.10) stoichiometry. 
The ESI-MS spectra of Zn(ClO4)2/L4 system, confirm the formation of mononuclear 
and dinuclear zinc complexes. The signals at m/z 402.02, 741.12 and 805.03 are 
assigned to [Zn(L4)H]+, [Zn(L4)2H3]+ and [Zn2(L4)2H]+ respectively (Figure A19). The 
signal at m/z 434.98 corresponds to [Zn3(L4)2]2+ species, the peak at m/z 636.48 
indicates the formation of [Zn4(L4)3]2+ complex. 
Also L5 forms the mononuclear and dinuclear species with zinc(II) ions. The signals on 
the ESI-MS spectrum were attributed to [Zn(L5)H]+ (m/z 478.06), [Zn(L5)H2 + ClO4-]+ 
(m/z 578.01), [Zn(L5)2H3]+ (m/z 893.18) and [Zn2(L5)2H]+ (m/z 959.09) (Figure A20). 
The ESI-MS spectrum of L6 and Zn(ClO4)2 solution is characterized by the presence of 
signal deriving from the 1:1 complex [Zn(L6)H]+ (m/z 459.06) stoichiometry (Figure 
A21).  
The ESI-MS spectra of the reaction mixture of Zn(ClO4)2/L8 (Figure A22) is 
characterized by the presence of few major peaks, attributed to the mononuclear and 
dinuclear species. The signals at m/z 373.00 and 683.06 corresponds to [Zn(L8)H]+ and 
[Zn(L8)2H3]+ species respectively. The formation of dinuclear complexes is confirmed 
by the signals at m/z 746.97 and 848.93 assigned to [Zn2(L8)2H]+ and [Zn2(L8)2H2 + 
ClO4-]+ respectively. 
The L1-L8 zinc complexes with stoichiometry 1:2, 3:2 and 4:3 (metal/ligand) molar 
ratio were not observed in potentiometric studies and may be the products formed only 
in the ESI-MS conditions. 
The ESI-MS spectrum of the Zn(ClO4)2/L7 system, shows the presence of mononuclear 
zinc complexes at m/z 338.03 and 613.14 assigned to [Zn(L7)]+ and [Zn(L7)2H]+ 
respectively (Figure A23). 
 
3.3.3.5. NMR studies 
 
NMR measurements have been used to study the coordination behavior of the ligands in 
aqueous solution towards the diamagnetic Zn2+ ions. 
122 
 
For easiness, all the ligands from L1 to L8 can be gathered into two groups: A) 
including L1, L2, L3 and L8, and B) including L4, L5, L6 and L7 ligands. The ligands 
in group A, bear two kojic rings bound together by a methylene bridge as in L1, plus a 
methyl side chain as in L8, or an o-vanillin or vanillin substituent as in L2 and L3, 
respectively. The ligands in group B, except L7, are characterized by the presence of 
nitrogen atoms in the linker between the two kojic acids residues: in particular, an 
ethylazanediyl bridge in L4 and L5, and a piperazine in L6. In L7 an ethylazanediyl 
connects one kojic unit to a phenyl ring. 
The different structures of the ligands are reflected in the different proton and carbon 
NMR signals. In Table 3.26 the assignment of 1H and 13C NMR chemical shifts of the 
free ligands from L1 to L8 in aqueous solution, at physiological pH 7.4 and at 298 K, 
are reported. 
Table 3.26. Assignments of 1H and 13C NMR chemical shifts of free L1-L2-L3-L8 and L4-L5-L6-L7 ligands in 
aqueous solution at physiological pH 7.4 and 298 K. 
1Hδ ppm 
        Ligand F-F' G-G' E 
     L1 6.422 4.396 4.110 
     
 
F-F' G-G' E 
 
L M N P 
L2 6.495 4.333 6.308 
 
6.745 6.862 6.993 3.785 
 
F-F' G-G' E 
 
L M N P 
L3 6.497 4.372 6.073 
 
6.849 6.847 6.987 3.750 
 
F-F' G-G' E D 
    L8 6.422 4.430 4.833 1.560 
     
13Cδ ppm 
        Ligand F G E 
     L1 110.050 60.012 29.362 
     
 
F-F' G-G' E 
 
L M N P 
L2 109.840 59.842 38.269 
 
120.986 120.500 112.310 56.298 
 
F-F' G-G' E 
 
L M N P 
L3 109.834 59.916 42.386 
 
121.697 115.872 112.993 56.042 
 
F-F' G-G' E D 
    L8 109.891 60.020 NA 11.981 
    1Hδ ppm 
       Ligand F-F' G-G' E-E' D 
   L4 6.392 4.386 3.766 2.440 
   
 
F-F' G-G' E-E' D L-L' M-M' N 
L5 6.242 4.325 3.868 3.805 7.286 7.255 7.207 
 
F-F' G-G' E-E' D-D' 
   L6 6.469-6.458 4.432 3.725-3.710 3.197-2.797 
   
 
F G E-E' D L-L' M-M' N 
L7 6.321 4.377 3.919-3.886 2.488 7.314 7.323 7.314 
        13Cδ ppm 
       Ligand F-F' G-G' E-E' D 
   L4 109.597 59.890 53.005 43.189 
   
 
F-F' G-G' E-E' D L-L' M-M' N 
L5 109.400 59.991 51.728 59.645 129.580 128.360 128.060 
 
F-F' G-G' E-E' D-D' 
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L6 NA NA NA NA 
   
 
F G E-E' D L-L' M-M' N 
L7 109.577 60.032 53.015-60.886 41.685 128.714 130.053 128.714 
 
It is possible to see that carbon and proton signals from the two kojic aromatic rings are 
overlapped, showing that they appear equivalent on the NMR time scale due to their 
relative rapid reorientation. Actually, a free rotation around all the bonds is also 
suggested by the diffuse degeneration of the δ values of the groups bearing geminal 
protons that show no resolution of H–H coupling constants. This behavior occurs in all 
the solvents used in the NMR analysis (H2O, DMSO and MeOD), as shown in Figure 
3.70 for L2 ligand, by way of example. 
 
 
Figure 3.70. Comparison of 2D 1H - 13C HSQC spectra of the free L2 ligand in different solvents: H2O-D2O 
(blue), MeOD (red) and DMSO (green) at 298 K. 
Zinc complexes with the ligands included in group A showed in water solution several 
species in equilibrium among them in the NMR time scale, as already reported in the 
literature for similar systems[172],[234],[235],[36]. The complexity of the NMR spectra stems 
from the coexistence of some species with different stoichiometry, as evidenced from 
the potentiometric study, and probably from isomers with the same stoichiometry but 
different spatial conformation. An example of this phenomenon is shown in Figure A24 
(appendix) for L3:Zn system. A comparable behavior is found for all the ligand in A 
group including L1, L2, L3 and L8.  
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The poor water solubility of L5 and L6 ligands gave rise to precipitation in presence of 
zinc ions and prevented an accurate analysis of the ligand-Zn system in aqueous 
environment. It was possible to give evidence of the L4 coordination ability toward Zn2+ 
ions, even though the coexistence of several species in equilibrium in the NMR time 
scale (Figure 3.71). These species are probably in equilibrium also among structural 
isomers, as confirmed by potentiometric study through which mononuclear and 
dinuclear species were detected at pH 6.  
 
 
Figure 3.71. Comparison of 1H 1D spectra of L4 free (red) and L4-ZnII system, 1:0.5 molar ratio (blue), at pH 
6. 
Despite the presence of several species, the general trend of the ∆δ changes makes 
possible to highlight a plausible mode of coordination involving the oxygen atoms from 
phenolate and carbonylic groups of the kojic ring.  
The coordination ability of L7 ligand was analyzed in water solution at pH 4 and 7.2. At 
acidic pH only [ZnL7H]+ complex is formed and mainly affects chemical shift of F 
proton, and in a lesser extend ∆δ of E proton (Figure A25). The 2D 1H-12C spectrum of 
L7 ligand with Zn2+ ions at pH 7.2 (Figure 3.72) shows a new predominant species after 
Zn2+ interaction. The analysis of ∆δ variations upon Zn2+ addition to the ligand solution 
resulted in a deshielded environment for G, E and F protons, consistent with a decrease 
in the electron density in the ring due the metal coordination to O-phenolate and O-
carbonylic. The downfield shifts of D and E’ protons and carbon nuclei frequency could 
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be explained by the torsion of metal coordination sphere respect to the rest of the 
molecule.  
 
Figure 3.72. Selected aliphatic region of 2D 1H-13C spectrum for the free L7 ligand (red), and L-Zn2+ system, 
2:1 molar ratio (blue), in H2O-D2O, at pH 7.2. The new resonances of L7 upon ZnII interaction are indicated 
by arrows and the chemical shifts differences Δδ = δbound – δfree and the combined ∆δtot= 
[(∆δH)2+(0.341·∆δC)2]1/2 are showed in the histogram. 
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3.3.4. Complex formation equilibria of KβAK ligand[1] 
 
3.3.4.1. Complex formation equilibria with Cu2+ and Zn2+ 
 
KβAK forms mononuclear complexes with copper ions at pH 2, which become 
dinuclear complexes at pH 3. The presence of one proton in the [CuLH]+ complex can 
be attributed to one kojic acid unit, and discards the possibility of ring-closed 
mononuclear coordination. At pH 6.23, the [Cu2L2] complex is formed, while at pH 
7.28, 8.83 we observe displacement of protons of the water molecules in the 
coordination sphere (Figure 3.73). The ESI-MS studies of the copper complexes at 
neutral pH (Figure A26, S27) confirm the formation of [CuLH]+ and [Cu2L2H]+ 
complexes.  
 
Figure 3.73. Speciation plots of ligands complexes with Cu2+ (left) and Zn2+ (right) calculated on the basis of 
stability constants reported in table 2 using 5∙10-4M ligand concentration and 1:1 metal to ligand molar ratio. 
Charges are omitted for simplicity. 
 
The interesting results arising from the ms/ms experiment (Figure A28) with 
mononuclear complex (442.994 m/z) make it possible to locate the metal ion in the 
unsymmetrical complex. Figure 3.74 shows the possible fragments that can be obtained 
from the two different complexes reported as A and Z, respectively. In Table 3.27 and 
Figure 3.74, with the exception of the A5-Z5 and A6-Z6 pairs, we can see that A1 
fragment of the complex is equal to Z1, A2 to Z2 and so forth.  A6, Z6 and A5 
fragments are not present in the spectrum, while Z5 yields an intensive signal. The 
presence of Z5 suggests that metal coordination by kojic acid (B) occurs closer to the 
nitrogen atom. The simulated spectra are in perfect agreement with the observed signals 
(Figure A27-29, Table A14). 
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Figure 3.74. Theoretical ms/ms fragments of the CuLH complex (442.997 m/z). 
 
Table 3.27. Signals (m/z values) obtained for the fragments of the [CuLH]+ complex, using a ligand 
concentration 1·10-4 M and metal to ligand molar ratio 1:1 in H2O:CH3OH (50:50) solution, pH 7. * 
Fragments not present in the spectrum. 
Type m/z Type m/z 
A1 172.93* Z1 172.93* 
A2 186.94 Z2 186.94 
A3 202.94 Z3 202.94 
A4 230.93 Z4 230.93 
A5 244.95* Z5 245.95 
A6 258.97* Z6 259.96* 
A7 273.98 Z7 273.98 
A8 301.97 Z8 301.97 
A9 317.97 Z9 317.97 
A10 331.98* Z10 331.98* 
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The stoichiometry of the zinc complexes is not different from that of copper complexes 
(Figure 3.73), although the zinc complexes are weaker (Table 3.28). The pZn (6.1) 
value is much lower than pCu (8.3). [ZnLH]+ complexes start to form at pH 4, whereas 
[Zn2L2H]+ complexes start to form at pH 5. At pH 7.9, the [Zn2L2] complex is formed 
and at pH 9.44 water molecules in the coordination sphere are deprotonated. The mono- 
and dinuclear complexes were confirmed by the ESI-MS experiments (Figure A30). 
The ms/ms experiment (Figure A31) with [ZnLH]+ complex (443.99 m/z) shows the 
coordination of zinc ions by the B kojic acid unit (Table A15, Figures S32,S33). 
 
Table 3.28. Stability constants of metal complexes calculated with HyperQuad program at 25°C and 0.1 M 
KCI ionic strength using the ligand concentration 5∙10−4 M and metal to ligand molar ratio 1:1. Charges are 
omitted for simplicity. Protonation constants of the ligands and overall stability constants (log βpqr) of the 
metal complexes were calculated by using eqs: pM + qH + rL = MpHqLr, βpqr =([MpHqLr])/( [M]p[H]q[L]r). 
Model Fe3+ Al3+ Cu2+ Zn2+ 
MLH 18.7(1)a 15.75(2)a 15.03(7)a 13.07(5)a 
M2L2H - 30.32(8)a 29.23(4)a 24.45(2)a 
M2L2 35.3(1)a 26.09(3)a 23.00(4)a 16.55(3)a 
M2L2H-1 32.12(9)a 20.4(2)a 15.72(4)a 7.11(4)a 
M2L2H-2 28.06(5)a 16.01(2)a 6.89(4)a - 
M2L2H-3 21.00(4)a 8.87(3)a - - 
M2L2H-4 12.35(4)a 0.73(3)a -12.63(6)a - 
M2L2H-6 -7.51(5)a -18.3(2)a   
pM* 18.5 12.7 8.3 6.1 
H-n are referred to hydroxo complexes. a Standard deviation values were calculated by the HyperQuad2013 program. 
* Negative logarithm of the concentration of the free metal in solution, calculated for total [ligand] = 10−5M and total 
[metal] = 10−6M at pH 7.4.  
 
 
129 
 
3.3.4.2. Iron and aluminium complexes 
 
The ligand starts forming monomeric complexes with iron ions at pH lower than 1. 
Their presence is indicated by the spectra within the range of 400-700 nm (Figure 3.75). 
The values for absorptivity with maximum absorption at 500 nm correspond to those of 
kojic acid complexes, confirming the formation of mononuclear complex. At pH 2, 
dinuclear complexes form with water molecules in the coordination sphere. In ESI-MS  
spectrum (Figure A34) we can observe an intensive signal at 434.995 m/z 
corresponding to [Fe2L2]2+ complex (Figure A34, Panel A) and a low intensity signal at 
453.005 m/z corresponding to [FeL(H2O)]+ complex (Figure A34, Panel B). The signal 
indicating [FeL(H2O)]+ could refer to a breakdown product of the [Fe2L2(H2O)2]2+ 
complex (Figure A34 Panel D) that we observe deprotonated at neutral pH.  
 
 
Figure 3.75. Spectra of the [FeLH]2+ complex in a pH range of 0.80-2.10 obtained using 5∙10-4M ligand 
concentration and 1:1 metal to ligand molar ratio and 1 cm path length. 
 
Figure 3.76. Speciation plots of ligand complexes with iron(III) (left) and Al3+ (right) calculated on the basis of 
stability constants reported in Table 3 using 5∙10-4M ligand concentration and 1:1 metal to ligand molar ratio. 
Charges are omitted for simplicity. 
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The stoichiometry of aluminium complexes is the same as that of iron complexes, 
although the pAl value (12.7) is lower than the pFe value (18.5) (Table 3.28). The 
mononuclear complex [AlLH]+ exists from pH 2 to pH 6 (Figure 3.76). The dinuclear 
complex [Al2L2H] starts to form at pH 3 and at pH 4.3 loses its last proton. The 
presence of mono (single charged) and dinuclear (double charged) complexes is 
confirmed by two overlapping signals at 406.039 m/z in the ESI-MS spectrum (Figure 
A35, panel A). Two of the coordination water molecules in the coordination sphere are 
forming most likely bridges between two aluminium ions. In the ESI-MS spectrum 
(Figure A35) we observe a signal at 424.050 m/z for [AlL(H2O)]+, which confirms the 
importance of water in the complex structure. The signal corresponding to [AlL(H2O)]+ 
could indicate a breakdown product of the [Al2L2(H2O)2]2+ complex that we observe 
deprotonated at neutral pH.  
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3.3.5. Complex formation equilibria of SC ligand 
 
3.3.5.1. Complex formation equilibria with Fe3+ 
 
The complex formation equilibria were studied by simultaneous spectrophotometric-
potentiometric measurements, both on a set of solutions at different concentrations of 
HCl from pH 0.4 to pH 2.6, and from basic titrations starting from pH 2.7. Some spectra 
collected during these titrations are presented in Figure 3.77. When pH increases from 
0.4 to 2 (red curves), a wide band appears at ~500 nm attributable to the complex 
[Fe(SC)H5]5+ on the basis of its similarity with the spectra of 1:1 iron complex with 
kojic acid[33]. When pH increases from 2 to 3.2, a new band appears at 479 nm, 
attributed to the formation of [Fe(SC)H4]4+, where two units of KA coordinate one Fe3+ 
ion, for the similarity in wavelength of maximum and absorptivity with the spectra of 
the 1:2 Fe:KA complex[33]. After pH 3.2 (blue curves) a new band at 395 nm increases 
with an isosbestic point at 485 nm. This band corresponds to the formation of the 
complex [Fe(SC)H3]3+ and Fe3+ is coordinated by all the three KA units, for similarity 
in wavelength of maximum and absorptivity with the spectra of the 1:3 Fe:KA 
complex[33]. At pH 7.3 (green curves) the complex deprotonates and at pH > 8.5 
precipitations of the neutral Fe(SC) complex occurs.  
 
 
Figure 3.77. Some spectra of the titration of Fe3+:SC 1:1 Me/L molar ratio [SC] = 2.36·10-4 M, at 0.1 M NaCl 
ionic strength and 25 ºC, 1cm optical path length. Red curves, pH 0.42-3.20; Blue curves, pH 3.37-6.20; Green 
curves, pH 6.70-8.35. 
By simultaneous fitting of the potentiometric and spectrophotometric data the stability 
constants in Table 3.29 were obtained. The first deprotonation of the [Fe(SC)H3]3+ 
complex occurs with pK 7.50 and the second and the third deprotonations occur 
simultaneously with pK 8.63. These values are lower than those of the free ligand (9.00, 
9.62 and 10.97) for the different charges of complex and free ligand (3+ and 0 
respectively). In Figure 3.78 the related speciation plot is reported. 
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Table 3.29. Stability constants of metal complexes calculated with HyperQuad program at 25°C and 0.1 M 
NaCI ionic strength using the ligand concentration [SC] = 2.36·10-4 M and metal to ligand molar ratio 1:1.  
Species Logβ pK 
[Fe(SC)H5]5+ 53.5 (6) - 
[Fe(SC)H4]4+ 52.12 (7) 1.38 
[Fe(SC)H3]3+ 48.12 (4) 4.00 
[Fe(SC)H2]2+ 40.62 (4) 7.50 
Fe(SC) 23.37 (5) 8.63 
pFe3+ 18.4  
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Figure 3.78. Speciation plots of SC complexes with Fe3+ calculated on the basis of stability constants reported 
in Table 3.29 using 2.36∙10-4 M ligand concentration and 1:1 metal to ligand molar ratio. Charges are omitted 
for simplicity. 
 
3.3.5.2. Complex formation equilibria with Ga3+ 
 
The study of formation of Ga3+ complexes with SC by use of direct potentiometry was 
hindered by the complete formation of complexes at the starting of the titration, so the  
study of the Ga3+:SC system required spectrophotometric measurements. Thus, the 
overall stability constants of the Ga3+ complexes with SC  were studied by 
spectrophotometric measurements on a set of solutions from pH 0.11 until pH 12, and 
by potentiometric titrations. Some of the collected spectra are presented in Figure 3.79.  
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Figure 3.79. Some absorbance spectra of the titration of Ga3+:SC 1:1 Me/L molar ratio [SC] = 9.86·10-5 M, at 
0.1 M NaCl ionic strength and 25 ºC, 1 cm optical path length (red, green, violet and blue curves), overlapping 
to the normalized free ligand SC spectra collected during a simultaneous potentiometric-spectrophotometric 
titration. 
Because of the completely filled d shell of the Ga3+ ion, it was not possible to perform 
spectrophotometric measurements in the visible region of the spectra. However, it was 
possible to take advantage of the spectral changes in the ultraviolet region, were the 
ligand absorbs.  
Figure 3.79 shows some spectra of the Ga3+-SC complex (1:1 molar ratio, [SC] = 
9.86·10-5 M) collected during the spectrophotometric titrations, overlapping to the 
spectra of free SC collected as discussed in section 3.2.7. Starting from very acidic pH, 
various differently protonated 1:1 complex are formed. Starting from pH 0.11, the band 
at 272 nm, corresponding to the fully protonated ligand starts to decrease and in the 
meantime two new bands, at 305 nm and at 256 nm, appear with the shift of the 
characteristic isosbestic of SC ligand from 291 nm to 287 nm. This trend can be 
observed until pH 7.5. Some sort of dissociation of the metal ion from the chelating 
groups takes place above pH 7.5. At pH > 8.03 the spectra of the chelate become similar 
to those of the free ligand (with a maximum at 315 nm), as shown in Figure 3.79, not 
accompanied by precipitation phenomena. This spectral behaviour, together with the 
potentiometric results, indicate the possible dissociation of some chelating KA moieties 
from Ga3+ and the formation of complex hydroxo-species avoiding the precipitation of 
the metal hydroxides. The calculated complex formation constants (the first three from 
the spectral results and the following from the titration data) are reported in Table 3.30 
together with the corresponding pK’s. 
Surely the pK 4.98 correspond to the formation of a hydroxo-compound, and 
presumably the last three (8.67 for two protons and 9.80) are relative to the 
deprotonation of the charged nitrogen atoms. The remaining pK’s are difficult to be 
attributed because they depend both on the formation of hydroxo-compounds and on the 
deprotonation of the OH group of the KA units, no more bounded to Ga3+. 
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Table 3.30. Stability constants of metal complexes calculated with HyperQuad program at 25°C and 0.1 M 
NaCI ionic strength using the ligand concentration [SC] = 4.88·10-4 M and metal to ligand molar ratio 1:1.  
 
Species Logβ pK 
[Ga(SC)H5]5+ 53.0   
[Ga(SC)H4]4+ 50.5 2.5 
[Ga(SC)H3]3+ 47.46 (4) 3.04 
[Ga(SC)H2]2+ 42.48 (3) 4.98 
[Ga(SC)H]+ 34.88 (3) 7.60 
[Ga(SC)H-1]- 18.67 (3) 8.105 
[Ga(SC)H-3]2- 1.33 (3) 8.67 
[Ga(SC)H-4]3- -8.47 (4) 9.8 
pGa3+ 20.2  
 
The decomposition of the spectra collected during the spectrophotometric Ga3+-SC 
titration in the Gaussian components (Figure 3.80) shows that from acidic pH the 
[Ga(SC)H5]5+ species is formed and one kojic acid unit is coordinating Ga3+ ion, while 
at pH 3.5 the third proton from KA units is lost, and from pH 7.6 the complex start to 
hydrolyze and the band of the totally deprotonated kojic acid reaches its maximum 
confirming that at least one or two KA units are no more involved in Ga3+ coordination. 
Figure 3.80 shows the speciation plots of the Ga3+-SC system calculated by the stability 
constants in Table 3.30. 
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Figure 3.80. A) Peak heights obtained by spectral decomposition vs. pH using Specpeak program[206]. B) 
Speciation plots of SC complexes with Ga3+ calculated on the basis of stability constants reported in Table 3.30 
using 9.86∙10-5M ligand concentration and 1:1 metal to ligand molar ratio. Charges are omitted for simplicity. 
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3.3.6. Complex formation equilibria of Losartan and Irbesartan ligands 
3.3.6.1. Cu2+ and Zn2+ complexes formation equilibria 
 
The complex formation equilibria with Cu2+ and Zn2+ were studied potentiometrically in 
a 80:20 MeOH/H2O solution due to the low solubility of the formed complexes both in 
water and 30:70 MeOH/H2O solution. The studies were carried out at 0.5 mM ligand 
concentration in 1:2 and 1:4 metal/ligand molar ratios. At 1mM ligand concentration 
complex precipitation occurrs. The results are reported in Table 3.31. 
 
Table 3.31. Complex formation constants, logβpqr and pM values at 25.0 ◦C and 0.1 M NaCl ionic strength in 
80:20 MeOH:H2O solution. The charges are omitted for the simplicity. 
Specie Irbesartan Losartan 
LH 4.98(1) 5.07(1) 
LH2 3.25(1) 2.56(1) 
CuL - 4.12(7) 
CuL2 6.89(3) 7.1(3) 
CuL2H-1 - 2.40(9) 
CuL2H-2 -4.03(1) -3.6(4) 
pCu2+ 6.7 7.4 
ZnL - 3.7(1) 
ZnL2 - 6.2(1) 
ZnL2H-1 0.42(8) 0.4(2) 
ZnL2H-2 -6.51(4) -6,69(8) 
pZn2+ 6.0 6.0 
 
In the following we indicate with I and L the completely deprotonated forms of 
Irbesartan and Losartan. A weak [CuI2] complex is formed between Irbesartan and 
copper ions from pH 4, replaced by a [CuI2H-2] complex from pH 5 (Figure 3.81A). 
Zinc forms with Irbesartan weaker complexes than copper with the same stoichiometry 
(Figure 3.81B, Table 3.31).  
The Cu2+/Losartan complexes are slightly stronger than those with Irbesartan (Table 
3.31). A 1:1 Cu/Losartan complex is already formed from pH 2.5, replaced by 1:2 
differently protonated complexes (Figure 3.81C). Also in this case, zinc complexes 
weaker than those of copper, with the same stoichiometry, are formed from pH 3 
(Figure 3.81D).  
Precipitation of copper complexes in 80:20 MeOH/H2O solution starts at pH~5, while 
zinc complexes precipitate above pH 7.5. The low solubility of copper complexes can 
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be attributed to the formation of the dimeric [Cu(Ligand)2(H2O)3]2 complex synthesized 
and characterized by Etcheverry et al.[236] Their FTIR and Raman studies demonstrated 
that copper ion in [Cu(Ligand)2(H2O)3]2 complex is coordinated to the ligand through 
the nitrogen atoms of the tetrazol moieties. The formation of a dimeric complex was 
revealed by EPR measurements at room temperature. The metal centers are in a 
tetragonal distorted environment. Minor amounts of a monomeric complex are also 
present. 
 
Figure 3.81. Speciation plots relative of copper and zinc complexes calculated using the stability constants in 
Table 3.31. Ligand concentration was 0.5 mM and a 1:2 metal to ligand ratio was used. The charges are 
omitted for the simplicity. 
Isothermal titration calorimetry by Denadai et al.[237] shows that complexation in water 
is a stepwise process, driven by enthalpy and entropy. 1:1 Cu2+/Losartan species are 
formed at low molar ratio, while a 1:2 Cu2+/Losartan species is formed at molar ratio 
greater than 1.[237] The 1:2 stoichiometry complex is enthalpically favored, due to the 
strong metal-ligand bond, improved by Ligand Field Stabilization Energy (LFSE). The 
entropic contribution has been attributed to the loss of water molecules occurring in 
complexation and to the loosening of complex molecular structure due to tetragonal 
distortion. The formation of copper-active Van der Waals interactions between the 
aliphatic chain of Losartan in the solid state stabilizes the Cu2+/Losartan complexes. 
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3.3.6.2. ESI-MS characterization of Cu2+ and Zn2+ complexes 
 
ESI-MS spectroscopy applied to Irbesartan and Losartan complexes with Cu2+ and Zn2+ 
confirms Denadai et al. [237] findings. In fact already the pure sartans’ ESI-MS spectra 
confirm that Van der Waals interactions between sartan aliphatic chains lead to the 
formation of dimers in solution: [2I+H]+ (857.472 m/z, C50H57N12O2), [2I+Na]+ (879.454 
m/z, C50H56N12O2Na), [2I+2Na]+ (901.436 m/z, C50H55N12O2Na), [2L+K+H]+ (883.285 
m/z, C44H46Cl2KN12O2), [2L+2K]+ (921.241 m/z, C44H45Cl2K2N12O2), [2L+3K]+ 
(959.199 m/z, C44H44Cl2K3N12O2) and [2L+3K+Na]+ (982.189 m/z, C44H45Cl2K3N12O2) 
(Figure A36D-F and Figure A37C-F). 
The ESI-MS signals of Irbesartan with Cu2+ ion can be attributed to [CuI+H]+ 
(491.162m/z, C25H28N6OCu, Figure A38A) and [CuI2+2H]+ (919.394 m/z, 
C50H56N12O2Cu, Figure A38B). The charge and empirical formula of the complexes 
suggest some redox reactions. Electrospray ionization with tandem mass spectrometry 
(MS/MS) of the [CuI+H]+ complex show four signals: 463.16 m/z, 448.14 m/z, 352.09 
m/z and 296.03 m/z, whose isotopic patterns perfectly fit (Figure A39A-D) to the 
complexes presented in Figure 3.82. The lowest m/z signal suggests copper ion 
coordination by tetrazol ring.  
 
 
Figure 3.82. Electrospray ionization with tandem mass spectrometry (MS/MS) spectrum of the [CuI+H]+ 
complex. The precursor ion selected for fragmentation in the MS/MS experiment is indicated by a dot.  
 
The ESI-MS spectrum of Irbesartan with zinc(II) confirms the formation of [ZnI]+ 
complex (C25H27N6OZn 491.155 m/z, Figure A40A) and of its mono- and bis-hydrated 
forms: [ZnI+H2O]+ and [ZnI+2H2O]+ (C25H29N6O2Zn 509.160 m/z, C25H31N6O3Zn 
527.131 m/z, Figure A40B and A40C, respectively). The signal at 919.395 m/z is 
attributed to the [ZnI2+H]+ complex (C50H55N12O2Zn, Figure A40D). MS/MS spectrum 
of the [ZnI]+ complex, even at low collision energy (15 eV), leads to the decomposition 
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of the complex. The MS/MS spectrum of the [ZnI2+H]+ complex shows three signals at 
491.16, 449.16 and 429.25 m/z, attributed to the [ZnI]+ complex, to the [C22H20N6OZn]+ 
fragment and to  [I+H]+ (Figure A41). 
The ESI-MS spectra of free Losartan solution, and with Cu2+ and Zn2+  ions are reported 
in Figure 3.83. 
 
 
Figure 3.83.ESI-MS spectra of Losartan A) pure, B) with copper at 1:1 molar ratio, and C) with zinc at 2:1 
molar ratio in the 400-470 m/z range. 
 
The signal at 461.124 m/z corresponds to Losartan [L+K+H]+ (C22H23ClKN6O). In the 
presence of metal ions two additional signals at 423.169 and 405.158 m/z are present 
attributable to [L+2H]+ (C22H24ClN6O) and  [L-H2O]+ (C22H22ClN6) respectively. One 
of the possible explanations of this phenomenon is that in the presence of these metal 
ions the reaction in Scheme 17 occurs. 
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Scheme 17. Suggested formation of 3-butyl-1-chloro-8-[2-(1H-tetrazol-5-yl)phenyl]-5,10-dihydroimidazo[1,5-
b]isoquinoline  by rearrangement of Losartan in presence of metal ions. 
 
ESI-MS spectrum of Losartan with copper (molar ratio 1:1) shows low intensity signals 
attributed to [CuL+H]+ (C22H23ClN6OCu 485.092 m/z, Figure A42A), [CuL2+2H]+ 
(C44H46Cl2N12O2Cu 907.252 m/z, Figure A42C), [Cu3L4]2+ (C88H88Cl4N24O4Cu3 
936.701 m/z, Figure A9D), [CuL2+H+K]+ (C44H45Cl2N12O2CuK 945.209 m/z, Figure 
A42E) and [Cu3L2]+ (C44H44Cl2N12O2Cu3 1031.098 m/z, Figure A42F). Charge and 
empirical formulae of [CuL+H]+, [CuL2+2H]+ and [CuL2+H+K]+ complexes suggest a 
redox reactions analogously to those observed with Irbesartan. MS/MS of the [CuL+H]+ 
complex, even at low collision energy (10 eV), leads to its decomposition. MS/MS 
spectrum of the [CuL2+2H]+ complex shows one signal at 461.134 m/z, which can be 
attributed to [L+K]+ (Figure A41). 
ESI-MS spectrum of Losartan with Zn2+ ion at 1:2 metal to ligand molar ratio shows 
three signals at 485.083, 907.245 and 937.701 m/z, which can be attributed to [ZnL]+ 
(C22H22ClN6OZn), [ZnL2+H]+ (C44H44Cl2N12O2Zn) and [Zn3L4]2+ (C88H88Cl4N24O4Zn3), 
respectively. 
The redox activity of Cu2+/Losartan complexes was previously observed by Etcheverry 
et al.[236] Their studies showed weak Superoxido Dismutase activity of  
[Cu(Ligand)2(H2O)3]2 complex at pH 10.2. 
 
3.3.6.3. NMR characterization of Zn2+ complexes  
 
Free Losartan ligand has been studied by NMR techniques in different solvents and 1H 
1D NMR spectra in D2O at pH 7.0, in MeOD-d4 and DMSO-d6 are shown in Figure 
A43. In Table A16 1H and 13C chemical shift assignments of signals of the free ligand 
are reported in the different solvents. The low solubility of the ligand in aqueous 
solution and the precipitation by adding Zn2+ ions at a 5-7 mM concentration of 
Losartan and 1:0.5 and 1:1  ligand/metal molar ratio prevented the NMR study in water. 
140 
 
For this reason the interaction of Losartan with Zn2+ ions has been followed in MeOD 
and DMSO. In Figure 3.84 the comparison of 1H 1D NMR spectra of Losartan:Zn2+ 
system in MeOD solvent at molar ratios of 1:0, 1:0.5 and 1:1 is shown, respectively.  
 
Figure 3.84. 1H 1D NMR spectra of Losartan:Zn2+ system in MeOD-d4 solvent in the molar ratio of 1:0, 1:0.5 
and 1:1 at 25˚C and pH 7.  
 
Perturbations were clearly observed in the aromatic region of the spectra starting at 
1:0.5 L:Zn2+ molar ratio. Indeed, changes in chemical shifts were detectable for H-22, 
the closest proton to tetrazolate moiety, together with H-19 and to a lesser extent for H-
13, -17, -14 and -16 from biphenyl, that are further away from the tetrazolate moiety. 
No overt changes were observed for the other protons of the molecule, except for a 
slight broadening of the signals. Based on these findings, tetrazole appears to be the 
anchoring site for Zn2+ ion, in agreement with the potentiometric and spectroscopic 
results. 
The more evident broadening of the signals at molar ratio 1:1 can be ascribed to the 
presence of chemical exchange in an intermediate regime with respect to the NMR 
timescale. The same behaviour of Losartan with Zn2+ ions was observed in DMSO-d6 
solution. Comparison of 1H 1D NMR spectra of free Losartan and Losartan:Zn2+ system 
at a molar ratio 1:1 is reported in Figure 3.85, and  aromatic region within 2D 1H-13C 
HSQC  spectra in Figure 3.86. In fact, H-22, H-20, H-19 and H-21 were the protons 
most affected after adding Zn2+ ions to the ligand solution, suggesting that the same 
coordination as in MeOD is retained also in DMSO-d6 solvent. 
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Figure 3.85. Comparison 1H 1D NMR spectra of free Losartan (red) and Losartan:Zn2+ system at a molar 
ratio of 1:1 (blue), in DMSO-d6 solvent, at 25˚C and pH 7. 
 
 
Figure 3.86. Comparison of 2D 1H-13C  HSQC NMR spectra of free Losartan (red) and Losartan:Zn2+ system 
at a  molar ratio of 1:1 (blue), in DMSO-d6 solvent, at 25˚C and pH 7. 
 
Also in the case of Irbesartan the spectra were obtained in MeOD solution where the 
ligand is soluble at the concentration used for NMR experiment. In Figure A44 the 1H 
1D NMR spectrum obtained in this solvent is shown, while in Figure A45 the 1H 2D 
COSY NMR spectra of aliphatic region in the same MeOD solution are shown. When 
adding Zn2+ ions to Irbesartan methanolic solution, perturbation in NMR spectra were 
detected. In Figure 3.87 a comparison of 1H 1D NMR spectra of Irbesartan:Zn2+ system 
at a  molar ratio of 1:0, 1:0.5 and 1:1 is shown. 
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Figure 3.87. 1H 1D NMR spectra of Irbesartan:Zn2+ system in MeOD-d4 solvent at a molar ratio of 1:0 (red), 
1:0.5 (green) and 1:1(blue) at 25˚C and pH 7. 
The most apparent feature emerging from 1H 1D spectra is related to the complete 
disappearance of the signal of the protons in the 7th position on the aliphatic chain, 
followed by a change in the multiplicity of the signal of the two protons in the 8th 
position, as expected and highlighted in the inset. This feature can be explained by the 
presence of a possible tautomerism induced by Zn2+ ions, as reported in the Scheme 18: 
 
 
Scheme 18. Possible tautomerism induced by Zn2+ ions. 
 
The signal of methylene proton on the 7th position can then shift towards lower field, 
under the water signal, as expected. Taking into account that protons and carbons of 
tetrazole and biphenyl moieties show only minor changes in their chemical shifts upon 
Zn2+ addition, we can suggest that the coordination site of Zn2+ ions can be mostly 
located on the imidazolic ring of Irbesartan ligand in our NMR conditions.  
 
 
 
143 
 
3.3.7. Complex formation equilibria of H4pedpa and H6dipedpa ligands 
3.3.7.1. Complex formation equilibria with La3+ 
 
The complex formation equilibria of La3+ with H4pedpa and H6dipedpa ligands have 
been studied by potentiometric titrations and in the case of H4pedpa ligand by 1H NMR 
titrations. The potentiometric results, analyzed with HyperQuad2013 program, gave the 
complexation schemes and complex formation constants reported in Tables 3.32 and 
3.33 which allowed to obtain the related speciation plots in Figures 3.88 and 3.90. 
H4pedpa forms from pH 2 a 1:1 neutral LaLH complex, in which presumably La3+ is 
bound through the three nitrogen atoms and two oxygen atoms of carboxylate groups, 
being the phosphonate group till protonated. This last proton is lost with pK 4.45, lower 
than that in the free ligand. This should imply the involvement of phosphonate in La3+ 
coordination. The complex loses a further proton from a coordinated water molecule 
with pK 10.08 giving a hydroxo-complex. 
 
Table 3.32. Stability constants of metal complexes calculated with HyperQuad program at 0.16 M NaCI ionic 
strength and 25°C using [H4pedpa] = 6.52·10-4 M ligand concentration and 1:1 metal to ligand molar ratio.  
Species log β log K 
LaLH 17.03 (3) 
 [LaL]- 12.58 (2) 4.45 
[LaLH-1]2- 2.50 (4) 10.08 
pLa3+ 12.4   
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Figure 3.88. Speciation plots of H4pedpa complexes with La3+ calculated on the basis of stability constants 
reported in Table 3.32 using 3.26∙10-3 M ligand concentration and 1:1.5 metal to ligand molar ratio. Charges 
are omitted for simplicity. 
From 1H NMR titrations of the H4pedpa ligand and of the mixture La3+: H4pedpa 1:1.5 
metal to ligand molar ratio, the implication of the phosphonate group in La3+ 
coordination is clear (Figure 3.89). Already in the spectrum of the free ligand, the 
resonances due to the H5 and H6 methylene groups show a fine structure (apparent 
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doublet of doublets) indicating the inequivalence of each proton within the same 
methylene, which is typical for a slow rotating methylene moiety. The frequency 
difference among the two protons of both H5 and H6 become even more pronounced 
upon complex formation, due to a further reduction of the methylene rotation about the 
C-C bonds. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.89. 1H NMR spectra of H4pedpa:La3+ system in D2O solvent at a molar ratio of 1.5:1 at 25˚C and pH 
range 3-11.9. 1H NMR spectra of H4pedpa ligand at pH 3 (red spectra). 
 
A similar complexation scheme is shown by H6dipedpa. From the potentiometric data, 
presumably the second phosphonate group is not involved in coordination. 1H NMR 
titrations are at the moment in progress, which will aid in attributing coordination 
schemes to the variously protonated complexes pointed out by potentiometry. The pLa3+ 
values for the two ligands are practically equal (Tables 3.32 and 3.33). 
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Table 3.33. Stability constants of metal complexes calculated with HyperQuad program at 0.16 M NaCI ionic 
strength and 25°C using [H6dipedpa] = 6.43·10-4 M ligand concentration and 1:1 metal to ligand molar ratio.  
Species log β log K 
La(LH3) 34.25 (3)  
[La(LH2)]- 30.95 (1) 3.3 
[La(LH)]2- 24.60 (1) 6.35 
[LaL]3- 14.26 (2) 10.34 
pLa3+ 12.7   
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Figure 3.90. Speciation plots of H6dipedpa complexes with La3+ calculated on the basis of stability constants 
reported in Table 3.33 using 6.43∙10-4 M ligand concentration and 1:1 metal to ligand molar ratio. Charges are 
omitted for simplicity. 
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3.4. Lipophilicity, drug-like descriptors and Biodistribution studies  of 
P1 ligand[147] 
3.4.1. Lipophilicity and drug-like descriptors 
 
Lipophilicity greatly influences the pharmacokinetic and pharmacodynamic profile of a 
drug, and the partition coefficient between water and n-octanol (log P) is the parameter 
in use for its evaluation. Log P of P1, and of DFP for comparison, were measured with 
the “shake-flask” method. The obtained values (Table 3.34) are quite similar, though 
that of P1 (-0.90) is slightly less than that of DFP (-0.82). The same lipophilicity order 
was obtained from in silico calculations, using QikProp program.[238] This program 
provides also a number of indicators of the pharmacokinetic profile of a drug, as the 
ability to cross the blood-brain barrier (log BB), the ability to be absorbed through the 
intestinal tract to the bloodstream (Caco-2 cell permeability) and the verification of 
Lipinski’s rule of five [9] (Table 3.34).  
Although P1 does not present any violation of the restricted Lipinski´s rule, it presents 
some limitations to barrier-crossing ability compared to DFP. In particular, P1 presents 
lower permeability through the Caco-2 membranes (higher than 500 nm/sec is 
considered good)[238], as well as through the blood-brain barrier (log BB < -1.0, poorly 
distributed to the brain) and thus lower bioavailability into the central nervous system. 
Interestingly the tautomeric diphenolic form H2Lb is characterized by slightly better 
pharmacokinetic descriptors than H2La, namely in terms of membrane permeability, due 
to the increased aromaticity of the molecule that involves a lipophilicity enhancement. 
 
Table 3.34. Experimental values of octanol/water coefficient log P for P1 (in the neutral forms H2La and H2Lb) 
and DFP, and calculated values for clog P, ability to cross the blood-brain barrier (log BB), ability to be 
absorbed through the intestinal track to the blood (Caco-2 cell permeability), bioavailability into the central 
nervous system  and the verification of Lipinski’s rule of five.[9] 
Name DFP H2La H2Lb 
MW 138 141 141 
logPa -0.82 -0.90 - 
clogPb 0.915 -0.795 0.520 
log BBb,c -0.254 -1.021 0.978 
Caco-2 Permeability (nm/s)b 1141 192 256 
CNSb +/- -- - 
Violations of Lipinsky rulesb 0 0 0 
aoctanol/water partition coefficients, values measured in the present work 
bPredicted values using program QikProp v.2.555 
cblood/brain partition coefficient  
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3.4.2. Biodistribution studies of P1 ligand 
 
To evaluate the efficacy of the new ligand P1 as a chelating agent for mobilization of 
metal ions, we studied the biodistribution profile of the well-established radiotracer 
67Ga-citrate in female mice with simultaneous intraperitoneal administration of the 
ligand solution. The effect of this chelator on the 67Ga uptake and clearance on the 
major organs and on the excretion can be viewed in comparison with the drug DFP 
(Figure 3.91).  
 
Figure 3.91. Biodistribution data in the most relevant organs, expressed as % I. A./g for 67Ga-citrate with 
simultaneous intraperitoneal injection of P1 or deferiprone, at 1, 24 and 48 h after administration in female 
Balb-C mice (n = 3). 
Although the effect of DFP on the biodistribution of radiotracer in metal-overload mice 
has been previously reported, those studies involved a different animal model 
(CD1)[51],[37]and so it was necessary to reevaluate it herein for Balb-C mice. 
The co-administration of the ligand P1 enhanced the overall excretion rate of 
radioactivity from whole animal body as efficiently as DFP, 24 and 48 h after 
administration. No significant differences in the radioactivity remaining in the carcass 
and in the rate of radioactivity elimination were found, except at 1 h. 
The main differences in the distribution profile are related with the blood clearance and 
the hepatic uptake at 1 h. P1 induces slower clearance from blood as well as lower liver 
uptake than DFP at 1 h after administration, which may be attributed to a highest level 
of plasmatic protein binding, eventually due to the 2-hydroxymethyl group and to some 
minor decrease on the lipophilicity.  
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Overall, this biodistribution profile, similar to that of DFP, shows an increase of the 
radiotracer elimination rate and attests the ability of the ligand to chelate the radiometal 
in vivo.  
Generally, ligands containing an identical chelating group possess similar pFe3+ values: 
for instance, 3-hydroxypyridin-2-one ligands possess pFe3+ values of 16, whereas the 
pFe3+ values for 3-hydroxypyridin-4-ones are around 20. However the introduction of 
adjacent functions can have a dramatic effect on pFe3+ values. It was previously 
established that the introduction of an amide function on the position 4 of 3-
hydroxypyridin-2-ones reduces the pK values increasing the pFe3+ values, due to the 
formation of a stable intramolecular hydrogen bond between the amide proton and the 
adjacent oxygen donor atom.[239] 
Catechol, with very large iron and proton binding constants, binds iron best in slightly 
basic solutions. It appears that the ligands with the best iron-binding potential have 
aromatic characters and form planar five-membered chelate rings with a high-spin ferric 
ion. There is a substantial amount of delocalization in the bonding of the catecholate 
anion to Fe3+, which contributes to the great stability of these complexes.[240] This is 
also possible for the iron hydroxypyridinone complexes. 
Among the hydroxypyridinones, the stepwise formation constants increase as the 
oxygen-binding groups move away from the ring nitrogen. This is evidence for the 
importance of the catechol-like resonance form of the iron-bound hydroxypyridinone, 
since in this aromatic resonance form the nitrogen has a positive charge and will be 
more stable further from the iron center. 
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3.5. Enzymatic inhibition studies of KβAK[1] 
 
Over the past 5 years we have synthesized several different kojic acid derivatives 
(Scheme 9 and Figure 1.8) with the aim of individuating effective iron and aluminium 
chelating agents. One of the requisites of a ligand used in chelation therapy is that it 
must not interfere with proper enzymatic activity. This issue was carefully considered 
when evaluating our molecules for tyrosinase inhibitory activity. In the present study, 
the results obtained on the tyrosinase inhibitory activity of seven biskojic derivatives 
and a mono kojic derivative L7 are compared.  
In Figure 3.92, the percentage inhibition of kojic acid (84%) is compared with that of its 
analogues. The results show that KβAK has the highest inhibition efficiency (91%), 
ligands L1-L5 have low inhibition efficiency (24-36%), while L6 and L7 have no 
influence whatsoever on tyrosinase activity.  
 
Figure 3.92. Diagram of tyrosinase inhibition. The percent inhibition of tyrosinase activity calculated as: % 
inhibition = (A-B)/A ∙ 100; A represents the absorbance at 476 nm without the test sample, and B represents 
the absorbance at 476 nm whit the test sample at the same substrate concentration. The experiment was 
repeated with different inhibitors concentrations: 0.069, 0.139 and 0.279 mM. 
 
Based on these preliminary results, we decided to investigate the inhibitory activity of 
the most promising ligand KβAK and compare with KA. Figure 3.93 shows the activity 
of the enzymes (Ctrl 1 and Ctrl 2) acting on the substrate L-tyrosine after 30 (A) and 90 
min (B), respectively. At increasing concentrations of KA, the tyrosinase-mediated 
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formation of the pigment dopachrome was delayed after 30 min (Figure 3.93A). In the 
presence of KβAK at the same concentration, the inhibitory activity became much 
stronger, as demonstrated by the complete lack of melanin formation even after 90 min 
of incubation (Figure 3.93B).  
 
Figure 3.93. Inhibitory effect of KA and KβAK on catalitic activity of mushroom tyrosinase after 30 min (A) 
and 90 min (B) of incubation. Two different concentrations (40 and 80 µM) were tested. 
IC50 values for tyrosinase inhibitors can vary for a number of reasons, including choice 
of assay conditions, rate determinations, solvent considerations, and also the purity of 
the tyrosinase.[241]For instance, reported IC50 values for kojic acid vary from 10 to 300 
µM.[241]Under our experimental conditions the IC50 value for KβAK was equal to 
6.8±0.9 µM, whereas that of kojic acid was amounting to 35.4±4.3 µM. Although our 
findings cannot explain the mechanism of KβAK inhibition, we can notice that the IC50 
of the new inhibitor is approximately 1/5 that of kojic acid. This result is lower than that 
of most effective Kojic-Phenylalanine-Kojic (1/382) reported in the literature[152].  
Our tyrosinase inhibition studies were performed and compared with the data of 
Kobayashi et al. prepared under the same experimental conditions[152].Nevertheless, the 
extracted mushroom enzymes had low homology with the more complex mammalian 
ones (22-24% sequence identity with 48-49% sequence coverage)[242]. Recent[242] 
reports suggest that inhibition studies with human tyrosinase could be more informative. 
The two-step synthesis of KβAK is time and cost-saving in comparison with the multi-
step synthesis of other kojic acid derivatives as tyrosinase inhibitors [152],[158]. In the 
catalytic activity test, KβAK proved to be a better inhibitor than kojic acid, and above 
all, was far more effective after 30 and 60 min (Figure 3.93). This strong inhibitory 
effect cannot be explained by the contemporary presence of two kojic acid units, since 
the L1-L6 and L9 ligands possess two kojic acid units and are less effective than KβAK 
and even kojic acid alone. Neither is L7 an antagonist of tyrosinase activity. Initially, 
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we hypothesized that the presence of an aromatic ring in the ligand structure (L2, L3, 
L5, and L7) could facilitate docking into the active site of tyrosinase, similarly to kojic 
acid conjugates with phenylanine[152]. According to this hypothesis, Phe90 residue could 
form π-π stacking interactions between the aromatic rings of the linker. However, the 
results of our laboratory tests showed exactly the contrary. Neither the hydrophilic chain 
between the two kojic units of L9, nor the shorter and more hydrophobic chains of L1 
and L4 resulted to be capable of increasing inhibitory activity, the latter two yielding 
slightly better results. 
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4. Conclusions 
 
4.1. P1 
 
P1 combines the hydroxypyridinone and catechol features: at low pH it coordinates 
efficiently metal ions as 5-hydroxy-2-(hydroxymethyl)pyridin-4(1H)-one, while at basic 
pH as 2-(hydroxymethyl)pyridine-3,4-diol. The presence of hydroxymethyl group 
favours the tautomeric equilibrium in the free ligand, due to the formation of the 
hydrogen bond N1…H8. The tautomeric transformation in the presence of metal ions 
occurs at lower pH than in the free ligand. On the basis of pFe3+ values, P1 should be 
considered a more efficient iron chelator (pFe3+ 22.0) than the clinically-used DFP 
(20.67)[201], its 3,4-hopo analogues (20.77) and far more effective than catechol (pFe 
14.7).[243] The high pFe3+ value of P1 depends on two different factors, namely (i) the 
high stability of the iron complexes, mainly attributed to the tautomeric rearrangement 
of pyridinone ligand into the catechol-like ligand; and (ii) the log K 9.00 of P1, lower 
than that determined for deferiprone by 0.82 units. The chelating ability of P1 toward 
aluminium, copper and zinc ions is not higher than that of the corresponding DFP and 
3,4-hopo, and this renders P1 a more selective iron chelator.  
The bio-distribution studies on mice showed that P1 is as effective as clinically-used 
DFP, notwithstanding the negative charge on the complex existing at physiological pH 
(where the species modelled as [FeL3H2]– is prevalent) could hinder in some extent the 
crossing of membranes, and thus iron excretion. The bioavailability parameters 
presented in Table 3.34 characterize P1 as a less effective compound than DFP, even if 
the difference between the parameters of H2La and H2Lb should mitigate this limit. The 
study of metabolism of P1 in living organisms could be of paramount importance, since 
it has been reported that 1’-hydroxyalkyl substituents prevent glucuronidation in vivo in 
hydroxypyridinones.  
These overall promising results urge further studies to verify in vivo if the toxicity, 
bioavailability and pharmacokinetic properties of P1 can open a new way to future 
clinical trials. 
 
4.2. L12-L15 
 
The detailed potentiometric, spectrophotometric, 1H NMR and calorimetric study of the 
protonation equilibria of L12-L15 ligands has allowed not only to obtain the protonation 
constants of each ligand and attribute each protonation steps to the basic groups of the 
ligands, but also to give evidence of the H-bonding intramolecular interactions that 
characterize the differently protonation species. 
The complex formation equilibria of these ligands have been characterized not only 
with the toxic metal ions Fe3+ and Al3+, but also with the two essential metal ions Cu2+ 
and Zn2+. The main formed complexes with all the studied metal ions are binuclear 2:2 
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metal/ligand complexes with various protonation degrees. The relative stability 
constants and the pM values were calculated, and the relative speciation plots were 
presented. The pFe3+ values 20.4 obtained with the L14 ligand is of particular interest, 
being comparable with that of Deferiprone, one of the chelators in use in the treatment 
of iron overload diseases. The overall results have furthermore allowed to propose 
detailed coordination schemes for the formed complexes.   
 
4.3. L1-L18 
 
The examined ligands are characterized, with the exception of L7 alone, by the presence 
of two kojic units joined by different linkers. They all form with Cu2+ dinuclear 
complexes with different degree of protonation, and L1, L4 and L5 form also 1:1 
complexes. Only L7 ligand forms mononuclear 1:1 and 1:2 complexes. In the case of 
Zn2+, mononuclear 1:1 and binuclear 2:2 complexes, are formed. 
On the base of our results we propose the coordination mode shown in the Scheme 19. 
We observe the same stoichiometry and coordination geometry for L1-L6 and L8 
ligands, whether or not a nitrogen atom is present in the linker. 
 
Scheme 19. Proposed coordination model for the dinuclear complex [Cu2(L4)2]. 
 
Besides the similarity of complexation model of all ligands, also the stability of the 
formed complexes is comparable, as evaluated from pM values (Tables 3.23 and 3.24). 
In particular, we have observed that the mean pCu2+ is about ten units lower than the 
corresponding pFe3+ value (Table 3.22), and pZn2+ is two-three units lower than pCu2+. 
On the basis of these results, the ligands L1-L8 are totally selective toward iron, i.e. also 
a presence of the essential metal ions Cu2+ and Zn2+ in large excess (> 100 times) does 
not perturb iron chelation. On the contrary, when the chelating agent exceeds the 
amount required to completely coordinate the present iron, copper is quantitatively 
bound by the available ligand even at micromolar concentration. Furthermore, the 
ligand still available after copper complexation will bind zinc, largely available in the 
organism, despite its very low stability. These considerations have been substantiated by 
speciation calculations, using Hyss program [180], the copper and zinc stability constants 
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reported in Tables 3.23  and 3.24 and the iron stability constants (Table 3.22), 
neglecting all the essential metal ion interactions with endogenous molecules. This 
speciation study gives evidence of a potential drawback of iron chelation therapy, i.e. 
the depletion of essential metal ions. This fact is amply reported in literature, above all 
for zinc because of its large amount in organism and because it is less strongly bound to 
endogenous macromolecules than copper[244],[245], [246], [247]. 
The evaluation of complex formation equilibria between any ligand proposed for toxic 
metal ion removal and the essential metal ions is a task of paramount importance. 
 
4.4. KβAK 
 
The neutral form of KβAK at physiological pH together with its low molecular weight 
suggests high bioavailability. The chemical properties are in agreement with Lipinski’s 
rules[9] for orally active drug (no more than 5 hydrogen bonds; no more than 10 
hydrogen bond acceptors; a molecular mass less than 500 Daltons) and candidate it for 
pharmaceutical applications.   
KβAK form with Fe3+, Al3+, Cu2+ and Zn2+ metals mono- and dinuclear complexes. The 
molecule is selective for trivalent ions with pFe and pAl higher than pCu and pZn 
values. The strength of iron and aluminium complexes with KβAK is similar to those 
formed with L2 and L4 (Table 4.1). Among previously synthesized bis-kojic acid 
derivatives, KβAK is the weakest copper and zinc chelator.  
 
Table 4.1. Comparison of pM values for KA, L1-L9 and KβAK ligands. [[33], [35], [37], [163], [36],[199]] 
pM* KA L1 L2 L3 L4 L5 L6 L7 L9 KβAK 
pFe 13.3[33] 23.1[33] 18.9[35] 22.2[35] 18.1[163] 19.3[163] 17.7[163] 16.7[163] 17.7[36] 18.5 
pAl 9.1[33] 12.8[33] 11.9[35] 13.9[35] 11.2[37] 11.6[37] 11.8[37]  9.9[37] 10.3[36] 12.7 
pCu 7.3 8.8[199] 10.2[199] 10.5[199] 10.3[199] 10.8[199] 8.5[199] 7.2[199] 9.7[36] 8.3 
pZn 6.1 6.6[199] 7.6[199] 7.9[199] 8.8[199] 7.1[199] 7.8[199] 6.1[199] 7.6[36] 6.1 
a Negative logarithm of the concentration of the free metal in solution, calculated for total [ligand] = 10-5 M and total 
[metal] = 10-6 M at pH 7.4. 
 
L1-L6 and L9 ligands form [CuL] and [Cu2L2] complexes, while KA and L7 ligands 
form [CuL2] complexes. The strength of the complexes, evaluated by pCu values (the 
higher the pCu the stronger the coordination), does not influence the inhibitory 
properties. In fact, the most effective inhibitory ligands (kojic acid and KβAK) had the 
lowest pCu values (Table 4.1).   
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The mechanisms underlying kojic acid inhibition are not yet fully understood and 
although our findings offer some insight, further research is warranted to explore this 
topic.   
In conclusion, the key to success of the KβAK as a tyrosinase inhibitor could rely on the 
peculiarities of the chain between the two kojic acid units.  Indeed, its hydrophobic 
properties are sufficient to allow for a perfect fit into the active site of the enzyme, 
without creating any unconformity with Phe90. However, this hypothesis is based solely 
on results obtained in the laboratory and needs to be confirmed by computational 
studies of docking and crystallographic data.  
 
4.5. SC 
 
SC ligand is the first hexadentate ligand derived from KA synthesized by our group, 
with the aim of obtaining a strong iron chelator forming a single 1:1 complex. It is 
formed by three KA units connected by a tris aminoethylamina. SC in the fully 
protonated form behaves as an hexaprotic acid (3 –OH groups on the KA units and three 
protonated nitrogen atoms in the connecting amine), and its protonation steps have been 
fully characterized by potentiometric, spectrophotometric and NMR techniques. 
The complex formation equilibria with Fe3+, the target metal ion, and with Ga3+ for 
possible medical applications have been studied. As expected only 1:1 differently 
protonated complexes are formed, in which Fe3+ is first coordinated by a single KA unit 
at very acidic pH, then by two and finally at pH 6 by all the three KA units. The formed 
pFe3+ value 18.4 is not high as expected, not better than those with the corresponding 
tetradentate chelators. 
It shows better coordinating properties toward Ga3+ with pGa3+ 20.2 about two units 
higher than that with Fe3+. We hope that a detailed quantum mechanical study will 
permit to clarify the reasons of the different chelating capacity toward the two metal 
ions, but also will give the necessary information to a correct design of improved 
hexadentate KA ligands. 
 
4.6. Losartan and Irbesartan 
 
The use of different complementary techniques has allowed both to give the protonation 
and complex formation constants of Irbesartan and Losartan with Cu2+ and Zn2+, and to 
attribute the protonation sequence and the coordination sites. The fluorescence behavior 
of both drugs was also explained in terms of presence of protonated/deprotonated 
species.  
In particular clear evidence of the binding of both metal ions through the tetrazole 
moiety is obtained, except for the Zn2+/Irbesartan system. In this case NMR 
measurements gave evidence of a possible tautomerism involving the imidazole ring 
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and the connected aliphatic chain. ESI-MS spectra remarked that in the 1:1 
Zn2+/Irbesartan complex one or two water molecules are present. 
 
4.7. Picolinic acid derivatives 
 
The preliminary results of La3+ complexes with the two new ligands synthesized by the 
group of Prof. Orvig show that both ligands form differently protonated 1:1 complexes. 
Further NMR, quantum chemical and X-ray diffraction studies are necessary to attribute 
a coordination scheme to the found complexes.  
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TableA1. Crystal data and structure refinement for L1. 
Empirical formula  C13 H12 O8 
Formula weight  296.23 
Temperature  100.0 K 
Wavelength  0.71073 Å 
Crystal system, space group  Monoclinic, C2/c 
Unit cell dimensions a = 20.527(3) Å,  =90° 
 b = 4.2812(5) Å,    
 c = 16.072(2) Å,  = 90° 
Volume 1238.1(3) Å3 
Z, calculated density 4, 1.589 Mg/m3 
Absorption coefficient 0.135 mm-1 
F(000) 616 
Crystal size 0.10 x 0.08 x 0.06 mm3 
Theta range for data collection 2.680 - 25.138° 
Limiting indices -22<=h<=24, -5<=k<=4, -
19<=l<=19 
Reflections collected/unique 5677/1104 [R(int) = 0.1183] 
Completeness to theta = 25.138° 99.5 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7452 and 0.6469 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1104 / 0 / 98 
Goodness-of-fit on F2 1.023 
Final R indices [I>2sigma(I)] R1 = 0.0474, wR2 = 0.0818 
R indices (all data) R1 = 0.1076, wR2 = 0.0988 
Largest diff. peak and hole 0.202 and -0.237 e.Å-3 
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TableA2. Crystal data and structure refinement for P1. 
 
      Identification code               15jnac842  
      Empirical formula                 C6H7NO3  
      Formula weight                    141.13  
      Temperature                       100(2) K  
      Wavelength                        0.71073 Å  
      Crystal system, space group       Orthorhombic,  P212121  
      Unit cell dimensions              a = 6.8410(4) Å    α = 90º 
                                        b = 7.0291(3) Å    β = 90º  
                                        c = 12.6402(4) Å   γ = 90º  
      Volume                            607.82(5) Å3  
      Z, Calculated density             4,  1.542 Mg/m3  
      Absorption coefficient            0.125 mm-1  
      F(000)                            296  
      Crystal size                      0.100 x 0.100 x 0.100 mm  
      Theta range for data collection   3.223º to 27.492º  
      Limiting indices               -8<=h<=8, -9<=k<=9, -14<=l<=16  
      Reflections collec./unique        8040/1390 [R(int) = 0.0245]  
      Completeness to theta = 25.242    99.9 %  
      Refinement method             Full-matrix least-squares on F2  
      Data / restraints / parameters    1390 / 0 / 91  
      Goodness-of-fit on F^2            1.094  
      Final R indices [I>2sigma(I)]     R1 = 0.0264, wR2 = 0.0666  
      R indices (all data)              R1 = 0.0278, wR2 = 0.0675  
      Absolute structure parameter      -0.5(4)  
      Extinction coefficient            n/a  
      Largest diff. peak and hole       0.251 and -0.186 e.Å-3  
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TableA3. Bond lengths [A] and angles [deg] for P1. 
           _____________________________________________________________  
   
            O(4)-C(4)                     1.2887(19)  
            O(5)-C(5)                     1.3555(19)  
            O(5)-H(5A)                    0.8400  
            O(8)-C(7)                     1.4200(19)  
            O(8)-H(8A)                    0.8400  
            N(1)-C(2)                     1.347(2)  
            N(1)-C(6)                     1.363(2)  
            N(1)-H(1A)                    0.8801  
            C(2)-C(3)                     1.372(2)  
            C(2)-C(7)                     1.510(2)  
            C(3)-C(4)                     1.416(2)  
            C(3)-H(3)                     0.9500  
            C(4)-C(5)                     1.435(2)  
            C(5)-C(6)                     1.363(2)  
            C(6)-H(6)                     0.9500  
            C(7)-H(7A)                    0.9900  
            C(7)-H(7B)                    0.9900  
   
            C(5)-O(5)-H(5A)             109.5  
            C(7)-O(8)-H(8A)             109.5  
            C(2)-N(1)-C(6)              121.93(14)  
            C(2)-N(1)-H(1A)             119.0  
            C(6)-N(1)-H(1A)             119.0  
            N(1)-C(2)-C(3)              119.81(15)  
            N(1)-C(2)-C(7)              116.69(14)  
            C(3)-C(2)-C(7)              123.50(15)  
            C(2)-C(3)-C(4)              121.22(15)  
            C(2)-C(3)-H(3)              119.4  
            C(4)-C(3)-H(3)              119.4  
            O(4)-C(4)-C(3)              123.79(15)  
            O(4)-C(4)-C(5)              119.91(15)  
            C(3)-C(4)-C(5)              116.29(14)  
            O(5)-C(5)-C(6)              118.62(14)  
            O(5)-C(5)-C(4)              121.21(14)  
            C(6)-C(5)-C(4)              120.17(14)  
            N(1)-C(6)-C(5)              120.46(15)  
            N(1)-C(6)-H(6)              119.8  
            C(5)-C(6)-H(6)              119.8  
            O(8)-C(7)-C(2)              112.54(13)  
            O(8)-C(7)-H(7A)             109.1  
            C(2)-C(7)-H(7A)             109.1  
            O(8)-C(7)-H(7B)             109.1  
            C(2)-C(7)-H(7B)             109.1  
            H(7A)-C(7)-H(7B)            107.8  
           _____________________________________________________________  
   
           Symmetry transformations used to generate equivalent atoms:  
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Figure A1. UV spectra collected during potentiometric titration of the ligand, CL 4.95 x 10-4 M, using a 0.2 cm 
optical path length. A pH 2.98-4.59, B 7.29-10.52, C pH 10.64-13.22. 240-340 nm spectral range. 
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Figure A2. Stacked 1D 1H NMR spectra in the aromatic region for P1 ligand by changing the pH from 
0.65 to 13.30, at 298 K. 
10 
 
TableA4. Chemical shifts assignment for 1H of P1 by changing the pH from 0.65 to 13.30, in aqueous 
solution (90%-10% H2O-D2O), at 298 K. 
 
pH H6 H3 H7 
0.65 7.911 7.032 NA 
1.00 7.938 7.084 NA 
1.67 7.949 7.082 4.723 
1.94 7.935 7.075 NA 
2.20 7.931 7.059 NA 
2.63 7.898 7.013 NA 
3.04 7.828 6.901 NA 
3.26 7.781 6.820 NA 
3.45 7.731 6.738 4.624 
3.38 7.748 6.774 NA 
3.81 7.653 6.626 4.585 
3.93 7.648 6.607 4.580 
4.04 7.632 6.583 4.580 
4.12 7.630 6.580 4.577 
5.04 7.564 6.479 4.545 
5.68 7.552 6.465 4.537 
5.96 7.563 6.474 4.547 
6.70 7.558 6.469 4.545 
7.07 7.554 6.467 4.544 
7.25 7.552 6.466 4.544 
8.00 7.534 6.462 4.539 
8.37 7.513 6.453 4.532 
8.64 7.467 6.435 4.517 
8.96 7.436 6.432 4.518 
9.05 7.405 6.419 4.508 
9.10 7.386 6.416 4.507 
9.38 7.331 6.393 4.488 
10.04 7.211 6.356 4.463 
10.10 7.202 6.355 4.464 
10.70 7.154 6.338 4.450 
11.02 7.147 6.336 4.448 
12.05 7.152 6.337 4.434 
12.30 7.168 6.342 4.421 
12.40 7.200 6.355 4.403 
12.86 7.221 6.355 4.374 
13.02 7.270 6.374 4.346 
13.20 7.270 6.349 4.273 
13.30 7.265 6.345 4.268 
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Figure A3. Experimental data for peaks of the P1 ligand at pD 7 in D2O solution are shown at the top of 
the panel and compared with the data calculated for the [C6H8O3N]+ (142.061 m/z, Panel A) 
[C6H7DO3N]+ (143.057 m/z, Panel B), [C6H6D2O3N]+ (144.063 m/z, Panel C), [C6H5D3O3N]+ (145.070 m/z, 
Panel D) and [C6H4D4O3N]+ (146.076 m/z Panel E). 
 
 
  
A 
B 
C 
D 
E 
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TableA5. ESI-MS m/z data of P1 in aqueous solution at different pH. 
pH  Negative Intensity Positive Intensity 
1.68 140.032 10000 142.054 15000 
6.13 140.034 8000 142.054 8000 
11.5 139.032 2500 - - 
13.7 139.033 4000 - - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TableA6. Selected optimized bond lengths (Å) and angles (°) for the differently protonated forms of P1a 
in the gas phase and in water (IEF-PCM SCRF model, in parenthesis).b          a The neutral form of P1 corresponds to 
H2L.  bAtom numbering scheme as in Figure 1. Molecular schemes as in Scheme 6. 
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 H3L+ H2La H2Lb H2Lc HLa– HLb– HLc– L2– 
N1-H1 
1.025 
(1.023) 
1.014 
(1.017) 
/ 
1.018 
(1.021) 
/ 
1.011 
(1.015) 
/ / 
N1-C2 
1.337 
(1.336) 
1.349 
(1.344) 
1.325 
(1.327) 
1.336 
(1.332) 
1.321 
(1.322) 
1.345 
(1.337) 
1.327 
(1.328) 
1.322 
(1.322) 
C2-C3 
1.389 
(1.388) 
1.373 
(1.378) 
1.400 
(1.399) 
1.397 
(1.397) 
1.411 
(1.410) 
1.383 
(1.384) 
1.398 
(1.398) 
1.404 
(1.404) 
C3-C4 
1.392 
(1.391) 
1.435 
(1.428) 
1.386 
(1.388) 
1.385 
(1.383) 
1.379 
(1.379) 
1.448 
(1.347) 
1.417 
(1.416) 
1.433 
(1.425) 
C4-O4 
1.325 
(1.324) 
1.237 
(1.294) 
1.351 
(1.342) 
1.310 
(1.319) 
1.335 
(1.337) 
1.235 
(1.248) 
1.265 
(1.269) 
1.258 
(1.266) 
O4-H4 
0.966 
(0.967) 
/ 
0.963 
(0.965) 
1.010 
(1.005) 
1.014 
(1.004) 
/ / / 
C4-C5 
1.425 
(1.423) 
1.470 
(1.463) 
1.408 
(1.412) 
1.467 
(1.459) 
1.452 
(1.448) 
1.523 
(1.509) 
1.455 
(1.451) 
1.519 
(1.502) 
C5-O5 
1.322 
(1.331) 
1.328 
(1.336) 
1.345 
(1.345) 
1.253 
(1.266) 
1.276 
(1.280) 
1.245 
(1.262) 
1.348 
(1.349) 
1.265 
(1.275) 
O5-H5 
0.968 
(0.969) 
0.987 
(0.987) 
0.966 
(0.968) 
/ / / 
0.998 
(0.992) 
/ 
C5-C6 
1.380 
(1.377) 
1.361 
(1.362) 
1.389 
(1.387) 
1.405 
(1.406) 
1.408 
(1.407) 
1.418 
(1.407) 
1.372 
(1.373) 
1.424 
(1.415) 
N1-C6 
1.349 
(1.348) 
1.374 
(1.368) 
1.334 
(1.337) 
1.362 
(1.361) 
1.348 
(1.349) 
1.382 
(1.377) 
1.356 
(1.355) 
1.365 
(1.363) 
C2-C7 
1.504 
(1.501) 
1.510 
(1.512) 
1.515 
(1.515) 
1.507 
(1.510) 
1.520 
(1.518) 
1.499 
(1.508) 
1.524 
(1.521) 
1.526 
(1.522) 
C7-O8 
1.393 
(1.395) 
1.405 
(1.402) 
1.384 
(1.393) 
1.405 
(1.402) 
1.391 
(1.396) 
1.419 
(1.408) 
1.391 
(1.395) 
1.396 
(1.398) 
O8-H8 
0.962 
(0.962) 
0.963 
(0.965) 
0.976 
(0.979) 
0.963 
(0.964) 
0.989 
(0.985) 
0.964 
(0.964) 
0.990 
(0.986) 
1.015 
(0.995) 
N1-C2-C3 
118.70 
(118.88) 
120.74 
(120.46) 
122.05 
(122.43) 
118.96 
(118.93) 
122.50 
(122.45) 
118.96 
(119.02) 
124.46 
(124.17) 
123.00 
(122.70) 
C2-C3-C4 
119.36 
(119.25) 
120.59 
(120.53) 
118.47 
(118.40) 
119.32 
(118.16) 
117.40 
(117.35) 
123.70 
(123.01) 
119.62 
(119.63) 
122.74 
(122.36) 
C3-C4-C5 
120.06 
(119.98) 
115.39 
(115.56) 
119.33 
(119.07) 
122.64 
(122.74) 
121.69 
(121.81) 
116.05 
(116.52) 
114.35 
(114.57) 
114.67 
(115.19) 
C4-C5-C6 
117.89 
(118.14) 
121.34 
(121.39) 
117.61 
(117.92) 
114.80 
(114.93) 
114.65 
(114.69) 
115.05 
(115.48) 
121.39 
(121.37) 
115.06 
(115.44) 
C5-C6-N1 
119.60 
(119.47) 
119.06 
(118.86) 
122.75 
(122.64) 
119.79 
(119.79) 
123.11 
(123.10) 
123.66 
(123.07) 
122.07 
(121.92) 
126.90 
(126.47) 
C6-N1-C2 
124.38 
(124.28) 
122.88 
(123.19) 
119.79 
(119.53) 
125.48 
(125.45) 
120.65 
(120.89) 
122.57 
(122.87) 
118.10 
(118.34) 
117.63 
(117.82) 
C2-N1-H1 
114.54 
(115.21) 
116.31 
(116.17) 
/ 
114.86 
(114.78) 
/ 
117.52 
(116.85) 
/ 
 
/ 
C5-C4-O4 
114.15 
(114.39) 
116.86 
(116.78) 
115.27 
(116.18) 
111.46 
(111.77) 
111.27 
(111.95) 
121.35 
(120.32) 
116.25 
(116.57) 
121.65 
(120.90) 
C4-O4-H4 
113.71 
(113.05) 
/ 
110.80 
(111.66) 
99.48 
(99.56) 
96.88 
(98.30) 
/ / / 
C6-C5-O5 
120.46 
(120.81) 
124.97 
(124.76) 
121.37 
(121.21) 
129.75 
(129.40) 
130.16 
(129.53) 
123.88 
(124.24) 
126.32 
(125.61) 
123.59 
(123.72) 
C5-O5-H5 
110.47 
(109.27) 
101.60 
(101.14) 
108.06 
(108.31) 
/ / / 
98.03 
(99.32) 
/ 
N1-C2-C7 
116.05 
(116.40) 
114.92 
(115.32) 
115.12 
(114.74) 
116.08 
(116.34) 
114.05 
(114.41) 
116.43 
(116.37) 
112.88 
(113.35) 
112.11 
(113.35) 
C2-C7-O8 
106.79 
(107.45) 
112.33 
(112.32) 
111.38 
(110.67) 
112.03 
(111.87) 
109.99 
(109.85) 
112.85 
(112.77) 
110.28 
(110.09) 
109.06 
(109.19) 
C7-O8-H8 
110.39 
(110.07) 
108.44 
(108.65) 
104.35 
(103.39) 
108.48 
(108.76) 
100.86 
(101.58) 
105.87 
(108.12) 
100.67 
(101.42) 
97.38 
(99.70) 
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Figure A4. DFT optimized geometries of the three possible neutral forms of ligand P1 in the gas phase, 
showing the different types of hydrogen bond-type interactions. 
 
 
 
 
 
Figure A5. Absorptivity spectra at 0.1 M KCl ionic strength, 25 °C of basic (a) and acidic titrations (b) of 
Kojic acid. 
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Figure A6. 1H NMR spectra for L12 ligand by changing the pH from 1.4 to 13.05, at 298 K. 
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Figure A7. Fe3+–P1 complexes. Experimental data for peak m/z = 333.998 (Panel A), 336.004 (Panel B), 
409.940 (Panel C), 499.029 (Panel D) and 515.010 (Panel E) are shown at the top of the panel and 
compared with the data calculated for the Fe3+ complex (lower panel). 
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TableA7. ESI-MS m/z data of Fe3+–P1 aqueous solution in different pH. 
 
pH Negative Intensity Positive Intensity Species 
2.16 - - 
336.004 
409.944 
515.002 
15000 
25000 
800 
[FeL2H2]+ 
[FeL2H2+Cl+K]+ 
[FeL3H3+K]+ 
3.25 - - 
336.005 
409.940 
515.006 
20000 
40000 
2500 
[FeL2H2]+ 
[FeL2H2+Cl+K]+ 
[FeL3H3+K]+ 
6.78 - - 515.015 25000 [FeL3H3+K]+ 
9.52 - - 515.005 15000 [FeL3H3+K]+ 
11.10 - - 515.008 12000 [FeL3H3+K]+ 
>11 
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- 
- 
- 
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Figure A8. Stacked 1D 1H NMR spectra of P1 ligand by increasing amount of Ga3+, as a diamagnetic 
probe of Fe3+, in phosphate buffer solution at 298 K.  
 
Figure A9. The comparison of the relative ratio of H3/H6 in term of peak integral and peak high ratio 
between pH 7 (black square) and pH 11.5 (orange rhombus). 
 
 
  
Ga:P1 
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Table A8. Selected optimized bond lengths (Å) and angles (°) for Fe3+–P1a complexes in the gas phase.b  
 
  
 Fe(HL)3 [Fe(L)3]3–  Fe(HL)3 [FeL3]3– 
Fe-O4 2.082 2.082 O5-Fe-O20 96.43 98.15 
Fe-O5 1.994 2.030 O4-C4-C5 116.58 116.71 
Fe-O12 2.082 2.081 O5-C5-C4 116.35 114.78 
Fe-O13 1.995 2.030 C2-N1-H1 116.02 / 
Fe-O20 2.081 2.081 C3-C2-C7 124.64 123.79 
Fe-O21 1.995 2.030 C2-C7-O8 112.30 109.61 
C4-O4 1.263 1.280 C7-O8-H8 108.22 99.08 
C5-05  1.287 1.295 O12-C12-C13 116.56 116.71 
C12-O12 1.263 1.280 O13-C13-C12 116.34 116.36 
C13-O13 1.287 1.295 C10-N9-H9 115.97 / 
C20-O20 1.263 1.280 C11-C10-C15 124.60 123.82 
C21-O21 1.287 1.295 C10-C15-O16 112.33 109.60 
N1-C2 1.343 1.324 C15-O16-H16 108.26 99.08 
N1-C6 1.368 1.356 O20-C20-C21 116.58 116.72 
N1-H1 1.015 / O21-C21-C20 116.34 116.35 
C4-C5 1.466 1.459 C18-N17-H17 116.02 / 
C2-C7 1.508 1.525 C19-C18-C23 124.60 123.79 
C7-O8 1.406 1.394 C18-C23-O24 112.33 109.60 
O8-H8 0.963 1.000 C23-O24-H24 108.25 99.08 
N9-C10 1.343 1.324 Fe-O4-C4-C3 -178.62 -179.71 
N9-C14 1.368 1.356 Fe-O5-C5-C6 177.91 179.45 
N9-H9 1.015 / Fe-O12-C12-C11 -179.17 -179.57 
C12-C13 1.466 1.459 Fe-O13-C13-C14 178.55 179.27 
C10-C15 1.508 1.525 Fe-O20-C20-C19 -178.87 -179.67 
C15-O16 1.406 1.394 Fe-O21-C21-C22 178.19 179.35 
O16-H16 0.963 1.000 O4-Fe-O13-C13 88.74 91.93 
N17-C18 1.343 1.324 O12-Fe-O21-C21 89.12 92.08 
N17-C22 1.368 1.356 O20-Fe-O5-C5 89.47 91.86 
N17-H17 1.015 / O4-C4-C5-O5 0.39 0.02 
C21-C20 1.466 1.459 C3-C2-N1-H1 -178.09 / 
C18-C23 1.508 1.525 C6-N1-C2-C7 -177.55 -179.95 
C23-O23 1.406 1.394 N1-C2-C7-O8 -26.57 0.19 
O23-H23 0.963 1.000 C2-C7-O8-H8 -74.65 -0.01 
Fe-O5-C5 114.96 114.78 O12-C12-C13-O13 0.35 0.28 
Fe-O4-C4 112.80 113.37 C11-C10-N9-H9 -178.22 / 
O4-Fe-O5 79.29 78.77 C14-N9-C10-C15 -177.46 -179.95 
O4-Fe-O13 96.15 98.15 N9-C10-C15-O16 -26.15 0.02 
Fe-O12-C12 112.84 113.38 C10-C15-O16-H16 -75.07 0.00 
Fe-O13-C13 114.96 114.75 O20-C20-C21-O21 0.38 0.30 
O12-Fe-O13 79.29 78.77 C19-C18-N17-H17 -178.14 / 
O12-Fe-O21 96.48 98.16 C22-N17-C18-C23 -177.52 -179.99 
Fe-O20-C20 112.83 113.39 N17-C18-C23-O24 -26.37 -0.05 
Fe-O21-C21 114.94 114.76 C18-C23-O24-H24 -74.83 0.08 
O20-Fe-O21 79.30 78.78    
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TableA9. Complex formation constants (log β) of P1 with Fe3+, Al3+, Cu2+ and Zn2+ ions, and literature complex formation constants of DFP and 3,4-hopo. The charges are 
omitted for simplicity. 
 
 
P1 
 
DFP 3,4-hopo 
Model Fe3+ Al3+ Cu2+ Zn2+ Model Fe3+ [1] Al3+ [2] Cu2+ [1] Zn2+ [3] Fe3+ [4] Al3+ Cu2+ [5] Zn2+ [5] 
MLH 25.92(9) 23.32(9) 21.78(7) 18.79(6) ML 15.01(1) 11.91 10.42 7.24 14.26(3) ---- 9.49 6.81 
ML2H2 49.12(1) 45.18(6) 41.42(7) 36.70(4) ML2H ---- ---- 21.98 
 
---- ---- ---- ---- 
ML2H ---- ---- 34.21(5)                  26.02(9)               ML2 27.03(1) 22.83 19.09 13.55 25.73(1) ---- 17.13 12.54 
ML2 ---- ---- 24.68(5)                   ---- ML2H-1 ---- ---- 8.49 2.30 ---- ---- ---- ---- 
ML3H3 71.43(6) 65.25(7) ---- ---- ML3 37.43(1) 32.25 ---- 15.2 34.91(1) ---- ---- ---- 
ML3H2 65.33(3)               58.30(4)                    ---- ----                   
ML3H 55.62(9)               47.48(5)                  ---- ----                   
ML3 44.63(5)               38.41(5)                    ---- ----                   
pMn+ 22.0 15.1 10.1 6.3 pMn+ 20.7 15.4 10.1 6.2 20.6 NF 9.7 6.4 
[1] V. M. Nurchi, G. Crisponi, T. Pivetta, M. Donatoni and M. Remelli, Journal of Inorganic Biochemistry, 2008, 102, 684-692. 
[2] D. J. Clevette, W. O. Nelson, A. Nordin, C. Orvig and S. Sjoeberg, Inorganic Chemistry, 1989, 28, 2079-2081. 
[3] T. Jakusch, K. Gaida-Schrantz, Y. Adachi, H. Sakurai, T. Kiss, L. Horvath, J. Inorg. Biochem., (2006), 100:1521-1526. 
[4] R. C. Scarrow, P. E. Riley, K. Abu-Dari, D. L. White and K. N. Raymond, Inorganic Chemistry, 1985, 24, 954-967.  
[5] H. Stunzi, L. Harris, D. Perrin and T. Teitei, Australian Journal of Chemistry, 1980, 33, 2207-2220. 
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TableA10. ESI-MS m/z data of Al3+–P1 aqueous solution at different pH. 
 
pH Negative Intensity Positive Intensity Species 
4.06 305.032 3000 - - [AlL2]- 
6.21 
305.032 
- 
5000 
- 
- 
486.049 
- 
25000 
[AlL2]- 
[AlL3H3+K]+ 
7.00 
305.032 
- 
- 
300 
- 
- 
- 
307.051 
448.101 
- 
15000 
300 
[AlL2]- 
[AlL2H2]+ 
[AlL3H3+H]+ 
7.70 - - 486.049 20000 [AlL3H3+K]+ 
10.83 
305.032 
- 
10000 
- 
- 
486.049 
- 
25000 
[AlL2]- 
[AlL3H3+K]+ 
>11 
305.043 
- 
- 
300 
- 
- 
- 
307.049 
470.074 
- 
1500 
1250 
[AlL2]- 
[AlL2H2]+ 
[AlL3H3+Na]+ 
 
 
Figure A10. Al3+–P1 complexes. Experimental data for peak m/z = 305.030 (Panel A), 307.056 (Panel B), 
448.101 (Panel C), 470.074 (Panel D) and 486.048 (Panel E) are shown at the top of the panel and 
compared with the data calculated for the Al3+ complex (lower panel). 
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Figure A11. Cu2+–P1 complexes. Experimental data for peak m/z = 236.924 (Panel A), 341.989 (Panel B), 
344.009 (Panel C), 365.985 (Panel D) and 381.963 (Panel E) are shown at the top of the panel and 
compared with the data calculated for the Cu2+ complex (lower panel). 
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TableA11. ESI-MS m/z data of Cu2+–P1 aqueous solution at different pH. 
 
pH Negative Intensity Positive Intensity Species 
3.90 236.924 1500 - - [CuL+Cl]- 
7.00 
- 
- 
- 
- 
344.009 
381.963 
200 
200 
[CuL2H2+H]+ 
[CuL2H2+K]+ 
>11 
341.989 
- 
- 
500 
- 
- 
- 
344.002 
365.985 
- 
2000 
2000 
[CuL2H]- 
[CuL2H2+H]+ 
[CuL2H2+Na]+ 
 
 
Figure A12.  Zn2+–P1 complexes. Experimental data (pH 7.0) for peak m/z = 382.970 are shown at the top 
of the panel and compared with the data calculated for the zinc(II) complex (lower panel). 
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Figure A13. ESI-MS spectra of the Cu(ClO4)2/L4 system in a ratio 1:1 at pH 7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A14 . ESI-MS spectra of the Cu(ClO4)2/L5 system in a ratio 1:1 at pH 7. 
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Figure A15. ESI-MS spectra of the Cu(ClO4)2/L7 system in a ratio 1:1 at pH 7. 
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Figure A16. ESI-MS spectra of the Zn(ClO4)2/L1 system in a ratio 1:1 at pH 7. 
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Figure A17. ESI-MS spectra of the Zn(ClO4)2/L2 system in a ratio 1:1 at pH 7. 
 
Figure A18. ESI-MS spectra of the Zn(ClO4)2/L3 system in a ratio 1:1 at pH 7. 
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Figure A19. ESI-MS spectra of the Zn(ClO4)2/L4 system in a ratio 1:1 at pH 7. 
 
Figure A20. ESI-MS spectra of the Zn(ClO4)2/L5 system in a ratio 1:1 at pH 7. 
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Figure A21. ESI-MS spectra of the Zn(ClO4)2/L6 system in a ratio 1:1 at pH 7. 
 
Figure A22. ESI-MS spectra of the Zn(ClO4)2/L8 system in a ratio 1:1 at pH 7. 
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Figure A23. ESI-MS spectra of the Zn(ClO4)2/L7 system in a ratio 1:1 at pH 7. 
 
Figure A24. Comparison of 1H 1D spectra of L3 free (red) and L3-ZnII system, 1:0.5 molar ratio (blue), at 
pH 8.4. 
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Figure A25. 2D 1H-13C spectrum for the free L7 ligand (red), and L-Zn(II) system, 1:1 molar ratio (black), 
in H2O-D2O, at pH 4.0. The new resonances of L7 upon ZnII interaction are indicated by arrows and the 
chemical shifts differences Δδ = δbound – δfree and the combined Δδtot= [(Δδ H)2+(0.341· Δδ C)2]1/2 are 
showed in the histogram. 
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Figure A26. The full spectrum of KβAK with Cu2+ solution in the molar ratio 1:1. Panel A) Experimental 
data for peak m/z = 442.9947 are shown at the top of the panel and compared with the data calculated 
for the [CuLH]+ (C16H14NO10Cu) complex (lower panels).  Panel B) Experimental data for peak m/z = 
461.0058 are shown and compared with the data calculated for the [CuLH(H2O)] + (C16H16NO11Cu) 
complex (lower panel). 
 
 
Figure A27. Expanded range of the product-ion spectrum of 810-910 m/z (from the spectrum in Fig S26). 
Panel A) Experimental data for peak m/z = 824.0589 are shown at the top of the panel and compared 
with the data calculated for the [CuL2H3]+ (C32H29N2O20Cu) complex (lower panels).  Panel B) 
Experimental data for peak m/z = 884.9732 are shown and compared with the data calculated for the 
[Cu2L2H] + (C32H27N2O20Cu2) complex (lower panel). 
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Figure A28. Electrospray ionization with tandem mass spectrometry (MS/MS) spectrum of the [CuLH]+ 
complex. The peak selected for fragmentation in the MS/MS experiment is indicated by a diamond. 
 
Figure A29. Electrospray ionization with tandem mass spectrometry (MS/MS) spectrum of the [CuLH]+ 
complex.  Comparisons between experimental and isotopic patterns of ions found in MS/MS 
experiments are presented in panels A-G. 
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TableA12. Comparison of m/z values (experimental and calculated) for the most abundant isotopic 
peaks of the [CuLH] + complex. 
compound 
calculated experimental elemental formula 
    
m/z value m/z value of complex compound calculated experimental elemental formula 
       m/z value m/z value of complex 
P1 186.9451 186.9399 C6H4O3Cu Z1 186.9451 186.9399 C6H4O3Cu 
P1+H 187.9485 187.9551 C6H5O3Cu Z1+H 187.9485 187.9551 C6H5O3Cu 
P2 202.9400 202.9734 C6HO4Cu Z2 202.9400 202.9734 C6HO4Cu 
P2+H 203.9478 203.9533 C6H5O4Cu Z2+H 203.9478 203.9533 C6H5O4Cu 
P3 230.0949 230.9946 C7H4O5Cu Z3 230.0949 230.9946 C7H4O5Cu 
P3+H 231.9428 231.9668 C7H5O5Cu Z3+H 231.9428 231.9668 C7H5O5Cu 
P4 -------- --------- C8H6O5Cu Z4 245.9566 245.9458 C7H5NO5Cu 
P4+H 245.9584 245.9566 C8H7O5Cu Z4+H -------- -------- C7H6NO5Cu 
P6 273.9771 273.9750 C9H9NO5Cu Z6 273.9771 273.9750 C9H9NO5Cu 
P6+H 274.9849 274.9826 C9H10NO5Cu Z6+H 274.9849 274.9826 C9H10NO5Cu 
P7 301.9720 301.9725 C10H9NO6Cu Z7 301.9720 301.9725 C10H9NO6Cu 
P8+H 318.9748 318.9713 C10H10NO7Cu P8+H 318.9748 318.9713 C10H10NO7Cu 
P8+2H 319.9826 319.9818 C10H11NO7Cu P8+2H 319.9826 319.9818 C10H11NO7Cu 
 
Figure A30. Fig. S 1. The full spectrum of KβAK with Zn2+ solution in the molar ratio 1:1.  The upper 
panel shows the isotopic patterns obtained for experimental data m/z = 443.9945 and m/z 462.0015 
compared to those calculated for [ZnLH]+ (C16H14NO10Zn) and the [ZnLH(H2O)]+ (C16H16NO11Zn). 
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Figure A31. Schematic presentation of the collision-induce dissociation fragmentation of [ZnLH] +. 
 
 
TableA13. Comparison of m/z values (experimental and calculated) for the most abundant isotopic 
peaks of the [ZnLH] + complex. 
 
compound 
calculated experimental elemental formula 
    
m/z value m/z value of complex compound calculated experimental elemental formula 
       m/z value m/z value of complex 
P1 203.9396 203.9646 C6H4O4Zn Z1 203.9396 203.9646 C6H4O4Zn 
P1+H 204.9474 204.9512 C6H5O4Zn Z1+H 204.9474 204.9512 C6H5O4Zn 
P2+H 275.9845 275.9833 C9H10NO5Zn Z2+H 275.9845 275.9833 C9H10NO5Zn 
P3+H 319.9743 319.9724 C10H10NO7Zn Z3+H 319.9743 319.9724 C10H10NO7Zn 
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Figure A32. Electrospray ionization with tandem mass spectrometry (MS/MS) spectrum of the [ZnLH]+ 
complex. The peak selected for fragmentation in the MS/MS experiment is indicated by a diamond. 
 
 
Figure A33. Electrospray ionization with tandem mass spectrometry (MS/MS) spectrum of the [ZnLH]+ 
complex. Comparisons between experimental and isotopic patterns of ions found in MS/MS 
experiments are presented in panels A-C. 
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Figure A34. The full spectrum of KβAK with Fe3+ solution in the molar ratio 1:1.  Panel A) Experimental 
data for peak m/z = 434.9948 are shown at the top of the panel and compared with the data calculated 
for the [Fe2L2]2+ (C32H26N2O20Fe2) complex (lower panels).  Panel B) Experimental data for peak m/z = 
453.0046 are shown and compared with the data calculated for the [FeL(H2O)]+ (C16H15NO11Fe) complex 
(lower panel). Panel C)Experimental data for peak m/z = 889.9407 are shown and compared with the 
data calculated for the [Fe2L2 H(H2O)] + (C32H30N2O21Fe2) complex (lower panel). Panel D) Experimental 
data for peak m/z = 904.9491 are shown at the top of the panel and compared with the data calculated 
for the [Fe2L2H(H2O)2] + (C32H29N2O21Fe2) complex (lower panel).   
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Figure A35. The full spectrum of  Kojic-βAla-Kojic with aluminium solution in the molar ratio 1:1. 
Panel A) Experimental data for peak m/z = 406.0391 are shown at the top of the panel and compared 
with the data calculated for the [Al2L2]2+ (C32H26N2O20Al2) and [AlLH]+ (C16H13NO10Al) complexes, 
respectively (lower panels). Panel B) Experimental data for peak m/z = 424.0526 are shown at the top of 
the panel and compared with the data calculated for the AlLH(H2O]+ complex (lower panel). 
 
 
Figure A36. The full ESI-MS spectrum of  Irbesartan solution. 
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A) Experimental data for peak m/z = 429.236 are shown at the top of the panel and compared with 
the data calculated for the [I+H]+ (C25H29N6O) (lower panel).  
 
 
B)  Experimental data for peak m/z = 451.220 are shown at the top of the panel and compared with 
the data calculated for the [I+Na]+ (C25H28N6O+Na) (lower panel).  
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C) Experimental data for peak m/z = 467.196 are shown at the top of the panel and compared with 
the data calculated for the [I+K]+ (C25H28N6O+K) (lower panel).  
 
D) Experimental data for peak m/z = 857.472 are shown at the top of the panel and compared with 
the data calculated for the [2I+H]+ (C50H57N12O2) (lower panel). 
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E) Experimental data for peak m/z = 879.454 are shown at the top of the panel and compared with 
the data calculated for the [2I+Na]+ (C50H56N12O2Na) (lower panel).
 
 
F) Experimental data for peak m/z = 901.436 are shown at the top of the panel and compared with 
the data calculated for the [2I+2Na]+ (C50H55N12O2Na2) (lower panel). 
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Figure 37. The full ESI-MS spectrum of  Losartan solution. 
 
A) Experimental data for peak m/z = 461.125 are shown at the top of the panel and compared with 
the data calculated for [L+K]+ (C22H23N6OKCl) (lower panel).  
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B) Experimental data for peak m/z = 483.108 are shown at the top of the panel and compared with the 
data calculated for [L+K+Na]+ (C22H22N6OKClNa) (lower panel).  
 
C) Experimental data for peak m/z = 883.285 are shown at the top of the panel and compared with the 
data calculated for [2L+K+H]+ (C44H46N12O2KCl2) (lower panel).  
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D) Experimental data for peak m/z = 921.241 are shown at the top of the panel and compared with the 
data calculated for [2L+2K]+ (C44H45N12O2K2Cl2) (lower panel).  
  
E) Experimental data for peak m/z = 959.199 are shown at the top of the panel and compared with the 
data calculated for [2L+3K]+ (C44H44N12O2K3Cl2) (lower panel).  
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F) Experimental data for peak m/z = 982.189 are shown at the top of the panel and compared with the 
data calculated for [2L+3K+Na]+ (C44H44N12O2K3Cl2Na) (lower panel).  
 
Figure A38. The full spectrum of  Irbesartan with copper solution in the molar ratio 1:2 (metal:ligand)  
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A) Experimental data for peak m/z = 491.162 are shown at the top of the panel and compared with 
the data calculated for the [CuI+H]+ (C25H28N6OCu) (lower panel).  
 
B) Experimental data for peak m/z = 919.394 are shown at the top of the panel and compared with 
the data calculated for the [CuI2+2H]+ (C50H56N12O2Cu) (lower panel).  
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Figure A39. Electrospray ionization with tandem mass spectrometry (MS/MS) spectrum of the [CuIH]+ 
complex. The peak selected for fragmentation in the MS/MS experiment is indicated by a diamond. 
 
A) Experimental data for peak m/z = 296.03 are shown at the top of the panel and compared with 
the data calculated for the C14H9N4Cu fragment (lower panel). 
 
 
296.03
327.26
352.09
380.09
448.14
463.16
491.16
+MS2(491.00), 0.0-0.4min #(2-24)
0.0
0.2
0.4
0.6
0.8
1.0
4x10
Intens.
300 320 340 360 380 400 420 440 460 480 m/z
296.03
297.04
298.03
299.04
+MS2(491.00), 0.0-0.4min #(2-24)
296.01
297.02
298.01
299.01
C14H9CuN4, M ,296.01
0
20
40
60
Intens.
[%]
0
20
40
60
80
100
[%]
295.5 296.0 296.5 297.0 297.5 298.0 298.5 299.0 299.5 m/z
52 
 
B) Experimental data for peak m/z = 352.09 are shown at the top of the panel and compared with 
the data calculated for the C16H11N5Cu fragment (lower panel).  
 
C) Experimental data for peak m/z = 448.14 are shown at the top of the panel and compared with 
the data calculated for the C22H21N6OCu fragment (lower panel).   
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D) Experimental data for peak m/z = 463.16 are shown at the top of the panel and compared with 
the data calculated for the C23H24N6OCu fragment (lower panel).  
 
 
Figure A40. The full spectrum of  Irbesartan with zinc solution in the molar ratio 1:2 (metal:ligand). 
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A) Experimental data for peak m/z = 491.162 are shown at the top of the panel and compared with 
the data calculated for the [ZnI+H]+ (C25H27N6OZn) complex (lower panel).  
 
B) Experimental data for peak m/z = 509.160 are shown at the top of the panel and compared with 
the data calculated for the [ZnI+H+H2O]+ (C25H29N6O2Zn) complex (lower panel).   
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C) Experimental data for peak m/z = 527.131 are shown at the top of the panel and compared with 
the data calculated for the [ZnI+H+2H2O]+ (C25H31N6O3Zn) complex (lower panel).   
 
D) Experimental data for peak m/z = 919.395 are shown at the top of the panel and compared with 
the data calculated for the [ZnI2+H]+ (C50H55N12O2Zn) complex (lower panel).   
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Figure A41. Electrospray ionization with tandem mass spectrometry (MS/MS) spectrum of the 
[ZnI2+H]+ complex. The peak selected for fragmentation in the MS/MS experiment is indicated by a 
diamond. The collision energy was set at 10 eV. 
 
A) Experimental data for peak m/z = 449.16 are shown at the top of the panel and compared with 
the data calculated for the (C22H20N6OZn) fragment (lower panel).  
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Figure A42. ESI-MS spectrum of losartan with copper solution in 1:1 molar ratio; 480-1040 m/z range. 
 
 
A) Experimental data for peak m/z = 485.092 are shown at the top of the panel and compared with 
the data calculated for [CuL+H]+ (C22H23ClN6OCu) (lower panel).   
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B) Experimental data for peak m/z = 499.081 are shown at the top of the panel and compared with 
the data calculated for [L+2K]+ (C22H22ClK2N6O) (lower panel).    
 
 
C) Experimental data for peak m/z = 907.252 are shown at the top of the panel and compared with 
the data calculated for [CuL2+2H]+ (C44H46Cl2N12O2Cu) (lower panel). 
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D) Experimental data for peak m/z = 936.701 are shown at the top of the panel and compared with 
the data calculated for [Cu3L4]2+ (C88H88Cl4N24O4Cu3) (lower panel). 
 
 
E) Experimental data for peak m/z = 945.209 are shown at the top of the panel and compared with 
the data calculated for [CuL2+K+H]+ (C44H45Cl2N12O2CuK) (lower panel). 
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F) Experimental data for peak m/z = 1031.098 are shown at the top of the panel and compared 
with the data calculated for [Cu3L2]+ (C44H44Cl2N12O2Cu3) (lower panel). 
 
 
Figure A43. 1H 1D NMR spectra of free Losartan in D2O at pH 7.0, MeOD-d4 and DMSO-d6 at T = 298. 
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TableA14. 1H and 13C chemical shift assignment of free Losartan in D2O at pH 7.0, MeOD-d4 and 
DMSO-d6 at T = 298.  
 
prot
on H2O 
DMSO
-d6 
MeOd-
d4 shape Coupling Constant 
integrat
ion 
carb
on H2O 
DMS
O-d6 
MeO
d-d4 
n° δ ppm δ ppm δ ppm 
multipli
city J Hz 
intensit
y n° 
δ 
ppm 
δ 
ppm 
δ 
ppm 
6 4,349 4,317* 4,449 singlet 
*doublet J=4,85 Hz 
(DMSO-d6) 2H 6 
51,24
4 
51,65
6 
51,69
1 
7 2,429 2,492 2,599 triplet 
J = 7,9 Hz; 7,6 Hz; 7,9 
Hz 2H 7 
25,59
1 
26,10
9 
25,86
8 
8 1,345 1,474 1,556 
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et   2H 8 
28,65
6 
29,39
7 
29,43
8 
9 1,093 1,247 1,322 sextet   2H 9 
21,33
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2 
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6 
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J=7.6 Hz; 7.32 Hz; 7.6 
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57 
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130,3
97 
OH NA 5,287§ 4,877 singlet § triplet J = 5 Hz  (DMSO-d6) 1H 
 
Figure A44. 1H 1D NMR spectra of free Irbesartan in MeOD-d4 at T = 298. 
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Figure A45. Aliphatic region of 1H 2D COSY NMR spectra of free Irbesartan in MeOD-d4 at T = 298.  
 
 
 
 
 
Figure A46. The full spectrum of L12 with Fe3+ solution in the molar ratio 1:1 in positive mode. 
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A) Experimental data for peak m/z = 466.973, 475.976, 484.991 and 493.980 are shown at the top of 
the panel and compared with the data calculated for the [Fe2(L12ox)H2]2+ (C40H24Fe2O20), 
[Fe2(L12ox)H2+H2O]2+ (C40H26Fe2O21), [Fe2(L12ox)H2+2H2O]2+ (C40H28Fe2O22) and 
[Fe2(L12ox)H2+3H2O]2+ (C40H30Fe2O23)   complexes (lower panels).   
 
FigureS 47. The full spectrum of L12 with Fe3+ solution in the molar ratio 1:1 in negative mode. 
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A) Experimental data for peak m/z = 1040.870 are shown at the top of the panel and compared 
with the data calculated for the [Fe2(L12ox)2H2+3Cl]- (C40H24Cl3Fe2O20)   complex (lower panel).   
 
 
Figure A48. The full spectrum of  L13 with Fe3+ solution in the molar ratio 1:1 in positive mode. 
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A) Experimental data for peak m/z = 469.995, 478.998 and 488.004 are shown at the top of the panel 
and compared with the data calculated for the [Fe2(L13)2H2]2+ (C40H28Fe2O20), 
[Fe2(L13)2H2+H2O]2+ (C40H30Fe2O21) and [Fe2(L13)2H2+2H2O]2+ (C40H32Fe2O22) complexes (lower 
panels).   
 
Figure A49. The full spectrum of  L15 with Fe3+ solution in the molar ratio 1:1 in positive mode. 
 
  
469.995
472.009 473.033 474.034
475.069
476.060
477.076
478.017
479.021
481.059 483.063 484.011 485.033
485.993
487.004 488.007
489.022
490.012
9.025
18.012
+MS, 0.0-0.5min #(2-27)
469.993
C40H28Fe2O20, M ,939.99
478.001
478.998
C40H30Fe2O21, M ,958.00
487.006
488.004
C40H32Fe2O22, M ,976.01
0
5
10
15
Intens.
[%]
0
20
40
60
80
100
[%]
0
20
40
60
80
100
[%]
0
20
40
60
80
100
[%]
470.0 472.5 475.0 477.5 480.0 482.5 485.0 487.5 490.0 m/z
125.010
165.040
247.044
313.260
401.078
441.991
490.979
537.390
607.128
636.031
857.027
+MS, 0.0-0.3min #(1-15)
0
20
40
60
80
100
Intens.
[%]
100 200 300 400 500 600 700 800 900 1000 m/z
66 
 
A) Experimental data for peak m/z = 441.991, 450.998 and 460.004 are shown at the top of the panel 
and compared with the data calculated for the [Fe2(L15)2H2]2+ (C38H28Fe2O18), 
[Fe2(L15)2H2+H2O]2+ (C38H30Fe2O19) and [Fe2(L15)2H2+2H2O]2+ (C38H32Fe2O20) (lower panels).   
 
Figure A50. The full spectrum of L12 with Al3+ solution in the molar ratio 1:1 in positive mode. 
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A) Experimental data for peak m/z = 441.035, 450.041 and 459.045 are shown at the top of the panel 
and compared with the data calculated for the [Al2(L12)2H2]2+ (C40H28Al2O20), 
[Al2(L12)2H2+H2O]2+ (C40H30Al2O21)  and [Al2(L12)2H2+2H2O]2+ (C40H32Al2O22) complexes (lower 
panels). 
 
 
B) Experimental data for peak m/z = 440.027, 449.033 and 458.038 are shown at the top of the panel 
and compared with the data calculated for the [Al2(L12ox)2H2]2+ (C40H26Al2O20), 
[Al2(L12ox)2H2+H2O]2+ (C40H28Al2O21)  and [Al2(L12ox)2H2+2H2O]2+ (C40H30Al2O22) complexes 
(lower panels). 
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Figure A51. The full spectrum of L12 with Al3+ solution in the molar ratio 1:1 in negative mode. 
 
 
A) Experimental data for peak m/z = 474.999 are shown at the top of the panel and compared with 
the data calculated for the [Al2(L12)2+2Cl]2- (C40H26Al2Cl2O20) complex (lower panel).   
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B) Experimental data for peak m/z = 915.036, 933.022 and 951.009 are shown at the top of the panel 
and compared with the data calculated for the [Al4(L12)4+2Cl]2-(C80H52Al4Cl2O40), 
[Al4(L12)4+2Cl+2H2O]2- (C80H56Al4Cl2O42) and [Al4(L12)4+2Cl+4H2O]2- (C80H60Al4Cl2O44) 
complexes.   
 
Figure A52. The full spectrum of  L13 with Al3+ solution in the molar ratio 1:1 in positive mode. 
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A) Experimental data for peak m/z = 441.029 and 459.040 are shown at the top of the panel and 
compared with the data calculated for the [Al2(L13)2H2]2+ (C40H28Al2O20) and 
[Al2(L13)2H2+2H2O]2+ (C40H32Al2O22)  complexes (lower panels).   
 
 
Figure A53. Electrospray ionization with tandem mass spectrometry (MS/MS) spectrum of the 
[Al2(L13)2H2]2+ complex. The peak selected for fragmentation in the MS/MS experiment is indicated by 
a diamond. 
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A) Experimental data for peak m/z = 459.040 are shown at the top of the panel and compared with 
the data calculated for the [Al(L13)H]+ (C40H28Al2O20) complex (lower panel).   
 
Figure A54. The full spectrum of  L14 with Al3+ solution in the molar ratio 1:1 in positive mode. 
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A) Experimental data for peak m/z = 413.038, 422.044 and 431.049 are shown at the top of the panel 
and compared with the data calculated for the [Al2(L14)2H2]2+ (C38H28Al2O18), 
[Al2(L14)2H2+H2O]2+ (C38H30Al2O19) and [Al2(L14)2H2+2H2O]2+ (C38H32Al2O20) complexes (lower 
panels).   
 
 
B) Experimental data for peak m/z = 607.077 are shown at the top of the panel and compared with 
the data calculated for the [Al2(L14)3H5]2+ (C57H44Al2O7) complex (lower panel).   
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Figure A55. Electrospray ionization with tandem mass spectrometry (MS/MS) spectrum of the 
[Al2(L14)2H2]2+ complex. The peak selected for fragmentation in the MS/MS experiment is indicated by 
a diamond. 
 
 
A) Experimental data for peak m/z = 413.041, 422.049 and 431.056 are shown at the top of the panel 
and compared with the data calculated for the [Al2(L14)2H2]2+ (C38H28Al2O18), 
[Al2(L14)2H2+H2O]2+ (C38H30Al2O19) and [Al2(L14)2H2+2H2O]2+ (C38H32Al2O20) complexes (lower 
panels).   
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Figure A56. The full spectrum of L12 with Cu2+ solution in the molar ratio 1:1 in positive mode. 
 
A) Experimental data for peak m/z = 475.974 and 493.980 are shown at the top of the panel and 
compared with the data calculated for the [Cu(L12ox)H2]+ (C20H13CuO10),  [Cu2(L12ox)2H4]2+ 
(C40H26Cu2O20) and [Cu(L12ox)H2+H2O]+ (C20H15CuO11) complexes (lower panels).   
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Figure A57. The full spectrum of  L13 with Cu2+ solution in the molar ratio 1:1 in positive mode. 
 
 
A) Experimental data for peak m/z = 477.986 are shown at the top of the panel and compared with 
the data calculated for the [Cu(L13)H2]+ (C20H15CuO10) and [Cu2(L13)2H4]2+ (C40H30Cu2O20) 
complexes (lower panels).   
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B) Experimental data for peak m/z = 954.960 are shown at the top of the panel and compared with 
the data calculated for the [Cu2(L13)2H]+ (C40H29Cu2O20) complex (lower panel).   
 
Figure A58. The full spectrum of  L14 with Cu2+ solution in the molar ratio 1:1 in positive mode. 
 
  
954.960
955.961
956.958
957.963
958.961
+MS, 0.0-0.2min #(2-14)
954.984
955.987
956.982
957.985
958.981
959.984
C40H29Cu2O20, M ,954.98
0
1
2
3
4
5
Intens.
[%]
0
20
40
60
80
100
[%]
955 956 957 958 959 960m/z
125.011
229.034
313.259
353.254
389.076
449.991
548.876
636.027
780.265
838.061
898.972
+MS, 0.0-0.2min #(2-13)
0
20
40
60
80
100
Intens.
[%]
200 400 600 800 1000 1200 1400 m/z
77 
 
A) Experimental data for peak m/z = 449.991 are shown at the top of the panel and compared with 
the data calculated for the [Cu(L14)H2]+ (C19H15CuO9) and [Cu2(L14)2H4]2+ (C38H30Cu2O18) 
complexes (lower panels).   
 
B) Experimental data for peak m/z = 838.061 are shown at the top of the panel and compared with 
the data calculated for the [Cu(L14)2H5]+ (C38H31CuO18) complex (lower panel).   
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C) Experimental data for peak m/z = 898.972 are shown at the top of the panel and compared with 
the data calculated for the [Cu2(L14)2H3]+ (C38H29Cu2O18) complex (lower panel).   
 
Figure A59. The full spectrum of  L15 with Cu2+ solution in the molar ratio 1:1 in positive mode. 
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A) Experimental data for peak m/z = 449.995 are shown at the top of the panel and compared with 
the data calculated for the [Cu(L15)H2]+ (C19H15CuO9) and [Cu2(L15)2H3]2+ (C38H30Cu2O18) (lower 
panels).   
 
 
B) Experimental data for peak m/z = 898.983 and 920.976 are shown at the top of the panel and 
compared with the data calculated for the [Cu2(L15)2H3]+ (C38H29Cu2O18) and [Cu2(L15)2H2+Na]+ 
(C38H28Cu2O18Na) complexes (lower panels).   
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Figure A60. The full spectrum of L12 with Zn2+ solution in the molar ratio 1:1 in positive mode. 
 
A) Experimental data for peak m/z = 476.972 and 478.979 are shown at the top of the panel and 
compared with the data calculated for the [Zn(L12ox)H2]+ (C20H13ZnO10) and [Zn(L12)H2]+ (C20H15ZnO10)    
complexes (lower panels).   
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Figure A61. The full spectrum of L12 with Zn2+ solution in the molar ratio 1:1 in negative mode. 
 
A) Experimental data for peak m/z = 477.096 are shown at the top of the panel and compared with 
the data calculated for the [Zn(L12)]- (C20H13ZnO10) complex (lower panel).   
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B) Experimental data for peak m/z = 512.952 are shown at the top of the panel and compared with 
the data calculated for the [Zn(L12)H+Cl]- (C20H14ZnClO10) complex (lower panel).   
 
C) Experimental data for peak m/z = 548.920 are shown at the top of the panel and compared with 
the data calculated for the [Zn(L12)H2+2Cl]- (C20H15ZnCl2O10) complex (lower panel).   
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Figure A62. The full spectrum of  L13 with Zn2+ solution in the molar ratio 1:1 in positive mode. 
 
A) Experimental data for peak m/z = 478.988 are shown at the top of the panel and compared with 
the data calculated for the [Zn2(L13)2H4]2+ (C40H30Zn2O20) and [Zn(L13)H2]+ (C20H15ZnO10) 
complexes (lower panels).   
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B) Experimental data for peak m/z = 496.998 and 514.977 are shown at the top of the panel and 
compared with the data calculated for the [Zn(L13)H2+H2O]+ (C20H17ZnO11) and 
[Zn(L13)H2+2H2O]+ (C20H19ZnO12) complexes (lower panels).   
 
C) Experimental data for peak m/z = 956.964 are shown at the top of the panel and compared with 
the data calculated for the [Zn2(L13)2H]+ (C40H29Zn2O20) and the [Zn4(L13)4H8]2+ (C80H58Zn4O40) 
complexes (lower panels).   
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Figure A63. The full spectrum of  L14 with Zn2+ solution in the molar ratio 1:1 in positive mode. 
 
A) Experimental data for peak m/z = 450.990 are shown at the top of the panel and compared with 
the data calculated for the [Zn2(L14)2H4]2+ (C38H30Zn2O18)  and [Zn(L14)H2]+ (C19H15ZnO9) 
complexes (lower panels).   
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Figure A64. The full spectrum of  L15 with Zn2+ solution in the molar ratio 1:1 in positive mode. 
 
 
A) Experimental data for peak m/z = 450.995 are shown at the top of the panel and compared with 
the data calculated for the [Zn(L15)H2]+ (C19H15O9Zn) and [Zn2(L15)2H4]2+ (C38H30Zn2O18) 
complexes (lower panels).   
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B) Experimental data for peak m/z = 469.006 and 486.977 are shown at the top of the panel and 
compared with the data calculated for the [Zn(L15)H2+H2O]+ (C19H17O10Zn) and 
[Zn(L15)H2+2H2O]+ (C19H19O11Zn) complexes (lower panels).   
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